// Regulatory agency types based on official sources (2025)
export type RegulatoryAgency = 'FDA' | 'EMA' | 'PMDA' | 'NMPA' | 'MFDS' | 'HSA' | 'TGA' | 'MOHRU';

// Regulatory approval interface with verified standards
export interface RegulatoryApproval {
  agency: RegulatoryAgency;
  status: 'approved' | 'pending' | 'not_approved' | 'withdrawn';
  approvalDate?: string;
  brandName?: string;
  indications?: string[];
  restrictions?: string[];
  riskCategory?: string;
  additionalWarnings?: string[];
  // Pathway-specific information
  approvalPathway?: 'standard' | 'accelerated' | 'priority' | 'conditional' | 'orphan' | 'sakigake' | 'breakthrough';
  reviewTime?: string; // Actual review time
  marketingAuthorizationHolder?: string;
}

// Regional dosing with verified standards
export interface RegionalDosing {
  region: 'USA' | 'EU' | 'Japan' | 'China' | 'Korea' | 'Singapore' | 'Australia' | 'Russia';
  adultDose: string;
  pediatricDose?: string;
  maxDose: string;
  notes?: string;
  // Regulatory-specific dosing requirements
  regulatoryNotes?: string;
}

export interface MedicationData {
  name: string;
  genericName: string;
  brandNames: string[];
  category: string;
  form: string;
  strength: string;
  route: string;
  standardDoseAdult: string;
  standardDosePediatric?: string;
  maxDailyDose: string;
  dosingFrequency: string;
  weightBasedDosing: boolean;
  weightBasedFormula?: string;
  renalAdjustment?: string;
  hepaticAdjustment?: string;
  contraindications: string[];
  drugInteractions: string[];
  sideEffects: string[];
  blackBoxWarning?: string;
  pregnancyCategory: string;
  administrationNotes?: string;
  storageRequirements?: string;
  specialPrecautions?: string;
  monitoringParameters: string[];
  labsRequired: string[];
  isControlled: boolean;
  controlledSchedule?: string;
  // International regulatory approvals
  regulatoryApprovals?: RegulatoryApproval[];
  regionalDosing?: RegionalDosing[];
  regionalContraindications?: { region: string; contraindications: string[] }[];
  internationalBrandNames?: { region: string; names: string[] }[];
  riskEvaluationProgram?: string; // REMS (FDA), Risk Management Plan (EMA), etc.
  marketStatus?: 'active' | 'discontinued' | 'shortage' | 'limited';
}

export const medicationsDatabase: MedicationData[] = [
  // CARDIOVASCULAR MEDICATIONS
  {
    name: "Lisinopril",
    genericName: "Lisinopril",
    brandNames: ["Prinivil", "Zestril"],
    category: "Cardiovascular - ACE Inhibitor",
    form: "Tablet",
    strength: "2.5mg, 5mg, 10mg, 20mg, 40mg",
    route: "Oral",
    standardDoseAdult: "10-40mg once daily",
    standardDosePediatric: "0.07mg/kg once daily",
    maxDailyDose: "80mg",
    dosingFrequency: "Once daily",
    weightBasedDosing: true,
    weightBasedFormula: "0.07mg/kg/day, max 0.6mg/kg/day",
    renalAdjustment: "CrCl 10-30: Start 2.5-5mg/day; CrCl <10: Start 2.5mg/day",
    hepaticAdjustment: "Use with caution in hepatic impairment",
    contraindications: ["History of angioedema", "Pregnancy", "Bilateral renal artery stenosis"],
    drugInteractions: ["Potassium supplements", "Potassium-sparing diuretics", "ARBs", "NSAIDs", "Lithium"],
    sideEffects: ["Dry cough", "Hyperkalemia", "Hypotension", "Dizziness", "Headache", "Fatigue"],
    blackBoxWarning: "Can cause fetal injury/death when used during pregnancy. Discontinue as soon as pregnancy is detected.",
    pregnancyCategory: "D",
    administrationNotes: "May be taken with or without food",
    storageRequirements: "Store at room temperature 20-25°C",
    monitoringParameters: ["Blood pressure", "Renal function", "Serum potassium"],
    labsRequired: ["BMP", "Potassium", "Creatinine"],
    isControlled: false,
    marketStatus: "active",
    regulatoryApprovals: [
      { agency: "FDA", status: "approved", approvalDate: "1987-12-29", brandName: "Prinivil/Zestril", indications: ["Hypertension", "Heart Failure", "Post-MI"], riskCategory: "Pregnancy Category D" },
      { agency: "EMA", status: "approved", approvalDate: "1988-06-15", brandName: "Zestril", indications: ["Hypertension", "Heart Failure", "Diabetic Nephropathy"], restrictions: ["Contraindicated in pregnancy"] },
      { agency: "PMDA", status: "approved", approvalDate: "1990-09-01", brandName: "Longes", indications: ["Hypertension", "Chronic Heart Failure"], riskCategory: "Contraindicated in pregnancy" },
      { agency: "NMPA", status: "approved", approvalDate: "1995-03-20", brandName: "力平之", indications: ["Hypertension", "Heart Failure"] },
      { agency: "MFDS", status: "approved", approvalDate: "1992-07-15", brandName: "제스트릴", indications: ["Hypertension", "Heart Failure", "Post-MI"] }
    ],
    regionalDosing: [
      { region: "USA", adultDose: "10-40mg once daily", maxDose: "80mg/day", notes: "Start 5mg if on diuretics" },
      { region: "EU", adultDose: "10-20mg once daily", maxDose: "40mg/day", notes: "Lower starting dose in elderly" },
      { region: "Japan", adultDose: "5-20mg once daily", maxDose: "40mg/day", notes: "Generally lower doses due to body weight" }
    ],
    internationalBrandNames: [
      { region: "Japan", names: ["Longes", "ロンゲス"] },
      { region: "China", names: ["力平之", "利普妥"] },
      { region: "Korea", names: ["제스트릴", "Zestril"] },
      { region: "Germany", names: ["Acerbon", "Coric"] },
      { region: "Spain", names: ["Zestril", "Doneka"] }
    ]
  },
  {
    name: "Metoprolol Succinate",
    genericName: "Metoprolol Succinate",
    brandNames: ["Toprol-XL"],
    category: "Cardiovascular - Beta Blocker",
    form: "Extended-release tablet",
    strength: "25mg, 50mg, 100mg, 200mg",
    route: "Oral",
    standardDoseAdult: "25-200mg once daily",
    standardDosePediatric: "Not established",
    maxDailyDose: "400mg",
    dosingFrequency: "Once daily",
    weightBasedDosing: false,
    renalAdjustment: "No adjustment needed",
    hepaticAdjustment: "Reduce dose in severe hepatic impairment",
    contraindications: ["Severe bradycardia", "AV block", "Decompensated heart failure", "Cardiogenic shock"],
    drugInteractions: ["Verapamil", "Diltiazem", "Clonidine", "MAOIs", "Other beta blockers"],
    sideEffects: ["Bradycardia", "Fatigue", "Dizziness", "Depression", "Cold extremities"],
    pregnancyCategory: "C",
    administrationNotes: "Tablets may be divided but not crushed. Take with or immediately after meals.",
    monitoringParameters: ["Heart rate", "Blood pressure", "ECG"],
    labsRequired: ["None routinely"],
    isControlled: false,
    marketStatus: "active",
    regulatoryApprovals: [
      { agency: "FDA", status: "approved", approvalDate: "1992-11-06", brandName: "Toprol-XL", indications: ["Hypertension", "Angina Pectoris", "Heart Failure"], riskCategory: "Pregnancy Category C" },
      { agency: "EMA", status: "approved", approvalDate: "1990-03-15", brandName: "Beloc-Zok", indications: ["Hypertension", "Angina", "Arrhythmia", "Heart Failure"] },
      { agency: "PMDA", status: "approved", approvalDate: "1983-09-20", brandName: "Seloken", indications: ["Hypertension", "Angina", "Tachyarrhythmia"], riskCategory: "Use with caution in pregnancy" },
      { agency: "NMPA", status: "approved", approvalDate: "1995-06-10", brandName: "倍他乐克", indications: ["Hypertension", "Angina", "Heart Failure"] },
      { agency: "MFDS", status: "approved", approvalDate: "1991-04-25", brandName: "셀로켄", indications: ["Hypertension", "Angina", "Arrhythmia"] }
    ],
    regionalDosing: [
      { region: "USA", adultDose: "25-200mg once daily", maxDose: "400mg/day", notes: "Start 25mg for heart failure" },
      { region: "EU", adultDose: "50-200mg once daily", maxDose: "400mg/day", notes: "Titrate based on heart rate response" },
      { region: "Japan", adultDose: "20-120mg once daily", maxDose: "240mg/day", notes: "Lower doses typical due to body weight differences" }
    ],
    internationalBrandNames: [
      { region: "Japan", names: ["Seloken", "セロケン"] },
      { region: "China", names: ["倍他乐克", "美托洛尔"] },
      { region: "Korea", names: ["셀로켄", "Seloken"] },
      { region: "Germany", names: ["Beloc-Zok", "Metoprolol-Succinat"] },
      { region: "Spain", names: ["Beloken", "Lopresor"] }
    ]
  },
  {
    name: "Amlodipine",
    genericName: "Amlodipine",
    brandNames: ["Norvasc"],
    category: "Cardiovascular - Calcium Channel Blocker",
    form: "Tablet",
    strength: "2.5mg, 5mg, 10mg",
    route: "Oral",
    standardDoseAdult: "5-10mg once daily",
    standardDosePediatric: "2.5-5mg once daily",
    maxDailyDose: "10mg",
    dosingFrequency: "Once daily",
    weightBasedDosing: false,
    renalAdjustment: "No adjustment needed",
    hepaticAdjustment: "Start 2.5mg in hepatic impairment",
    contraindications: ["Hypersensitivity to dihydropyridines", "Severe hypotension"],
    drugInteractions: ["CYP3A4 inhibitors", "Simvastatin", "Cyclosporine"],
    sideEffects: ["Peripheral edema", "Flushing", "Headache", "Dizziness", "Fatigue"],
    pregnancyCategory: "C",
    administrationNotes: "May be taken with or without food",
    monitoringParameters: ["Blood pressure", "Heart rate", "Peripheral edema"],
    labsRequired: ["None routinely"],
    isControlled: false,
    marketStatus: "active",
    regulatoryApprovals: [
      { agency: "FDA", status: "approved", approvalDate: "1992-07-31", brandName: "Norvasc", indications: ["Hypertension", "Chronic Stable Angina", "Vasospastic Angina"], riskCategory: "Pregnancy Category C" },
      { agency: "EMA", status: "approved", approvalDate: "1990-09-10", brandName: "Norvasc", indications: ["Hypertension", "Angina Pectoris"], restrictions: ["Use with caution in pregnancy"] },
      { agency: "PMDA", status: "approved", approvalDate: "1993-03-25", brandName: "Norvasc/Amlodin", indications: ["Hypertension", "Angina Pectoris"], riskCategory: "Use with caution in pregnancy" },
      { agency: "NMPA", status: "approved", approvalDate: "1996-05-15", brandName: "络活喜", indications: ["Hypertension", "Angina"] },
      { agency: "MFDS", status: "approved", approvalDate: "1994-02-20", brandName: "노바스크", indications: ["Hypertension", "Angina Pectoris"] }
    ],
    regionalDosing: [
      { region: "USA", adultDose: "5-10mg once daily", maxDose: "10mg/day", notes: "Start 5mg; 2.5mg for small/frail patients" },
      { region: "EU", adultDose: "5-10mg once daily", maxDose: "10mg/day", notes: "Titrate over 1-2 weeks" },
      { region: "Japan", adultDose: "2.5-5mg once daily", maxDose: "10mg/day", notes: "Often start at 2.5mg due to body weight" }
    ],
    internationalBrandNames: [
      { region: "Japan", names: ["Norvasc", "ノルバスク", "Amlodin", "アムロジン"] },
      { region: "China", names: ["络活喜", "氨氯地平"] },
      { region: "Korea", names: ["노바스크", "Norvasc"] },
      { region: "Germany", names: ["Norvasc", "Amlodipin"] },
      { region: "Spain", names: ["Norvasc", "Astudal"] }
    ]
  },
  {
    name: "Atorvastatin",
    genericName: "Atorvastatin",
    brandNames: ["Lipitor"],
    category: "Cardiovascular - Statin",
    form: "Tablet",
    strength: "10mg, 20mg, 40mg, 80mg",
    route: "Oral",
    standardDoseAdult: "10-80mg once daily",
    standardDosePediatric: "10-20mg once daily (ages 10-17)",
    maxDailyDose: "80mg",
    dosingFrequency: "Once daily",
    weightBasedDosing: false,
    renalAdjustment: "No adjustment needed",
    hepaticAdjustment: "Contraindicated in active liver disease",
    contraindications: ["Active liver disease", "Pregnancy", "Breastfeeding", "Unexplained elevated transaminases"],
    drugInteractions: ["Gemfibrozil", "Niacin", "Cyclosporine", "CYP3A4 inhibitors", "Warfarin"],
    sideEffects: ["Myalgia", "Elevated transaminases", "Rhabdomyolysis", "Headache", "GI upset"],
    blackBoxWarning: "Rare cases of rhabdomyolysis with acute renal failure secondary to myoglobinuria.",
    pregnancyCategory: "X",
    administrationNotes: "May be taken at any time of day with or without food",
    monitoringParameters: ["LFTs", "Lipid panel", "CK if symptomatic"],
    labsRequired: ["Lipid panel", "LFTs", "A1c"],
    isControlled: false,
    marketStatus: "active",
    regulatoryApprovals: [
      { agency: "FDA", status: "approved", approvalDate: "1996-12-17", brandName: "Lipitor", indications: ["Hyperlipidemia", "Primary Prevention of CVD", "Secondary Prevention of CVD"], riskCategory: "Pregnancy Category X" },
      { agency: "EMA", status: "approved", approvalDate: "1997-03-10", brandName: "Lipitor", indications: ["Hypercholesterolemia", "Prevention of Cardiovascular Events"], restrictions: ["Contraindicated in pregnancy"] },
      { agency: "PMDA", status: "approved", approvalDate: "2000-06-16", brandName: "Lipitor", indications: ["Hypercholesterolemia", "Familial Hypercholesterolemia"], riskCategory: "Contraindicated in pregnancy" },
      { agency: "NMPA", status: "approved", approvalDate: "1999-09-20", brandName: "立普妥", indications: ["Hyperlipidemia", "Coronary Heart Disease Prevention"] },
      { agency: "MFDS", status: "approved", approvalDate: "1998-05-15", brandName: "리피토", indications: ["Hypercholesterolemia", "Mixed Dyslipidemia"] }
    ],
    regionalDosing: [
      { region: "USA", adultDose: "10-80mg once daily", maxDose: "80mg/day", notes: "Start 10-20mg; 40-80mg for aggressive LDL reduction" },
      { region: "EU", adultDose: "10-80mg once daily", maxDose: "80mg/day", notes: "Individualize based on LDL goal" },
      { region: "Japan", adultDose: "5-20mg once daily", maxDose: "40mg/day", notes: "Lower doses effective in Asian populations" }
    ],
    internationalBrandNames: [
      { region: "Japan", names: ["Lipitor", "リピトール"] },
      { region: "China", names: ["立普妥", "阿托伐他汀"] },
      { region: "Korea", names: ["리피토", "Lipitor"] },
      { region: "Germany", names: ["Sortis", "Atorvastatin"] },
      { region: "Spain", names: ["Cardyl", "Lipitor"] }
    ]
  },
  {
    name: "Losartan",
    genericName: "Losartan",
    brandNames: ["Cozaar"],
    category: "Cardiovascular - ARB",
    form: "Tablet",
    strength: "25mg, 50mg, 100mg",
    route: "Oral",
    standardDoseAdult: "25-100mg once or twice daily",
    standardDosePediatric: "0.7mg/kg once daily (max 50mg)",
    maxDailyDose: "100mg",
    dosingFrequency: "Once or twice daily",
    weightBasedDosing: true,
    weightBasedFormula: "0.7mg/kg/day, max 1.4mg/kg/day",
    renalAdjustment: "Start lower dose in renal impairment",
    hepaticAdjustment: "Start 25mg in hepatic impairment",
    contraindications: ["Pregnancy", "History of angioedema with ARBs/ACEIs", "Concomitant aliskiren in diabetes"],
    drugInteractions: ["ACE inhibitors", "Potassium supplements", "Potassium-sparing diuretics", "NSAIDs", "Lithium"],
    sideEffects: ["Dizziness", "Hyperkalemia", "Hypotension", "Fatigue", "Diarrhea"],
    blackBoxWarning: "Can cause fetal injury/death when used during pregnancy.",
    pregnancyCategory: "D",
    administrationNotes: "May be taken with or without food",
    monitoringParameters: ["Blood pressure", "Renal function", "Serum potassium"],
    labsRequired: ["BMP", "Potassium", "Creatinine"],
    isControlled: false,
    marketStatus: "active",
    regulatoryApprovals: [
      { agency: "FDA", status: "approved", approvalDate: "1995-04-14", brandName: "Cozaar", indications: ["Hypertension", "Diabetic Nephropathy", "Stroke Risk Reduction"], riskCategory: "Pregnancy Category D" },
      { agency: "EMA", status: "approved", approvalDate: "1994-06-09", brandName: "Cozaar", indications: ["Essential Hypertension", "Type 2 Diabetic Nephropathy", "Chronic Heart Failure"], restrictions: ["Contraindicated in pregnancy"] },
      { agency: "PMDA", status: "approved", approvalDate: "1998-06-30", brandName: "Nu-Lotan", indications: ["Hypertension", "Type 2 Diabetic Nephropathy"], riskCategory: "Contraindicated in pregnancy" },
      { agency: "NMPA", status: "approved", approvalDate: "1998-11-15", brandName: "科素亚", indications: ["Hypertension", "Diabetic Nephropathy"] },
      { agency: "MFDS", status: "approved", approvalDate: "1997-03-20", brandName: "코자", indications: ["Hypertension", "Diabetic Nephropathy", "Heart Failure"] }
    ],
    regionalDosing: [
      { region: "USA", adultDose: "25-100mg once or twice daily", maxDose: "100mg/day", notes: "Start 50mg; 25mg if volume depleted" },
      { region: "EU", adultDose: "50-100mg once daily", maxDose: "100mg/day", notes: "May divide into twice daily for better effect" },
      { region: "Japan", adultDose: "25-50mg once daily", maxDose: "100mg/day", notes: "Lower starting doses recommended" }
    ],
    internationalBrandNames: [
      { region: "Japan", names: ["Nu-Lotan", "ニューロタン"] },
      { region: "China", names: ["科素亚", "氯沙坦"] },
      { region: "Korea", names: ["코자", "Cozaar"] },
      { region: "Germany", names: ["Lorzaar", "Losartan"] },
      { region: "Spain", names: ["Cozaar", "Losartan"] }
    ]
  },
  {
    name: "Furosemide",
    genericName: "Furosemide",
    brandNames: ["Lasix"],
    category: "Cardiovascular - Loop Diuretic",
    form: "Tablet, Injection",
    strength: "20mg, 40mg, 80mg; IV: 10mg/mL",
    route: "Oral, IV",
    standardDoseAdult: "20-80mg once or twice daily",
    standardDosePediatric: "1-2mg/kg/dose",
    maxDailyDose: "600mg",
    dosingFrequency: "Once or twice daily",
    weightBasedDosing: true,
    weightBasedFormula: "1-2mg/kg/dose, max 6mg/kg/day",
    renalAdjustment: "Higher doses may be needed in renal impairment",
    hepaticAdjustment: "Use with caution; may precipitate hepatic coma",
    contraindications: ["Anuria", "Hepatic coma", "Severe electrolyte depletion"],
    drugInteractions: ["Aminoglycosides", "Cisplatin", "Digoxin", "Lithium", "NSAIDs"],
    sideEffects: ["Electrolyte imbalances", "Ototoxicity", "Dehydration", "Hypotension", "Hyperuricemia"],
    pregnancyCategory: "C",
    administrationNotes: "Take in morning to avoid nighttime diuresis. IV: Give slowly over 1-2 min",
    monitoringParameters: ["Electrolytes", "Renal function", "Blood pressure", "Weight"],
    labsRequired: ["BMP", "Magnesium", "Uric acid"],
    isControlled: false,
    marketStatus: "active",
    regulatoryApprovals: [
      { agency: "FDA", status: "approved", approvalDate: "1966-07-22", brandName: "Lasix", indications: ["Edema", "Heart Failure", "Hypertension", "Acute Pulmonary Edema"], riskCategory: "Pregnancy Category C" },
      { agency: "EMA", status: "approved", approvalDate: "1964-03-15", brandName: "Lasix", indications: ["Edema", "Cardiac Failure", "Renal Failure", "Hepatic Cirrhosis"], restrictions: ["Use only if clearly needed in pregnancy"] },
      { agency: "PMDA", status: "approved", approvalDate: "1965-09-01", brandName: "Lasix", indications: ["Edema", "Heart Failure", "Renal Disease", "Hypertension"], riskCategory: "Use with caution in pregnancy" },
      { agency: "NMPA", status: "approved", approvalDate: "1985-04-10", brandName: "速尿", indications: ["Edema", "Heart Failure", "Ascites"] },
      { agency: "MFDS", status: "approved", approvalDate: "1975-08-20", brandName: "라식스", indications: ["Edema", "Heart Failure", "Hypertension"] }
    ],
    regionalDosing: [
      { region: "USA", adultDose: "20-80mg once or twice daily", maxDose: "600mg/day", notes: "May need higher doses in renal impairment" },
      { region: "EU", adultDose: "20-80mg/day", maxDose: "500mg/day", notes: "Start low and titrate; IV for acute situations" },
      { region: "Japan", adultDose: "20-40mg once or twice daily", maxDose: "250mg/day", notes: "Lower doses typically sufficient" }
    ],
    internationalBrandNames: [
      { region: "Japan", names: ["Lasix", "ラシックス"] },
      { region: "China", names: ["速尿", "呋塞米"] },
      { region: "Korea", names: ["라식스", "Lasix"] },
      { region: "Germany", names: ["Lasix", "Furosemid"] },
      { region: "Spain", names: ["Seguril", "Furosemida"] }
    ]
  },
  {
    name: "Hydrochlorothiazide",
    genericName: "Hydrochlorothiazide",
    brandNames: ["Microzide", "HydroDIURIL"],
    category: "Cardiovascular - Thiazide Diuretic",
    form: "Tablet, Capsule",
    strength: "12.5mg, 25mg, 50mg",
    route: "Oral",
    standardDoseAdult: "12.5-50mg once daily",
    standardDosePediatric: "1-2mg/kg/day",
    maxDailyDose: "100mg",
    dosingFrequency: "Once daily",
    weightBasedDosing: true,
    weightBasedFormula: "1-2mg/kg/day",
    renalAdjustment: "Ineffective if CrCl <30; use loop diuretic instead",
    hepaticAdjustment: "Use with caution",
    contraindications: ["Anuria", "Sulfonamide allergy", "Severe renal impairment"],
    drugInteractions: ["Digoxin", "Lithium", "NSAIDs", "Corticosteroids"],
    sideEffects: ["Hypokalemia", "Hyponatremia", "Hyperuricemia", "Hyperglycemia", "Photosensitivity"],
    pregnancyCategory: "B",
    administrationNotes: "Take in morning to avoid nighttime diuresis",
    monitoringParameters: ["Electrolytes", "Renal function", "Blood pressure", "Blood glucose"],
    labsRequired: ["BMP", "Uric acid", "Lipid panel"],
    isControlled: false
  },
  {
    name: "Warfarin",
    genericName: "Warfarin Sodium",
    brandNames: ["Coumadin", "Jantoven"],
    category: "Cardiovascular - Anticoagulant",
    form: "Tablet",
    strength: "1mg, 2mg, 2.5mg, 3mg, 4mg, 5mg, 6mg, 7.5mg, 10mg",
    route: "Oral",
    standardDoseAdult: "2-10mg once daily, adjusted by INR",
    maxDailyDose: "Individualized to INR",
    dosingFrequency: "Once daily",
    weightBasedDosing: false,
    renalAdjustment: "No specific adjustment",
    hepaticAdjustment: "Use with caution; may require lower doses",
    contraindications: ["Active bleeding", "Hemorrhagic stroke", "Pregnancy", "Unsupervised patients"],
    drugInteractions: ["NSAIDs", "Aspirin", "Antibiotics", "Antifungals", "Vitamin K-containing foods"],
    sideEffects: ["Bleeding", "Bruising", "Purple toe syndrome", "Skin necrosis"],
    blackBoxWarning: "May cause major or fatal bleeding. Regular monitoring of INR required.",
    pregnancyCategory: "X",
    administrationNotes: "Take at same time each day. Maintain consistent vitamin K intake.",
    monitoringParameters: ["INR", "Signs of bleeding", "Hemoglobin"],
    labsRequired: ["INR", "PT", "CBC"],
    isControlled: false,
    marketStatus: "active",
    regulatoryApprovals: [
      { agency: "FDA", status: "approved", approvalDate: "1954-06-08", brandName: "Coumadin", indications: ["Venous Thromboembolism", "Atrial Fibrillation", "Mechanical Heart Valves", "Post-MI"], riskCategory: "Pregnancy Category X" },
      { agency: "EMA", status: "approved", approvalDate: "1955-01-20", brandName: "Coumadin", indications: ["DVT/PE Prophylaxis", "Atrial Fibrillation", "Prosthetic Heart Valves"], restrictions: ["Contraindicated in pregnancy"] },
      { agency: "PMDA", status: "approved", approvalDate: "1962-04-15", brandName: "Warfarin", indications: ["Thromboembolism", "Atrial Fibrillation"], riskCategory: "Contraindicated in pregnancy" },
      { agency: "NMPA", status: "approved", approvalDate: "1980-09-25", brandName: "华法林", indications: ["Thromboembolism", "Atrial Fibrillation", "Valve Replacement"] },
      { agency: "MFDS", status: "approved", approvalDate: "1970-12-10", brandName: "쿠마딘", indications: ["Venous Thromboembolism", "Atrial Fibrillation"] }
    ],
    regionalDosing: [
      { region: "USA", adultDose: "2-10mg once daily", maxDose: "Individualized by INR", notes: "Target INR 2.0-3.0 for most indications" },
      { region: "EU", adultDose: "2-10mg once daily", maxDose: "Individualized by INR", notes: "Start 5mg; adjust based on INR" },
      { region: "Japan", adultDose: "1-5mg once daily", maxDose: "Individualized by INR", notes: "Lower doses needed; Asian patients more sensitive" }
    ],
    internationalBrandNames: [
      { region: "Japan", names: ["Warfarin", "ワーファリン"] },
      { region: "China", names: ["华法林", "华令"] },
      { region: "Korea", names: ["쿠마딘", "Coumadin"] },
      { region: "Germany", names: ["Marcumar", "Coumadin"] },
      { region: "Spain", names: ["Aldocumar", "Sintrom"] }
    ]
  },
  {
    name: "Clopidogrel",
    genericName: "Clopidogrel",
    brandNames: ["Plavix"],
    category: "Cardiovascular - Antiplatelet",
    form: "Tablet",
    strength: "75mg, 300mg",
    route: "Oral",
    standardDoseAdult: "75mg once daily; Loading: 300-600mg",
    maxDailyDose: "75mg maintenance",
    dosingFrequency: "Once daily",
    weightBasedDosing: false,
    renalAdjustment: "No adjustment needed",
    hepaticAdjustment: "Use with caution in severe hepatic impairment",
    contraindications: ["Active bleeding", "Severe hepatic impairment"],
    drugInteractions: ["Omeprazole", "Esomeprazole", "Warfarin", "NSAIDs"],
    sideEffects: ["Bleeding", "Bruising", "TTP", "GI upset", "Rash"],
    blackBoxWarning: "Reduced effectiveness in CYP2C19 poor metabolizers. Consider alternative therapy.",
    pregnancyCategory: "B",
    administrationNotes: "May be taken with or without food. Avoid with omeprazole.",
    monitoringParameters: ["Signs of bleeding", "CBC"],
    labsRequired: ["CBC", "Consider CYP2C19 genotyping"],
    isControlled: false
  },
  {
    name: "Digoxin",
    genericName: "Digoxin",
    brandNames: ["Lanoxin", "Digitek"],
    category: "Cardiovascular - Cardiac Glycoside",
    form: "Tablet, Injection",
    strength: "0.0625mg, 0.125mg, 0.25mg; IV: 0.25mg/mL",
    route: "Oral, IV",
    standardDoseAdult: "0.125-0.25mg once daily",
    standardDosePediatric: "10-15mcg/kg/day divided",
    maxDailyDose: "0.5mg",
    dosingFrequency: "Once daily",
    weightBasedDosing: true,
    weightBasedFormula: "10-15mcg/kg/day",
    renalAdjustment: "Reduce dose significantly in renal impairment",
    hepaticAdjustment: "No adjustment needed",
    contraindications: ["Ventricular fibrillation", "AV block", "Hypertrophic cardiomyopathy with obstruction"],
    drugInteractions: ["Amiodarone", "Verapamil", "Quinidine", "Diuretics", "Antacids"],
    sideEffects: ["Arrhythmias", "Nausea", "Vomiting", "Visual disturbances", "Confusion"],
    pregnancyCategory: "C",
    administrationNotes: "Monitor levels closely. Therapeutic range: 0.5-2.0 ng/mL",
    monitoringParameters: ["Digoxin level", "Electrolytes", "Renal function", "ECG"],
    labsRequired: ["Digoxin level", "BMP", "Magnesium"],
    isControlled: false
  },

  // DIABETES MEDICATIONS
  {
    name: "Metformin",
    genericName: "Metformin Hydrochloride",
    brandNames: ["Glucophage", "Glucophage XR", "Fortamet"],
    category: "Endocrine - Biguanide",
    form: "Tablet, Extended-release tablet",
    strength: "500mg, 850mg, 1000mg; ER: 500mg, 750mg, 1000mg",
    route: "Oral",
    standardDoseAdult: "500-1000mg twice daily with meals",
    standardDosePediatric: "500mg twice daily (ages 10+)",
    maxDailyDose: "2550mg (immediate), 2000mg (extended)",
    dosingFrequency: "Two to three times daily with meals",
    weightBasedDosing: false,
    renalAdjustment: "eGFR 30-45: Max 1000mg/day; eGFR <30: Contraindicated",
    hepaticAdjustment: "Avoid in hepatic impairment",
    contraindications: ["Renal impairment (eGFR <30)", "Metabolic acidosis", "Diabetic ketoacidosis"],
    drugInteractions: ["Iodinated contrast", "Alcohol", "Carbonic anhydrase inhibitors"],
    sideEffects: ["GI upset", "Diarrhea", "Vitamin B12 deficiency", "Lactic acidosis (rare)"],
    blackBoxWarning: "Lactic acidosis is a rare but serious metabolic complication.",
    pregnancyCategory: "B",
    administrationNotes: "Take with meals. Hold before contrast procedures.",
    monitoringParameters: ["A1c", "Renal function", "Vitamin B12"],
    labsRequired: ["A1c", "BMP", "B12"],
    isControlled: false,
    marketStatus: "active",
    regulatoryApprovals: [
      { agency: "FDA", status: "approved", approvalDate: "1994-12-29", brandName: "Glucophage", indications: ["Type 2 Diabetes Mellitus"], riskCategory: "Pregnancy Category B" },
      { agency: "EMA", status: "approved", approvalDate: "1957-01-15", brandName: "Glucophage", indications: ["Type 2 Diabetes", "Pre-diabetes", "PCOS"], restrictions: ["Hold before contrast procedures"] },
      { agency: "PMDA", status: "approved", approvalDate: "1961-03-10", brandName: "Melbin", indications: ["Type 2 Diabetes Mellitus"], riskCategory: "Use with caution in pregnancy" },
      { agency: "NMPA", status: "approved", approvalDate: "1999-05-20", brandName: "格华止", indications: ["Type 2 Diabetes", "Metabolic Syndrome"] },
      { agency: "MFDS", status: "approved", approvalDate: "1998-09-15", brandName: "글루코파지", indications: ["Type 2 Diabetes Mellitus"] }
    ],
    regionalDosing: [
      { region: "USA", adultDose: "500-1000mg twice daily", maxDose: "2550mg/day", notes: "Start 500mg BID; titrate weekly" },
      { region: "EU", adultDose: "500-1000mg two to three times daily", maxDose: "3000mg/day", notes: "Higher max dose in EU" },
      { region: "Japan", adultDose: "250-500mg two to three times daily", maxDose: "2250mg/day", notes: "Lower starting doses recommended" }
    ],
    internationalBrandNames: [
      { region: "Japan", names: ["Melbin", "メルビン", "Glycoran", "グリコラン"] },
      { region: "China", names: ["格华止", "二甲双胍"] },
      { region: "Korea", names: ["글루코파지", "Glucophage"] },
      { region: "Germany", names: ["Siofor", "Glucophage"] },
      { region: "Spain", names: ["Dianben", "Metformina"] }
    ]
  },
  {
    name: "Glipizide",
    genericName: "Glipizide",
    brandNames: ["Glucotrol", "Glucotrol XL"],
    category: "Endocrine - Sulfonylurea",
    form: "Tablet, Extended-release tablet",
    strength: "5mg, 10mg; ER: 2.5mg, 5mg, 10mg",
    route: "Oral",
    standardDoseAdult: "5-10mg once or twice daily",
    maxDailyDose: "40mg",
    dosingFrequency: "Once or twice daily",
    weightBasedDosing: false,
    renalAdjustment: "Start with lower doses in renal impairment",
    hepaticAdjustment: "Reduce dose in hepatic impairment",
    contraindications: ["Type 1 diabetes", "Diabetic ketoacidosis", "Sulfonamide allergy"],
    drugInteractions: ["Beta blockers", "Fluoroquinolones", "Sulfonamides", "Alcohol"],
    sideEffects: ["Hypoglycemia", "Weight gain", "GI upset", "Photosensitivity"],
    pregnancyCategory: "C",
    administrationNotes: "Take 30 minutes before meals. ER: Take with breakfast.",
    monitoringParameters: ["Blood glucose", "A1c", "Signs of hypoglycemia"],
    labsRequired: ["A1c", "Fasting glucose"],
    isControlled: false
  },
  {
    name: "Insulin Glargine",
    genericName: "Insulin Glargine",
    brandNames: ["Lantus", "Basaglar", "Toujeo"],
    category: "Endocrine - Long-acting Insulin",
    form: "Injection",
    strength: "100 units/mL, 300 units/mL (Toujeo)",
    route: "Subcutaneous",
    standardDoseAdult: "10 units once daily, titrate to target",
    standardDosePediatric: "0.2-0.4 units/kg/day",
    maxDailyDose: "Individualized",
    dosingFrequency: "Once daily at same time",
    weightBasedDosing: true,
    weightBasedFormula: "0.2-0.4 units/kg/day starting, adjust to target",
    renalAdjustment: "May need reduced dose in renal impairment",
    hepaticAdjustment: "May need reduced dose in hepatic impairment",
    contraindications: ["Hypoglycemia", "Hypersensitivity to insulin"],
    drugInteractions: ["Beta blockers", "ACE inhibitors", "Thiazolidinediones"],
    sideEffects: ["Hypoglycemia", "Weight gain", "Lipodystrophy", "Injection site reactions"],
    pregnancyCategory: "C",
    administrationNotes: "Inject subcutaneously once daily. Do not mix with other insulins.",
    storageRequirements: "Refrigerate unopened. Room temp up to 28 days after opening.",
    monitoringParameters: ["Blood glucose", "A1c", "Signs of hypoglycemia"],
    labsRequired: ["A1c", "Fasting glucose", "BMP"],
    isControlled: false,
    marketStatus: "active",
    regulatoryApprovals: [
      { agency: "FDA", status: "approved", approvalDate: "2000-04-20", brandName: "Lantus", indications: ["Type 1 Diabetes", "Type 2 Diabetes"], riskCategory: "Pregnancy Category C" },
      { agency: "EMA", status: "approved", approvalDate: "2000-06-09", brandName: "Lantus", indications: ["Type 1 Diabetes", "Type 2 Diabetes"], restrictions: ["Monitor closely during pregnancy"] },
      { agency: "PMDA", status: "approved", approvalDate: "2003-10-16", brandName: "Lantus", indications: ["Diabetes Mellitus requiring insulin"], riskCategory: "Use with caution in pregnancy" },
      { agency: "NMPA", status: "approved", approvalDate: "2004-08-25", brandName: "来得时", indications: ["Type 1 Diabetes", "Type 2 Diabetes"] },
      { agency: "MFDS", status: "approved", approvalDate: "2003-06-20", brandName: "란투스", indications: ["Type 1 Diabetes", "Type 2 Diabetes"] }
    ],
    regionalDosing: [
      { region: "USA", adultDose: "10 units once daily, titrate to target", maxDose: "Individualized", notes: "Titrate by 2 units every 3 days to FBG target" },
      { region: "EU", adultDose: "10 units once daily", maxDose: "Individualized", notes: "Adjust based on fasting glucose" },
      { region: "Japan", adultDose: "4-10 units once daily", maxDose: "Individualized", notes: "Often start lower due to insulin sensitivity" }
    ],
    internationalBrandNames: [
      { region: "Japan", names: ["Lantus", "ランタス"] },
      { region: "China", names: ["来得时", "甘精胰岛素"] },
      { region: "Korea", names: ["란투스", "Lantus"] },
      { region: "Germany", names: ["Lantus", "Toujeo"] },
      { region: "Spain", names: ["Lantus", "Toujeo"] }
    ]
  },
  {
    name: "Insulin Lispro",
    genericName: "Insulin Lispro",
    brandNames: ["Humalog", "Admelog"],
    category: "Endocrine - Rapid-acting Insulin",
    form: "Injection",
    strength: "100 units/mL",
    route: "Subcutaneous, IV",
    standardDoseAdult: "Based on carbohydrate intake and blood glucose",
    standardDosePediatric: "Based on carbohydrate intake and blood glucose",
    maxDailyDose: "Individualized",
    dosingFrequency: "With meals",
    weightBasedDosing: true,
    weightBasedFormula: "Total daily: 0.5-1 unit/kg; meal-time portion varies",
    renalAdjustment: "May need reduced dose in renal impairment",
    hepaticAdjustment: "May need reduced dose in hepatic impairment",
    contraindications: ["Hypoglycemia", "Hypersensitivity to insulin"],
    drugInteractions: ["Beta blockers", "ACE inhibitors", "Thiazolidinediones"],
    sideEffects: ["Hypoglycemia", "Weight gain", "Lipodystrophy", "Injection site reactions"],
    pregnancyCategory: "B",
    administrationNotes: "Inject within 15 minutes before or immediately after meals.",
    storageRequirements: "Refrigerate unopened. Room temp up to 28 days after opening.",
    monitoringParameters: ["Blood glucose", "A1c", "Signs of hypoglycemia"],
    labsRequired: ["A1c", "Pre/post-meal glucose", "BMP"],
    isControlled: false
  },
  {
    name: "Sitagliptin",
    genericName: "Sitagliptin",
    brandNames: ["Januvia"],
    category: "Endocrine - DPP-4 Inhibitor",
    form: "Tablet",
    strength: "25mg, 50mg, 100mg",
    route: "Oral",
    standardDoseAdult: "100mg once daily",
    maxDailyDose: "100mg",
    dosingFrequency: "Once daily",
    weightBasedDosing: false,
    renalAdjustment: "CrCl 30-50: 50mg/day; CrCl <30: 25mg/day",
    hepaticAdjustment: "No adjustment needed",
    contraindications: ["Type 1 diabetes", "Diabetic ketoacidosis"],
    drugInteractions: ["Digoxin", "ACE inhibitors"],
    sideEffects: ["Upper respiratory infection", "Headache", "Pancreatitis (rare)"],
    pregnancyCategory: "B",
    administrationNotes: "May be taken with or without food",
    monitoringParameters: ["A1c", "Renal function", "Signs of pancreatitis"],
    labsRequired: ["A1c", "BMP", "Lipase if symptomatic"],
    isControlled: false
  },
  {
    name: "Empagliflozin",
    genericName: "Empagliflozin",
    brandNames: ["Jardiance"],
    category: "Endocrine - SGLT2 Inhibitor",
    form: "Tablet",
    strength: "10mg, 25mg",
    route: "Oral",
    standardDoseAdult: "10-25mg once daily",
    maxDailyDose: "25mg",
    dosingFrequency: "Once daily in morning",
    weightBasedDosing: false,
    renalAdjustment: "eGFR 30-45: 10mg/day; eGFR <30: Not recommended for glycemic control",
    hepaticAdjustment: "No adjustment needed",
    contraindications: ["Type 1 diabetes", "Diabetic ketoacidosis", "Severe renal impairment for glycemic use"],
    drugInteractions: ["Diuretics", "Insulin", "Sulfonylureas"],
    sideEffects: ["UTI", "Genital mycotic infections", "Volume depletion", "Ketoacidosis"],
    pregnancyCategory: "C",
    administrationNotes: "Take in morning with or without food",
    monitoringParameters: ["A1c", "Renal function", "Blood pressure", "Signs of ketoacidosis"],
    labsRequired: ["A1c", "BMP", "Urinalysis"],
    isControlled: false
  },
  {
    name: "Liraglutide",
    genericName: "Liraglutide",
    brandNames: ["Victoza", "Saxenda"],
    category: "Endocrine - GLP-1 Receptor Agonist",
    form: "Injection",
    strength: "6mg/mL pen",
    route: "Subcutaneous",
    standardDoseAdult: "0.6mg daily x1 week, then 1.2-1.8mg daily",
    maxDailyDose: "1.8mg (Victoza), 3mg (Saxenda)",
    dosingFrequency: "Once daily",
    weightBasedDosing: false,
    renalAdjustment: "Use with caution; no dose adjustment",
    hepaticAdjustment: "Use with caution",
    contraindications: ["Personal/family history of MTC", "MEN 2 syndrome"],
    drugInteractions: ["Insulin", "Sulfonylureas", "Oral medications (delay absorption)"],
    sideEffects: ["Nausea", "Vomiting", "Diarrhea", "Pancreatitis", "Injection site reactions"],
    blackBoxWarning: "Risk of thyroid C-cell tumors in rodents. Unknown relevance to humans.",
    pregnancyCategory: "C",
    administrationNotes: "Inject subcutaneously in abdomen, thigh, or upper arm. Titrate slowly.",
    storageRequirements: "Refrigerate. Room temp for 30 days after first use.",
    monitoringParameters: ["A1c", "Weight", "Signs of pancreatitis", "Thyroid function"],
    labsRequired: ["A1c", "Lipase", "TSH"],
    isControlled: false
  },

  // ANTIBIOTICS
  {
    name: "Amoxicillin",
    genericName: "Amoxicillin",
    brandNames: ["Amoxil", "Trimox"],
    category: "Antibiotic - Penicillin",
    form: "Capsule, Tablet, Suspension",
    strength: "250mg, 500mg, 875mg; Susp: 125mg/5mL, 250mg/5mL",
    route: "Oral",
    standardDoseAdult: "250-500mg every 8 hours or 500-875mg every 12 hours",
    standardDosePediatric: "25-45mg/kg/day divided every 8-12 hours",
    maxDailyDose: "3000mg",
    dosingFrequency: "Every 8-12 hours",
    weightBasedDosing: true,
    weightBasedFormula: "25-45mg/kg/day divided every 8-12 hours",
    renalAdjustment: "CrCl 10-30: Max 500mg q12h; CrCl <10: Max 500mg q24h",
    hepaticAdjustment: "No adjustment needed",
    contraindications: ["Penicillin allergy", "History of amoxicillin-related hepatic dysfunction"],
    drugInteractions: ["Probenecid", "Methotrexate", "Warfarin"],
    sideEffects: ["Diarrhea", "Nausea", "Rash", "Allergic reactions"],
    pregnancyCategory: "B",
    administrationNotes: "May be taken with or without food",
    monitoringParameters: ["Signs of allergic reaction", "Renal function with prolonged use"],
    labsRequired: ["BMP with prolonged use"],
    isControlled: false
  },
  {
    name: "Amoxicillin-Clavulanate",
    genericName: "Amoxicillin-Clavulanate",
    brandNames: ["Augmentin", "Augmentin ES"],
    category: "Antibiotic - Penicillin/Beta-lactamase Inhibitor",
    form: "Tablet, Suspension",
    strength: "250/125mg, 500/125mg, 875/125mg; XR: 1000/62.5mg",
    route: "Oral",
    standardDoseAdult: "500mg every 8 hours or 875mg every 12 hours",
    standardDosePediatric: "25-45mg/kg/day (amoxicillin component) divided every 8-12 hours",
    maxDailyDose: "4000mg amoxicillin",
    dosingFrequency: "Every 8-12 hours",
    weightBasedDosing: true,
    weightBasedFormula: "25-45mg/kg/day amoxicillin component",
    renalAdjustment: "CrCl <30: Do not use 875mg tablet; reduce dose",
    hepaticAdjustment: "Monitor LFTs; may cause cholestatic hepatitis",
    contraindications: ["Penicillin allergy", "Previous cholestatic jaundice/hepatic dysfunction"],
    drugInteractions: ["Probenecid", "Methotrexate", "Warfarin", "Oral contraceptives"],
    sideEffects: ["Diarrhea", "Nausea", "Vomiting", "Rash", "Hepatotoxicity"],
    pregnancyCategory: "B",
    administrationNotes: "Take with food to reduce GI upset. XR: Take with meal.",
    monitoringParameters: ["LFTs with prolonged use", "Signs of allergic reaction"],
    labsRequired: ["LFTs", "CBC"],
    isControlled: false
  },
  {
    name: "Azithromycin",
    genericName: "Azithromycin",
    brandNames: ["Zithromax", "Z-Pak"],
    category: "Antibiotic - Macrolide",
    form: "Tablet, Suspension, Injection",
    strength: "250mg, 500mg, 600mg; Susp: 100mg/5mL, 200mg/5mL; IV: 500mg",
    route: "Oral, IV",
    standardDoseAdult: "500mg day 1, then 250mg days 2-5; or 500mg daily x 3 days",
    standardDosePediatric: "10mg/kg day 1, then 5mg/kg days 2-5",
    maxDailyDose: "500mg",
    dosingFrequency: "Once daily",
    weightBasedDosing: true,
    weightBasedFormula: "10mg/kg day 1, then 5mg/kg days 2-5",
    renalAdjustment: "No adjustment needed",
    hepaticAdjustment: "Use with caution in hepatic impairment",
    contraindications: ["Macrolide allergy", "History of cholestatic jaundice with azithromycin"],
    drugInteractions: ["QT-prolonging drugs", "Warfarin", "Digoxin", "Cyclosporine"],
    sideEffects: ["Diarrhea", "Nausea", "Abdominal pain", "QT prolongation", "Hepatotoxicity"],
    pregnancyCategory: "B",
    administrationNotes: "May take with or without food. Complete full course.",
    monitoringParameters: ["ECG if risk factors", "LFTs with prolonged use"],
    labsRequired: ["LFTs if symptomatic"],
    isControlled: false
  },
  {
    name: "Ciprofloxacin",
    genericName: "Ciprofloxacin",
    brandNames: ["Cipro", "Cipro XR"],
    category: "Antibiotic - Fluoroquinolone",
    form: "Tablet, Suspension, Injection",
    strength: "250mg, 500mg, 750mg; XR: 500mg, 1000mg; IV: 200mg/100mL, 400mg/200mL",
    route: "Oral, IV",
    standardDoseAdult: "250-750mg every 12 hours (oral); 200-400mg every 8-12 hours (IV)",
    standardDosePediatric: "10-20mg/kg/day divided every 12 hours (limited use)",
    maxDailyDose: "1500mg oral, 1200mg IV",
    dosingFrequency: "Every 12 hours",
    weightBasedDosing: true,
    weightBasedFormula: "10-20mg/kg/day divided every 12 hours",
    renalAdjustment: "CrCl 30-50: Reduce dose; CrCl <30: Give every 18-24 hours",
    hepaticAdjustment: "No adjustment needed",
    contraindications: ["Fluoroquinolone allergy", "Tendon disorders", "Myasthenia gravis", "Children <18 years (relative)"],
    drugInteractions: ["Theophylline", "Warfarin", "Antacids", "Sucralfate", "Tizanidine"],
    sideEffects: ["Nausea", "Diarrhea", "Tendinitis/rupture", "QT prolongation", "CNS effects"],
    blackBoxWarning: "Risk of tendinitis and tendon rupture. Risk of peripheral neuropathy. May exacerbate myasthenia gravis.",
    pregnancyCategory: "C",
    administrationNotes: "Take 2 hours before or 6 hours after antacids/minerals. Hydrate well.",
    monitoringParameters: ["Tendon pain", "QT interval if risk factors", "Renal function"],
    labsRequired: ["BMP", "ECG if risk factors"],
    isControlled: false
  },
  {
    name: "Levofloxacin",
    genericName: "Levofloxacin",
    brandNames: ["Levaquin"],
    category: "Antibiotic - Fluoroquinolone",
    form: "Tablet, Injection",
    strength: "250mg, 500mg, 750mg; IV: 500mg/100mL, 750mg/150mL",
    route: "Oral, IV",
    standardDoseAdult: "250-750mg once daily",
    maxDailyDose: "750mg",
    dosingFrequency: "Once daily",
    weightBasedDosing: false,
    renalAdjustment: "CrCl 20-49: Adjust dose; CrCl <20: 500mg then 250mg q48h",
    hepaticAdjustment: "No adjustment needed",
    contraindications: ["Fluoroquinolone allergy", "Tendon disorders", "Myasthenia gravis"],
    drugInteractions: ["Warfarin", "Antacids", "NSAIDs", "Corticosteroids", "QT-prolonging drugs"],
    sideEffects: ["Nausea", "Diarrhea", "Headache", "Tendinitis/rupture", "QT prolongation"],
    blackBoxWarning: "Risk of tendinitis and tendon rupture. Risk of peripheral neuropathy.",
    pregnancyCategory: "C",
    administrationNotes: "Take 2 hours before or 2 hours after antacids. Oral bioavailability equals IV.",
    monitoringParameters: ["Tendon pain", "QT interval if risk factors", "Blood glucose"],
    labsRequired: ["BMP", "Blood glucose"],
    isControlled: false
  },
  {
    name: "Doxycycline",
    genericName: "Doxycycline",
    brandNames: ["Vibramycin", "Doryx", "Oracea"],
    category: "Antibiotic - Tetracycline",
    form: "Capsule, Tablet, Suspension",
    strength: "50mg, 100mg; DR: 40mg, 50mg, 150mg",
    route: "Oral, IV",
    standardDoseAdult: "100mg every 12 hours or 200mg once daily",
    standardDosePediatric: "2.2mg/kg every 12 hours (>8 years old)",
    maxDailyDose: "200mg",
    dosingFrequency: "Once or twice daily",
    weightBasedDosing: true,
    weightBasedFormula: "2.2mg/kg every 12 hours, max 100mg/dose",
    renalAdjustment: "No adjustment needed",
    hepaticAdjustment: "Use with caution",
    contraindications: ["Tetracycline allergy", "Children <8 years (dental staining)", "Pregnancy"],
    drugInteractions: ["Antacids", "Iron", "Warfarin", "Oral contraceptives", "Barbiturates"],
    sideEffects: ["Photosensitivity", "GI upset", "Esophageal ulceration", "Dental discoloration"],
    pregnancyCategory: "D",
    administrationNotes: "Take with full glass of water. Remain upright 30 minutes after. Avoid sun.",
    monitoringParameters: ["Signs of photosensitivity", "GI tolerability"],
    labsRequired: ["None routinely"],
    isControlled: false
  },
  {
    name: "Cephalexin",
    genericName: "Cephalexin",
    brandNames: ["Keflex"],
    category: "Antibiotic - Cephalosporin (1st gen)",
    form: "Capsule, Tablet, Suspension",
    strength: "250mg, 500mg, 750mg; Susp: 125mg/5mL, 250mg/5mL",
    route: "Oral",
    standardDoseAdult: "250-500mg every 6 hours",
    standardDosePediatric: "25-50mg/kg/day divided every 6-8 hours",
    maxDailyDose: "4000mg",
    dosingFrequency: "Every 6-12 hours",
    weightBasedDosing: true,
    weightBasedFormula: "25-50mg/kg/day divided every 6-8 hours",
    renalAdjustment: "CrCl 10-50: q8-12h; CrCl <10: q12-24h",
    hepaticAdjustment: "No adjustment needed",
    contraindications: ["Cephalosporin allergy", "Severe penicillin allergy (10% cross-reactivity)"],
    drugInteractions: ["Probenecid", "Metformin", "Warfarin"],
    sideEffects: ["Diarrhea", "Nausea", "Rash", "Allergic reactions"],
    pregnancyCategory: "B",
    administrationNotes: "May be taken with or without food",
    monitoringParameters: ["Signs of allergic reaction", "Diarrhea"],
    labsRequired: ["None routinely"],
    isControlled: false
  },
  {
    name: "Ceftriaxone",
    genericName: "Ceftriaxone",
    brandNames: ["Rocephin"],
    category: "Antibiotic - Cephalosporin (3rd gen)",
    form: "Injection",
    strength: "250mg, 500mg, 1g, 2g vials",
    route: "IV, IM",
    standardDoseAdult: "1-2g every 12-24 hours",
    standardDosePediatric: "50-100mg/kg/day divided every 12-24 hours",
    maxDailyDose: "4g",
    dosingFrequency: "Every 12-24 hours",
    weightBasedDosing: true,
    weightBasedFormula: "50-100mg/kg/day, max 4g/day",
    renalAdjustment: "No adjustment for renal impairment alone",
    hepaticAdjustment: "Max 2g/day in combined hepatic/renal impairment",
    contraindications: ["Cephalosporin allergy", "Neonates with hyperbilirubinemia", "Calcium-containing IV solutions in neonates"],
    drugInteractions: ["Calcium-containing products", "Warfarin"],
    sideEffects: ["Diarrhea", "Rash", "Biliary sludging", "Allergic reactions"],
    pregnancyCategory: "B",
    administrationNotes: "IV: Infuse over 30 minutes. Do not mix with calcium in same line.",
    monitoringParameters: ["Signs of allergic reaction", "LFTs with prolonged use"],
    labsRequired: ["LFTs", "CBC"],
    isControlled: false
  },
  {
    name: "Vancomycin",
    genericName: "Vancomycin",
    brandNames: ["Vancocin"],
    category: "Antibiotic - Glycopeptide",
    form: "Injection, Capsule (oral for C. diff)",
    strength: "IV: 500mg, 750mg, 1g, 1.5g vials; Oral: 125mg, 250mg capsules",
    route: "IV, Oral (C. diff only)",
    standardDoseAdult: "IV: 15-20mg/kg every 8-12 hours; Oral: 125mg every 6 hours",
    standardDosePediatric: "IV: 15mg/kg every 6 hours",
    maxDailyDose: "4g IV",
    dosingFrequency: "Every 6-12 hours",
    weightBasedDosing: true,
    weightBasedFormula: "15-20mg/kg/dose every 8-12 hours",
    renalAdjustment: "Significant adjustment needed based on CrCl",
    hepaticAdjustment: "No adjustment needed",
    contraindications: ["Vancomycin allergy"],
    drugInteractions: ["Aminoglycosides", "NSAIDs", "Other nephrotoxic drugs"],
    sideEffects: ["Red man syndrome", "Nephrotoxicity", "Ototoxicity", "Phlebitis"],
    pregnancyCategory: "C",
    administrationNotes: "IV: Infuse over at least 60 minutes. Monitor levels.",
    monitoringParameters: ["Vancomycin levels (trough)", "Renal function", "CBC"],
    labsRequired: ["Vancomycin trough", "BMP", "CBC"],
    isControlled: false
  },
  {
    name: "Trimethoprim-Sulfamethoxazole",
    genericName: "Trimethoprim-Sulfamethoxazole",
    brandNames: ["Bactrim", "Bactrim DS", "Septra"],
    category: "Antibiotic - Sulfonamide",
    form: "Tablet, Suspension",
    strength: "SS: 80/400mg, DS: 160/800mg; Susp: 40/200mg per 5mL",
    route: "Oral, IV",
    standardDoseAdult: "DS 1 tablet every 12 hours; or 8-20mg/kg/day TMP divided",
    standardDosePediatric: "8-12mg/kg/day TMP divided every 12 hours",
    maxDailyDose: "320mg TMP/day (typical); higher for PCP",
    dosingFrequency: "Every 12 hours",
    weightBasedDosing: true,
    weightBasedFormula: "8-12mg/kg/day TMP component divided every 12 hours",
    renalAdjustment: "CrCl 15-30: 50% dose; CrCl <15: Avoid",
    hepaticAdjustment: "Use with caution",
    contraindications: ["Sulfonamide allergy", "Megaloblastic anemia", "G6PD deficiency", "Pregnancy at term"],
    drugInteractions: ["Warfarin", "Methotrexate", "Phenytoin", "ACE inhibitors"],
    sideEffects: ["Rash", "Nausea", "Hyperkalemia", "Bone marrow suppression", "Steven-Johnson syndrome"],
    pregnancyCategory: "D",
    administrationNotes: "Take with full glass of water. Maintain adequate hydration.",
    monitoringParameters: ["Potassium", "Renal function", "CBC", "Rash"],
    labsRequired: ["BMP", "CBC"],
    isControlled: false
  },

  // PAIN MEDICATIONS
  {
    name: "Acetaminophen",
    genericName: "Acetaminophen",
    brandNames: ["Tylenol", "Panadol"],
    category: "Analgesic/Antipyretic",
    form: "Tablet, Capsule, Liquid, Suppository",
    strength: "325mg, 500mg, 650mg; Liquid: 160mg/5mL; IV: 1000mg/100mL",
    route: "Oral, Rectal, IV",
    standardDoseAdult: "325-1000mg every 4-6 hours",
    standardDosePediatric: "10-15mg/kg every 4-6 hours",
    maxDailyDose: "4000mg (3000mg if liver disease or alcohol use)",
    dosingFrequency: "Every 4-6 hours as needed",
    weightBasedDosing: true,
    weightBasedFormula: "10-15mg/kg/dose, max 75mg/kg/day",
    renalAdjustment: "CrCl <10: Extend interval to every 8 hours",
    hepaticAdjustment: "Reduce dose; max 2g/day in chronic liver disease",
    contraindications: ["Severe hepatic impairment", "Acetaminophen allergy"],
    drugInteractions: ["Warfarin", "Alcohol", "Isoniazid", "Other hepatotoxic drugs"],
    sideEffects: ["Hepatotoxicity (overdose)", "Allergic reactions (rare)"],
    blackBoxWarning: "Contains acetaminophen. Severe liver damage may occur if more than 4g/day taken.",
    pregnancyCategory: "B",
    administrationNotes: "Check all medications for acetaminophen content to avoid overdose",
    monitoringParameters: ["LFTs with chronic use", "Signs of hepatotoxicity"],
    labsRequired: ["LFTs if prolonged use"],
    isControlled: false
  },
  {
    name: "Ibuprofen",
    genericName: "Ibuprofen",
    brandNames: ["Advil", "Motrin"],
    category: "Analgesic - NSAID",
    form: "Tablet, Capsule, Suspension",
    strength: "200mg, 400mg, 600mg, 800mg; Susp: 100mg/5mL",
    route: "Oral, IV",
    standardDoseAdult: "200-800mg every 6-8 hours",
    standardDosePediatric: "5-10mg/kg every 6-8 hours",
    maxDailyDose: "3200mg (Rx); 1200mg (OTC)",
    dosingFrequency: "Every 6-8 hours",
    weightBasedDosing: true,
    weightBasedFormula: "5-10mg/kg/dose every 6-8 hours",
    renalAdjustment: "Avoid in severe renal impairment",
    hepaticAdjustment: "Use with caution",
    contraindications: ["NSAID allergy", "Active GI bleeding", "Severe renal impairment", "CABG surgery"],
    drugInteractions: ["Aspirin", "Anticoagulants", "ACE inhibitors", "Diuretics", "Lithium"],
    sideEffects: ["GI upset", "GI bleeding", "Renal impairment", "Hypertension", "Cardiovascular events"],
    blackBoxWarning: "NSAIDs cause increased risk of serious cardiovascular and GI events.",
    pregnancyCategory: "C (D in 3rd trimester)",
    administrationNotes: "Take with food or milk to reduce GI upset",
    monitoringParameters: ["Renal function", "Blood pressure", "Signs of GI bleeding"],
    labsRequired: ["BMP with prolonged use"],
    isControlled: false
  },
  {
    name: "Naproxen",
    genericName: "Naproxen",
    brandNames: ["Aleve", "Naprosyn", "Anaprox"],
    category: "Analgesic - NSAID",
    form: "Tablet, Suspension",
    strength: "220mg, 250mg, 375mg, 500mg; DR: 375mg, 500mg",
    route: "Oral",
    standardDoseAdult: "250-500mg every 12 hours",
    standardDosePediatric: "5-7mg/kg every 8-12 hours",
    maxDailyDose: "1500mg initially, then 1000mg",
    dosingFrequency: "Every 8-12 hours",
    weightBasedDosing: true,
    weightBasedFormula: "5-7mg/kg/dose every 8-12 hours",
    renalAdjustment: "Avoid if CrCl <30",
    hepaticAdjustment: "Use with caution",
    contraindications: ["NSAID allergy", "Active GI bleeding", "Severe renal impairment", "CABG surgery"],
    drugInteractions: ["Aspirin", "Anticoagulants", "ACE inhibitors", "Diuretics", "Methotrexate"],
    sideEffects: ["GI upset", "GI bleeding", "Edema", "Dizziness", "Cardiovascular events"],
    blackBoxWarning: "NSAIDs cause increased risk of serious cardiovascular and GI events.",
    pregnancyCategory: "C (D in 3rd trimester)",
    administrationNotes: "Take with food or milk. DR tablets: swallow whole.",
    monitoringParameters: ["Renal function", "Blood pressure", "Signs of GI bleeding"],
    labsRequired: ["BMP with prolonged use"],
    isControlled: false
  },
  {
    name: "Oxycodone",
    genericName: "Oxycodone",
    brandNames: ["OxyContin", "Roxicodone"],
    category: "Analgesic - Opioid",
    form: "Tablet, Capsule, Solution, Extended-release tablet",
    strength: "5mg, 10mg, 15mg, 20mg, 30mg; ER: 10mg-80mg",
    route: "Oral",
    standardDoseAdult: "IR: 5-15mg every 4-6 hours; ER: Per opioid tolerance",
    maxDailyDose: "No ceiling, but titrate carefully",
    dosingFrequency: "IR: Every 4-6 hours; ER: Every 12 hours",
    weightBasedDosing: false,
    renalAdjustment: "Start with 25-50% of normal dose",
    hepaticAdjustment: "Start with 33-50% of normal dose",
    contraindications: ["Opioid allergy", "Respiratory depression", "Paralytic ileus", "MAOIs within 14 days"],
    drugInteractions: ["CNS depressants", "Benzodiazepines", "CYP3A4 inhibitors", "MAOIs"],
    sideEffects: ["Constipation", "Nausea", "Sedation", "Respiratory depression", "Physical dependence"],
    blackBoxWarning: "Risk of addiction, abuse, and misuse. Risk of life-threatening respiratory depression. Concomitant use with benzodiazepines may result in death.",
    pregnancyCategory: "C (D with prolonged use)",
    administrationNotes: "ER: Swallow whole, do not crush, chew, or dissolve. Use stool softeners.",
    monitoringParameters: ["Pain level", "Respiratory status", "Sedation level", "Bowel function"],
    labsRequired: ["Consider baseline LFTs"],
    isControlled: true,
    controlledSchedule: "Schedule II"
  },
  {
    name: "Hydrocodone/Acetaminophen",
    genericName: "Hydrocodone Bitartrate/Acetaminophen",
    brandNames: ["Vicodin", "Norco", "Lortab"],
    category: "Analgesic - Opioid Combination",
    form: "Tablet, Solution",
    strength: "5mg/325mg, 7.5mg/325mg, 10mg/325mg",
    route: "Oral",
    standardDoseAdult: "5-10mg hydrocodone every 4-6 hours as needed",
    standardDosePediatric: "Not recommended for pediatric use",
    maxDailyDose: "Maximum 4g acetaminophen/day",
    dosingFrequency: "Every 4-6 hours as needed",
    weightBasedDosing: false,
    renalAdjustment: "Use with caution; reduce dose in severe impairment",
    hepaticAdjustment: "Avoid or reduce dose; acetaminophen hepatotoxicity risk",
    contraindications: ["Opioid allergy", "Acetaminophen allergy", "Respiratory depression", "Severe hepatic impairment", "MAOIs within 14 days"],
    drugInteractions: ["CNS depressants", "Benzodiazepines", "Alcohol", "CYP3A4 inhibitors", "MAOIs", "Other acetaminophen products"],
    sideEffects: ["Constipation", "Nausea", "Sedation", "Dizziness", "Respiratory depression", "Hepatotoxicity"],
    blackBoxWarning: "Risk of addiction, abuse, and misuse. Risk of life-threatening respiratory depression. Acetaminophen has been associated with acute liver failure, at times resulting in liver transplant and death.",
    pregnancyCategory: "C (D with prolonged use)",
    administrationNotes: "Take with or without food. Monitor total acetaminophen intake from all sources. Use stool softeners.",
    monitoringParameters: ["Pain level", "Respiratory status", "Liver function", "Total acetaminophen intake"],
    labsRequired: ["LFTs periodically"],
    isControlled: true,
    controlledSchedule: "Schedule II",
    marketStatus: "active",
    regulatoryApprovals: [
      { agency: "FDA", status: "approved", approvalDate: "1983-02-14", brandName: "Vicodin", indications: ["Moderate to Moderately Severe Pain"], riskCategory: "Pregnancy Category C/D", additionalWarnings: ["Maximum 4g acetaminophen/day", "High abuse potential"] },
      { agency: "EMA", status: "restricted", approvalDate: "1990-06-20", brandName: "Not widely marketed", indications: ["Pain Management"], restrictions: ["Limited availability in EU due to opioid combination concerns"] },
      { agency: "PMDA", status: "approved", approvalDate: "2011-01-21", brandName: "Norspan", indications: ["Moderate to Severe Pain"], riskCategory: "Narcotics control", additionalWarnings: ["Strict dispensing regulations"] },
      { agency: "NMPA", status: "restricted", approvalDate: "2005-08-15", brandName: "氢可酮/对乙酰氨基酚", indications: ["Severe Pain"], restrictions: ["Limited to hospital use"] },
      { agency: "MFDS", status: "restricted", approvalDate: "2008-03-10", brandName: "하이드로코돈/아세트아미노펜", indications: ["Moderate to Severe Pain"], restrictions: ["Controlled distribution"] }
    ],
    regionalDosing: [
      { region: "USA", adultDose: "5-10mg hydrocodone q4-6h", maxDose: "Max 4g acetaminophen/day", notes: "Most commonly prescribed opioid in US; watch acetaminophen limits" },
      { region: "EU", adultDose: "Not widely used", maxDose: "Alternative opioids preferred", notes: "Combination not commonly marketed in EU" },
      { region: "Japan", adultDose: "2.5-5mg hydrocodone equivalent q6h", maxDose: "Strict limits", notes: "Lower doses; strict narcotic controls" }
    ],
    internationalBrandNames: [
      { region: "Japan", names: ["ノルスパン", "Norspan"] },
      { region: "China", names: ["氢可酮/对乙酰氨基酚", "复方氢可酮"] },
      { region: "Korea", names: ["하이드로코돈정", "Hydrocodone"] },
      { region: "Germany", names: ["Hydrocodon", "Dihydrocodein"] },
      { region: "USA", names: ["Vicodin", "Norco", "Lortab"] }
    ],
    riskEvaluationProgram: "FDA opioid REMS required"
  },
  {
    name: "Morphine",
    genericName: "Morphine Sulfate",
    brandNames: ["MS Contin", "Kadian", "Roxanol"],
    category: "Analgesic - Opioid",
    form: "Tablet, Capsule, Solution, Extended-release, Injection",
    strength: "IR: 15mg, 30mg; ER: 15mg-200mg; IV: 2-15mg/mL",
    route: "Oral, IV, IM, SC, Epidural",
    standardDoseAdult: "IR: 10-30mg every 4 hours; IV: 2-10mg every 2-4 hours",
    standardDosePediatric: "0.1-0.2mg/kg every 4 hours",
    maxDailyDose: "No ceiling, but titrate carefully",
    dosingFrequency: "IR: Every 4 hours; ER: Every 8-12 or 24 hours",
    weightBasedDosing: true,
    weightBasedFormula: "0.1-0.2mg/kg/dose",
    renalAdjustment: "Reduce dose 25-75% based on CrCl",
    hepaticAdjustment: "Reduce dose significantly",
    contraindications: ["Opioid allergy", "Respiratory depression", "Paralytic ileus", "MAOIs within 14 days"],
    drugInteractions: ["CNS depressants", "Benzodiazepines", "MAOIs", "Anticholinergics"],
    sideEffects: ["Constipation", "Nausea", "Sedation", "Respiratory depression", "Hypotension", "Urinary retention"],
    blackBoxWarning: "Risk of addiction, abuse, and misuse. Risk of life-threatening respiratory depression.",
    pregnancyCategory: "C (D with prolonged use)",
    administrationNotes: "ER formulations should not be crushed. IV: Give slowly.",
    monitoringParameters: ["Pain level", "Respiratory status", "Blood pressure", "Bowel function"],
    labsRequired: ["None routinely"],
    isControlled: true,
    controlledSchedule: "Schedule II",
    marketStatus: "active",
    regulatoryApprovals: [
      { agency: "FDA", status: "approved", approvalDate: "1941-05-01", brandName: "Morphine Sulfate", indications: ["Severe Pain", "Post-surgical Pain", "Cancer Pain"], riskCategory: "Pregnancy Category C/D", additionalWarnings: ["REMS required", "High abuse potential"] },
      { agency: "EMA", status: "approved", approvalDate: "1950-01-15", brandName: "MST Continus", indications: ["Severe Pain", "Cancer Pain", "Palliative Care"], restrictions: ["Controlled substance", "Prescription monitoring required"] },
      { agency: "PMDA", status: "approved", approvalDate: "1952-08-20", brandName: "MS Contin", indications: ["Severe Pain", "Cancer Pain"], riskCategory: "Narcotics control", additionalWarnings: ["Strict dispensing regulations"] },
      { agency: "NMPA", status: "approved", approvalDate: "1985-06-10", brandName: "吗啡", indications: ["Severe Pain", "Cancer Pain"] },
      { agency: "MFDS", status: "approved", approvalDate: "1975-03-25", brandName: "모르핀", indications: ["Severe Pain", "Cancer Pain", "Post-surgical Pain"] }
    ],
    regionalDosing: [
      { region: "USA", adultDose: "IR: 10-30mg q4h; IV: 2-10mg q2-4h", maxDose: "No ceiling, titrate carefully", notes: "Opioid-naive: start low" },
      { region: "EU", adultDose: "IR: 5-20mg q4h", maxDose: "Individualized", notes: "Lower starting doses recommended" },
      { region: "Japan", adultDose: "IR: 5-10mg q4-6h", maxDose: "Individualized", notes: "Lower doses due to body weight; strict regulations" }
    ],
    internationalBrandNames: [
      { region: "Japan", names: ["MS Contin", "MSコンチン", "Optiso", "オプソ"] },
      { region: "China", names: ["吗啡", "美施康定"] },
      { region: "Korea", names: ["모르핀", "MS Contin"] },
      { region: "Germany", names: ["MST", "Capros"] },
      { region: "Spain", names: ["Sevredol", "MST Continus"] }
    ],
    riskEvaluationProgram: "FDA REMS required for extended-release formulations"
  },
  {
    name: "Gabapentin",
    genericName: "Gabapentin",
    brandNames: ["Neurontin", "Gralise"],
    category: "Analgesic - Anticonvulsant",
    form: "Capsule, Tablet, Solution",
    strength: "100mg, 300mg, 400mg, 600mg, 800mg",
    route: "Oral",
    standardDoseAdult: "300mg TID, titrate to 1800-3600mg/day",
    standardDosePediatric: "10-15mg/kg/day divided TID",
    maxDailyDose: "3600mg",
    dosingFrequency: "Three times daily",
    weightBasedDosing: true,
    weightBasedFormula: "10-15mg/kg/day divided TID",
    renalAdjustment: "CrCl 30-59: Max 1400mg/day; CrCl 15-29: Max 700mg/day; CrCl <15: Max 300mg/day",
    hepaticAdjustment: "No adjustment needed",
    contraindications: ["Hypersensitivity to gabapentin"],
    drugInteractions: ["Antacids", "Opioids", "CNS depressants"],
    sideEffects: ["Dizziness", "Somnolence", "Peripheral edema", "Ataxia", "Weight gain"],
    blackBoxWarning: "Increased risk of suicidal thoughts or behavior.",
    pregnancyCategory: "C",
    administrationNotes: "May be taken with or without food. Taper to discontinue.",
    monitoringParameters: ["Pain level", "Mood/suicidal ideation", "Renal function"],
    labsRequired: ["BMP"],
    isControlled: false,
    marketStatus: "active",
    regulatoryApprovals: [
      { agency: "FDA", status: "approved", approvalDate: "1993-12-30", brandName: "Neurontin", indications: ["Epilepsy", "Postherpetic Neuralgia"], riskCategory: "Pregnancy Category C" },
      { agency: "EMA", status: "approved", approvalDate: "1995-05-26", brandName: "Neurontin", indications: ["Epilepsy", "Peripheral Neuropathic Pain"], restrictions: ["Monitor for suicidal ideation"] },
      { agency: "PMDA", status: "approved", approvalDate: "2006-07-21", brandName: "Gabapen", indications: ["Epilepsy", "Neuropathic Pain"], riskCategory: "Use with caution in pregnancy" },
      { agency: "NMPA", status: "approved", approvalDate: "1999-10-15", brandName: "加巴喷丁", indications: ["Epilepsy", "Neuropathic Pain"] },
      { agency: "MFDS", status: "approved", approvalDate: "1998-04-20", brandName: "뉴론틴", indications: ["Epilepsy", "Neuropathic Pain", "Postherpetic Neuralgia"] }
    ],
    regionalDosing: [
      { region: "USA", adultDose: "300mg TID, titrate to 1800-3600mg/day", maxDose: "3600mg/day", notes: "Start 300mg on day 1, titrate up" },
      { region: "EU", adultDose: "300-600mg TID", maxDose: "3600mg/day", notes: "Titrate over 3 days minimum" },
      { region: "Japan", adultDose: "200-400mg TID", maxDose: "2400mg/day", notes: "Lower max doses typically used" }
    ],
    internationalBrandNames: [
      { region: "Japan", names: ["Gabapen", "ガバペン"] },
      { region: "China", names: ["加巴喷丁", "诺必达"] },
      { region: "Korea", names: ["뉴론틴", "Neurontin"] },
      { region: "Germany", names: ["Neurontin", "Gabapentin"] },
      { region: "Spain", names: ["Neurontin", "Gabapentina"] }
    ]
  },
  {
    name: "Pregabalin",
    genericName: "Pregabalin",
    brandNames: ["Lyrica"],
    category: "Analgesic - Anticonvulsant",
    form: "Capsule, Solution",
    strength: "25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg, 300mg",
    route: "Oral",
    standardDoseAdult: "150-600mg/day divided BID-TID",
    maxDailyDose: "600mg",
    dosingFrequency: "Two to three times daily",
    weightBasedDosing: false,
    renalAdjustment: "CrCl 30-60: Max 300mg/day; CrCl 15-30: Max 150mg/day; CrCl <15: Max 75mg/day",
    hepaticAdjustment: "No adjustment needed",
    contraindications: ["Hypersensitivity to pregabalin"],
    drugInteractions: ["Opioids", "CNS depressants", "ACE inhibitors", "Thiazolidinediones"],
    sideEffects: ["Dizziness", "Somnolence", "Weight gain", "Peripheral edema", "Blurred vision"],
    blackBoxWarning: "Increased risk of suicidal thoughts or behavior.",
    pregnancyCategory: "C",
    administrationNotes: "May be taken with or without food. Taper to discontinue.",
    monitoringParameters: ["Pain level", "Mood/suicidal ideation", "Renal function", "Weight"],
    labsRequired: ["BMP", "CPK if muscle symptoms"],
    isControlled: true,
    controlledSchedule: "Schedule V"
  },

  // RESPIRATORY MEDICATIONS
  {
    name: "Albuterol",
    genericName: "Albuterol Sulfate",
    brandNames: ["ProAir", "Ventolin", "Proventil"],
    category: "Respiratory - Beta-2 Agonist",
    form: "MDI, Nebulizer solution, Tablet",
    strength: "MDI: 90mcg/puff; Neb: 0.083%, 0.5%; Tab: 2mg, 4mg",
    route: "Inhalation, Oral",
    standardDoseAdult: "MDI: 2 puffs every 4-6 hours; Neb: 2.5mg every 4-6 hours",
    standardDosePediatric: "MDI: 1-2 puffs every 4-6 hours; Neb: 0.1-0.15mg/kg every 4-6 hours",
    maxDailyDose: "MDI: 12 puffs/day; Neb: 15mg",
    dosingFrequency: "Every 4-6 hours as needed",
    weightBasedDosing: true,
    weightBasedFormula: "0.1-0.15mg/kg/dose nebulized",
    renalAdjustment: "No adjustment needed",
    hepaticAdjustment: "No adjustment needed",
    contraindications: ["Hypersensitivity to albuterol or milk proteins"],
    drugInteractions: ["Beta blockers", "MAOIs", "TCAs", "Digoxin"],
    sideEffects: ["Tachycardia", "Tremor", "Palpitations", "Nervousness", "Hypokalemia"],
    pregnancyCategory: "C",
    administrationNotes: "Shake MDI well before use. Rinse mouth after use.",
    monitoringParameters: ["Heart rate", "Respiratory status", "Potassium"],
    labsRequired: ["Potassium with frequent use"],
    isControlled: false
  },
  {
    name: "Fluticasone Propionate",
    genericName: "Fluticasone Propionate",
    brandNames: ["Flovent HFA", "Flovent Diskus"],
    category: "Respiratory - Inhaled Corticosteroid",
    form: "MDI, Diskus",
    strength: "HFA: 44mcg, 110mcg, 220mcg; Diskus: 50mcg, 100mcg, 250mcg",
    route: "Inhalation",
    standardDoseAdult: "88-440mcg twice daily",
    standardDosePediatric: "88-176mcg twice daily (ages 4-11)",
    maxDailyDose: "880mcg",
    dosingFrequency: "Twice daily",
    weightBasedDosing: false,
    renalAdjustment: "No adjustment needed",
    hepaticAdjustment: "Use with caution",
    contraindications: ["Primary treatment of status asthmaticus", "Hypersensitivity to fluticasone"],
    drugInteractions: ["Ritonavir", "Ketoconazole", "Other CYP3A4 inhibitors"],
    sideEffects: ["Oral candidiasis", "Hoarseness", "Pharyngitis", "Headache"],
    pregnancyCategory: "C",
    administrationNotes: "Rinse mouth after use. Not for acute bronchospasm.",
    monitoringParameters: ["Peak flow", "Symptom control", "Growth in children"],
    labsRequired: ["None routinely"],
    isControlled: false
  },
  {
    name: "Montelukast",
    genericName: "Montelukast Sodium",
    brandNames: ["Singulair"],
    category: "Respiratory - Leukotriene Receptor Antagonist",
    form: "Tablet, Chewable tablet, Granules",
    strength: "10mg, Chewable: 4mg, 5mg; Granules: 4mg",
    route: "Oral",
    standardDoseAdult: "10mg once daily in evening",
    standardDosePediatric: "4mg (2-5 years), 5mg (6-14 years) once daily in evening",
    maxDailyDose: "10mg",
    dosingFrequency: "Once daily in evening",
    weightBasedDosing: false,
    renalAdjustment: "No adjustment needed",
    hepaticAdjustment: "No adjustment needed for mild-moderate",
    contraindications: ["Hypersensitivity to montelukast"],
    drugInteractions: ["Phenobarbital", "Rifampin"],
    sideEffects: ["Headache", "Abdominal pain", "Behavioral changes", "Upper respiratory infection"],
    blackBoxWarning: "Serious neuropsychiatric events reported including suicidal thinking and behavior.",
    pregnancyCategory: "B",
    administrationNotes: "Take in evening. Granules can be mixed with food.",
    monitoringParameters: ["Asthma symptoms", "Neuropsychiatric symptoms"],
    labsRequired: ["None routinely"],
    isControlled: false
  },
  {
    name: "Prednisone",
    genericName: "Prednisone",
    brandNames: ["Deltasone", "Rayos"],
    category: "Respiratory/Anti-inflammatory - Corticosteroid",
    form: "Tablet, Solution",
    strength: "1mg, 2.5mg, 5mg, 10mg, 20mg, 50mg",
    route: "Oral",
    standardDoseAdult: "40-60mg/day for 5-10 days (asthma exacerbation)",
    standardDosePediatric: "1-2mg/kg/day (max 60mg) for 3-10 days",
    maxDailyDose: "80mg acute; varies for chronic",
    dosingFrequency: "Once daily or divided",
    weightBasedDosing: true,
    weightBasedFormula: "1-2mg/kg/day, max 60mg/day",
    renalAdjustment: "No adjustment needed",
    hepaticAdjustment: "Active prednisone; may need higher doses",
    contraindications: ["Systemic fungal infections", "Live vaccines during high-dose therapy"],
    drugInteractions: ["NSAIDs", "Warfarin", "Diuretics", "Vaccines", "Antidiabetics"],
    sideEffects: ["Hyperglycemia", "Insomnia", "Mood changes", "Weight gain", "Osteoporosis"],
    pregnancyCategory: "C",
    administrationNotes: "Take with food. Taper if used >2 weeks. Give in morning if once daily.",
    monitoringParameters: ["Blood glucose", "Blood pressure", "Weight", "Bone density (long-term)"],
    labsRequired: ["Blood glucose", "Electrolytes"],
    isControlled: false,
    marketStatus: "active",
    regulatoryApprovals: [
      { agency: "FDA", status: "approved", approvalDate: "1955-02-21", brandName: "Deltasone", indications: ["Inflammatory Conditions", "Allergic Reactions", "Autoimmune Disorders", "Asthma"], riskCategory: "Pregnancy Category C" },
      { agency: "EMA", status: "approved", approvalDate: "1955-06-10", brandName: "Decortin", indications: ["Inflammatory Diseases", "Allergic Conditions", "Rheumatic Disorders"] },
      { agency: "PMDA", status: "approved", approvalDate: "1956-03-15", brandName: "Predonine", indications: ["Inflammatory Diseases", "Allergic Disorders", "Autoimmune Conditions"], riskCategory: "Use with caution in pregnancy" },
      { agency: "NMPA", status: "approved", approvalDate: "1980-08-20", brandName: "强的松", indications: ["Inflammatory Conditions", "Allergic Reactions", "Autoimmune Disorders"] },
      { agency: "MFDS", status: "approved", approvalDate: "1970-11-15", brandName: "프레드니손", indications: ["Inflammatory Diseases", "Allergic Conditions"] }
    ],
    regionalDosing: [
      { region: "USA", adultDose: "40-60mg/day for acute; 5-10mg/day maintenance", maxDose: "80mg/day acute", notes: "Morning dosing preferred; taper after prolonged use" },
      { region: "EU", adultDose: "30-60mg/day for acute conditions", maxDose: "100mg/day", notes: "Gradual tapering essential" },
      { region: "Japan", adultDose: "20-60mg/day for acute; 5-10mg/day maintenance", maxDose: "60mg/day", notes: "Lower doses often effective in Asian patients" }
    ],
    internationalBrandNames: [
      { region: "Japan", names: ["Predonine", "プレドニン"] },
      { region: "China", names: ["强的松", "泼尼松"] },
      { region: "Korea", names: ["프레드니손", "Prednisone"] },
      { region: "Germany", names: ["Decortin", "Prednisolon"] },
      { region: "Spain", names: ["Dacortin", "Prednisona"] }
    ]
  },

  // GI MEDICATIONS
  {
    name: "Omeprazole",
    genericName: "Omeprazole",
    brandNames: ["Prilosec"],
    category: "GI - Proton Pump Inhibitor",
    form: "Capsule, ODT, Suspension",
    strength: "10mg, 20mg, 40mg",
    route: "Oral",
    standardDoseAdult: "20-40mg once daily",
    standardDosePediatric: "0.7-3.3mg/kg/day once daily",
    maxDailyDose: "40mg",
    dosingFrequency: "Once daily before breakfast",
    weightBasedDosing: true,
    weightBasedFormula: "0.7-3.3mg/kg/day, max 40mg/day",
    renalAdjustment: "No adjustment needed",
    hepaticAdjustment: "Max 20mg/day in hepatic impairment",
    contraindications: ["Hypersensitivity to PPIs", "Concomitant rilpivirine"],
    drugInteractions: ["Clopidogrel", "Methotrexate", "Digoxin", "Warfarin", "HIV medications"],
    sideEffects: ["Headache", "Diarrhea", "C. diff infection", "Bone fractures", "Vitamin B12 deficiency"],
    pregnancyCategory: "C",
    administrationNotes: "Take 30-60 minutes before eating. Swallow capsules whole.",
    monitoringParameters: ["Symptom relief", "Magnesium (long-term)", "B12 (long-term)"],
    labsRequired: ["Magnesium with long-term use"],
    isControlled: false,
    marketStatus: "active",
    regulatoryApprovals: [
      { agency: "FDA", status: "approved", approvalDate: "1989-09-14", brandName: "Prilosec", indications: ["GERD", "Erosive Esophagitis", "H. pylori Eradication", "Zollinger-Ellison Syndrome"], riskCategory: "Pregnancy Category C" },
      { agency: "EMA", status: "approved", approvalDate: "1988-04-05", brandName: "Losec", indications: ["GERD", "Peptic Ulcer", "H. pylori Eradication"], restrictions: ["Long-term use requires monitoring"] },
      { agency: "PMDA", status: "approved", approvalDate: "1991-09-27", brandName: "Omepral", indications: ["Gastric Ulcer", "Duodenal Ulcer", "Reflux Esophagitis"], riskCategory: "Use with caution in pregnancy" },
      { agency: "NMPA", status: "approved", approvalDate: "1995-11-15", brandName: "洛赛克", indications: ["Peptic Ulcer", "GERD", "H. pylori Eradication"] },
      { agency: "MFDS", status: "approved", approvalDate: "1993-08-20", brandName: "로섹", indications: ["Gastric Ulcer", "GERD", "Erosive Esophagitis"] }
    ],
    regionalDosing: [
      { region: "USA", adultDose: "20-40mg once daily", maxDose: "40mg/day", notes: "OTC dose: 20mg once daily for 14 days" },
      { region: "EU", adultDose: "20-40mg once daily", maxDose: "40mg/day", notes: "May use 10mg for maintenance" },
      { region: "Japan", adultDose: "10-20mg once daily", maxDose: "40mg/day", notes: "Lower doses often effective" }
    ],
    internationalBrandNames: [
      { region: "Japan", names: ["Omepral", "オメプラール"] },
      { region: "China", names: ["洛赛克", "奥美拉唑"] },
      { region: "Korea", names: ["로섹", "Losec"] },
      { region: "Germany", names: ["Antra", "Omeprazol"] },
      { region: "Spain", names: ["Losec", "Omeprazol"] }
    ]
  },
  {
    name: "Pantoprazole",
    genericName: "Pantoprazole Sodium",
    brandNames: ["Protonix"],
    category: "GI - Proton Pump Inhibitor",
    form: "Tablet, Injection",
    strength: "20mg, 40mg; IV: 40mg",
    route: "Oral, IV",
    standardDoseAdult: "40mg once daily",
    maxDailyDose: "40mg oral; 80mg IV",
    dosingFrequency: "Once or twice daily",
    weightBasedDosing: false,
    renalAdjustment: "No adjustment needed",
    hepaticAdjustment: "Max 40mg/day in severe impairment",
    contraindications: ["Hypersensitivity to PPIs", "Concomitant rilpivirine"],
    drugInteractions: ["Methotrexate", "Atazanavir", "Warfarin"],
    sideEffects: ["Headache", "Diarrhea", "C. diff infection", "Bone fractures"],
    pregnancyCategory: "B",
    administrationNotes: "May be taken with or without food. Swallow tablets whole.",
    monitoringParameters: ["Symptom relief", "Magnesium (long-term)"],
    labsRequired: ["Magnesium with long-term use"],
    isControlled: false,
    marketStatus: "active",
    regulatoryApprovals: [
      { agency: "FDA", status: "approved", approvalDate: "2000-02-02", brandName: "Protonix", indications: ["GERD", "Erosive Esophagitis", "Zollinger-Ellison Syndrome"], riskCategory: "Pregnancy Category B" },
      { agency: "EMA", status: "approved", approvalDate: "1994-08-24", brandName: "Pantozol", indications: ["GERD", "Peptic Ulcer Disease", "H. pylori Eradication"] },
      { agency: "PMDA", status: "approved", approvalDate: "2006-08-24", brandName: "Takepron", indications: ["Gastric Ulcer", "Reflux Esophagitis"], riskCategory: "Use with caution in pregnancy" },
      { agency: "NMPA", status: "approved", approvalDate: "2001-06-30", brandName: "泮托拉唑", indications: ["Peptic Ulcer", "GERD", "Stress Ulcer Prophylaxis"] },
      { agency: "MFDS", status: "approved", approvalDate: "1999-12-10", brandName: "판토프라졸", indications: ["Gastric Ulcer", "GERD", "Erosive Esophagitis"] }
    ],
    regionalDosing: [
      { region: "USA", adultDose: "40mg once daily", maxDose: "40mg oral; 80mg IV", notes: "IV for patients unable to take oral" },
      { region: "EU", adultDose: "40mg once daily", maxDose: "80mg/day", notes: "May use 20mg for maintenance" },
      { region: "Japan", adultDose: "20-40mg once daily", maxDose: "40mg/day", notes: "Often start at 20mg" }
    ],
    internationalBrandNames: [
      { region: "Japan", names: ["Takepron", "タケプロン"] },
      { region: "China", names: ["泮托拉唑", "潘妥洛克"] },
      { region: "Korea", names: ["판토프라졸", "Pantoloc"] },
      { region: "Germany", names: ["Pantozol", "Pantoprazol"] },
      { region: "Spain", names: ["Pantecta", "Pantoprazol"] }
    ]
  },
  {
    name: "Famotidine",
    genericName: "Famotidine",
    brandNames: ["Pepcid"],
    category: "GI - H2 Receptor Antagonist",
    form: "Tablet, Suspension, Injection",
    strength: "10mg, 20mg, 40mg; Susp: 40mg/5mL; IV: 20mg/50mL",
    route: "Oral, IV",
    standardDoseAdult: "20-40mg twice daily or 40mg at bedtime",
    standardDosePediatric: "0.5mg/kg/dose every 12 hours",
    maxDailyDose: "80mg",
    dosingFrequency: "Once or twice daily",
    weightBasedDosing: true,
    weightBasedFormula: "0.5mg/kg/dose every 12 hours, max 40mg/dose",
    renalAdjustment: "CrCl 10-50: Give every 24 hours; CrCl <10: Give every 36-48 hours",
    hepaticAdjustment: "No adjustment needed",
    contraindications: ["Hypersensitivity to famotidine or H2 blockers"],
    drugInteractions: ["Atazanavir", "Dasatinib", "Cefuroxime"],
    sideEffects: ["Headache", "Dizziness", "Constipation", "Diarrhea"],
    pregnancyCategory: "B",
    administrationNotes: "May be taken with or without food",
    monitoringParameters: ["Symptom relief"],
    labsRequired: ["None routinely"],
    isControlled: false
  },
  {
    name: "Ondansetron",
    genericName: "Ondansetron",
    brandNames: ["Zofran"],
    category: "GI - Antiemetic",
    form: "Tablet, ODT, Solution, Injection",
    strength: "4mg, 8mg; ODT: 4mg, 8mg; IV: 2mg/mL",
    route: "Oral, IV, IM",
    standardDoseAdult: "4-8mg every 8 hours; Chemo: 24mg once before",
    standardDosePediatric: "0.1-0.15mg/kg every 8 hours",
    maxDailyDose: "24mg",
    dosingFrequency: "Every 8 hours or once before chemotherapy",
    weightBasedDosing: true,
    weightBasedFormula: "0.1-0.15mg/kg/dose, max 8mg/dose",
    renalAdjustment: "No adjustment needed",
    hepaticAdjustment: "Max 8mg/day in severe hepatic impairment",
    contraindications: ["Hypersensitivity to ondansetron", "Concomitant apomorphine"],
    drugInteractions: ["Apomorphine", "QT-prolonging drugs", "Tramadol", "SSRIs"],
    sideEffects: ["Headache", "Constipation", "QT prolongation", "Serotonin syndrome"],
    pregnancyCategory: "B",
    administrationNotes: "ODT: Place on tongue, dissolves rapidly. May take with or without food.",
    monitoringParameters: ["Nausea/vomiting", "ECG if risk factors"],
    labsRequired: ["ECG if high doses or risk factors"],
    isControlled: false
  },
  {
    name: "Metoclopramide",
    genericName: "Metoclopramide",
    brandNames: ["Reglan"],
    category: "GI - Antiemetic/Prokinetic",
    form: "Tablet, Solution, Injection",
    strength: "5mg, 10mg; Soln: 5mg/5mL; IV: 5mg/mL",
    route: "Oral, IV, IM",
    standardDoseAdult: "10mg 30 minutes before meals and at bedtime",
    standardDosePediatric: "0.1-0.2mg/kg/dose up to 4 times daily",
    maxDailyDose: "40mg",
    dosingFrequency: "Four times daily",
    weightBasedDosing: true,
    weightBasedFormula: "0.1-0.2mg/kg/dose, max 10mg/dose",
    renalAdjustment: "CrCl <40: Reduce dose by 50%",
    hepaticAdjustment: "Reduce dose in severe impairment",
    contraindications: ["GI obstruction", "Pheochromocytoma", "Seizure disorder", "Tardive dyskinesia"],
    drugInteractions: ["Antipsychotics", "MAOIs", "Narcotics", "Anticholinergics"],
    sideEffects: ["Drowsiness", "Restlessness", "Tardive dyskinesia", "Extrapyramidal symptoms"],
    blackBoxWarning: "Prolonged treatment can cause tardive dyskinesia, which may be irreversible.",
    pregnancyCategory: "B",
    administrationNotes: "Take 30 minutes before meals. Limit use to <12 weeks.",
    monitoringParameters: ["Signs of tardive dyskinesia", "EPS symptoms"],
    labsRequired: ["None routinely"],
    isControlled: false
  },

  // PSYCHIATRIC MEDICATIONS
  {
    name: "Sertraline",
    genericName: "Sertraline Hydrochloride",
    brandNames: ["Zoloft"],
    category: "Psychiatric - SSRI",
    form: "Tablet, Oral solution",
    strength: "25mg, 50mg, 100mg; Solution: 20mg/mL",
    route: "Oral",
    standardDoseAdult: "50mg once daily, may increase to 200mg/day",
    standardDosePediatric: "25mg once daily, increase as needed",
    maxDailyDose: "200mg",
    dosingFrequency: "Once daily",
    weightBasedDosing: false,
    renalAdjustment: "No adjustment needed",
    hepaticAdjustment: "Use lower doses in hepatic impairment",
    contraindications: ["MAOIs within 14 days", "Pimozide", "Disulfiram (with oral solution)"],
    drugInteractions: ["MAOIs", "Pimozide", "Warfarin", "Triptans", "Tramadol"],
    sideEffects: ["Nausea", "Diarrhea", "Insomnia", "Sexual dysfunction", "Dry mouth"],
    blackBoxWarning: "Increased risk of suicidal thinking and behavior in children, adolescents, and young adults.",
    pregnancyCategory: "C",
    administrationNotes: "May be taken with or without food. Oral solution must be diluted before use.",
    monitoringParameters: ["Mood", "Suicidal ideation", "Sexual function"],
    labsRequired: ["Consider sodium in elderly"],
    isControlled: false
  },
  {
    name: "Escitalopram",
    genericName: "Escitalopram Oxalate",
    brandNames: ["Lexapro"],
    category: "Psychiatric - SSRI",
    form: "Tablet, Oral solution",
    strength: "5mg, 10mg, 20mg; Solution: 5mg/5mL",
    route: "Oral",
    standardDoseAdult: "10mg once daily, may increase to 20mg/day",
    standardDosePediatric: "10mg once daily (ages 12+)",
    maxDailyDose: "20mg",
    dosingFrequency: "Once daily",
    weightBasedDosing: false,
    renalAdjustment: "No adjustment in mild-moderate; caution in severe",
    hepaticAdjustment: "Max 10mg/day in hepatic impairment",
    contraindications: ["MAOIs within 14 days", "Pimozide"],
    drugInteractions: ["MAOIs", "Pimozide", "Triptans", "NSAIDs", "Anticoagulants"],
    sideEffects: ["Nausea", "Insomnia", "Fatigue", "Sexual dysfunction", "QT prolongation"],
    blackBoxWarning: "Increased risk of suicidal thinking and behavior in children, adolescents, and young adults.",
    pregnancyCategory: "C",
    administrationNotes: "May be taken with or without food. Take in morning or evening.",
    monitoringParameters: ["Mood", "Suicidal ideation", "QT interval if risk factors"],
    labsRequired: ["ECG if risk factors", "Sodium in elderly"],
    isControlled: false
  },
  {
    name: "Fluoxetine",
    genericName: "Fluoxetine Hydrochloride",
    brandNames: ["Prozac", "Sarafem"],
    category: "Psychiatric - SSRI",
    form: "Capsule, Tablet, Oral solution, Delayed-release capsule",
    strength: "10mg, 20mg, 40mg; DR: 90mg weekly; Solution: 20mg/5mL",
    route: "Oral",
    standardDoseAdult: "20mg once daily, may increase to 80mg/day",
    standardDosePediatric: "10-20mg once daily",
    maxDailyDose: "80mg",
    dosingFrequency: "Once daily (weekly for DR)",
    weightBasedDosing: false,
    renalAdjustment: "No adjustment needed",
    hepaticAdjustment: "Reduce dose; use lower doses",
    contraindications: ["MAOIs within 14 days", "Pimozide", "Thioridazine"],
    drugInteractions: ["MAOIs", "Pimozide", "Thioridazine", "Tamoxifen", "Warfarin"],
    sideEffects: ["Nausea", "Headache", "Insomnia", "Anxiety", "Sexual dysfunction"],
    blackBoxWarning: "Increased risk of suicidal thinking and behavior in children, adolescents, and young adults.",
    pregnancyCategory: "C",
    administrationNotes: "May take with or without food. Long half-life allows once daily dosing.",
    monitoringParameters: ["Mood", "Suicidal ideation", "Weight"],
    labsRequired: ["Consider sodium in elderly"],
    isControlled: false
  },
  {
    name: "Bupropion",
    genericName: "Bupropion Hydrochloride",
    brandNames: ["Wellbutrin", "Wellbutrin SR", "Wellbutrin XL", "Zyban"],
    category: "Psychiatric - NDRI",
    form: "Tablet, SR tablet, XL tablet",
    strength: "75mg, 100mg; SR: 100mg, 150mg, 200mg; XL: 150mg, 300mg, 450mg",
    route: "Oral",
    standardDoseAdult: "IR: 100mg TID; SR: 150mg BID; XL: 150-300mg once daily",
    maxDailyDose: "450mg",
    dosingFrequency: "IR: TID; SR: BID; XL: Once daily",
    weightBasedDosing: false,
    renalAdjustment: "Max 150mg/day in severe renal impairment",
    hepaticAdjustment: "Max 150mg every other day in severe hepatic impairment",
    contraindications: ["Seizure disorder", "Eating disorders", "MAOIs within 14 days", "Abrupt alcohol/sedative withdrawal"],
    drugInteractions: ["MAOIs", "CYP2D6 substrates", "Drugs lowering seizure threshold"],
    sideEffects: ["Insomnia", "Headache", "Dry mouth", "Seizures", "Weight loss"],
    blackBoxWarning: "Increased risk of suicidal thinking and behavior in children, adolescents, and young adults.",
    pregnancyCategory: "C",
    administrationNotes: "Do not crush SR/XL. Space doses at least 8 hours apart (IR/SR).",
    monitoringParameters: ["Mood", "Suicidal ideation", "Blood pressure"],
    labsRequired: ["None routinely"],
    isControlled: false
  },
  {
    name: "Alprazolam",
    genericName: "Alprazolam",
    brandNames: ["Xanax", "Xanax XR"],
    category: "Psychiatric - Benzodiazepine",
    form: "Tablet, ODT, XR tablet, Solution",
    strength: "0.25mg, 0.5mg, 1mg, 2mg; XR: 0.5mg, 1mg, 2mg, 3mg",
    route: "Oral",
    standardDoseAdult: "0.25-0.5mg TID; XR: 0.5-1mg once daily",
    maxDailyDose: "10mg (anxiety); 4mg (panic)",
    dosingFrequency: "IR: Two to three times daily; XR: Once daily",
    weightBasedDosing: false,
    renalAdjustment: "No adjustment needed",
    hepaticAdjustment: "Start 0.25mg BID-TID; avoid in severe impairment",
    contraindications: ["Narrow-angle glaucoma", "Concomitant ketoconazole/itraconazole"],
    drugInteractions: ["Opioids", "CNS depressants", "CYP3A4 inhibitors", "Alcohol"],
    sideEffects: ["Sedation", "Ataxia", "Memory impairment", "Dependence", "Respiratory depression"],
    blackBoxWarning: "Concomitant use with opioids may result in profound sedation, respiratory depression, coma, and death.",
    pregnancyCategory: "D",
    administrationNotes: "XR: Swallow whole. Do not discontinue abruptly.",
    monitoringParameters: ["Sedation", "Respiratory status", "Signs of dependence"],
    labsRequired: ["None routinely"],
    isControlled: true,
    controlledSchedule: "Schedule IV"
  },
  {
    name: "Lorazepam",
    genericName: "Lorazepam",
    brandNames: ["Ativan"],
    category: "Psychiatric - Benzodiazepine",
    form: "Tablet, Solution, Injection",
    strength: "0.5mg, 1mg, 2mg; IV: 2mg/mL, 4mg/mL",
    route: "Oral, IV, IM",
    standardDoseAdult: "Oral: 2-6mg/day divided; IV: 0.5-2mg every 6-8 hours",
    standardDosePediatric: "0.05mg/kg/dose every 4-8 hours",
    maxDailyDose: "10mg",
    dosingFrequency: "Two to three times daily",
    weightBasedDosing: true,
    weightBasedFormula: "0.05mg/kg/dose, max 2mg/dose",
    renalAdjustment: "No adjustment needed",
    hepaticAdjustment: "Reduce dose in hepatic impairment",
    contraindications: ["Narrow-angle glaucoma", "Respiratory depression", "Sleep apnea"],
    drugInteractions: ["Opioids", "CNS depressants", "Alcohol"],
    sideEffects: ["Sedation", "Ataxia", "Respiratory depression", "Dependence", "Paradoxical reactions"],
    blackBoxWarning: "Concomitant use with opioids may result in profound sedation, respiratory depression, coma, and death.",
    pregnancyCategory: "D",
    administrationNotes: "IV: Give slowly over 2-5 minutes. May be given IM. Taper to discontinue.",
    monitoringParameters: ["Sedation", "Respiratory status", "Signs of dependence"],
    labsRequired: ["None routinely"],
    isControlled: true,
    controlledSchedule: "Schedule IV"
  },
  {
    name: "Quetiapine",
    genericName: "Quetiapine Fumarate",
    brandNames: ["Seroquel", "Seroquel XR"],
    category: "Psychiatric - Atypical Antipsychotic",
    form: "Tablet, XR tablet",
    strength: "25mg, 50mg, 100mg, 200mg, 300mg, 400mg; XR: 50mg-400mg",
    route: "Oral",
    standardDoseAdult: "Schizophrenia: 150-750mg/day; Bipolar: 300-800mg/day",
    standardDosePediatric: "Varies by indication",
    maxDailyDose: "800mg",
    dosingFrequency: "IR: Two to three times daily; XR: Once daily",
    weightBasedDosing: false,
    renalAdjustment: "No adjustment needed",
    hepaticAdjustment: "Start 25mg/day; titrate slowly",
    contraindications: ["Hypersensitivity to quetiapine"],
    drugInteractions: ["CYP3A4 inhibitors/inducers", "CNS depressants", "Antihypertensives"],
    sideEffects: ["Sedation", "Weight gain", "Metabolic syndrome", "Orthostatic hypotension", "QT prolongation"],
    blackBoxWarning: "Increased mortality in elderly patients with dementia-related psychosis. Increased risk of suicidal thinking in young adults.",
    pregnancyCategory: "C",
    administrationNotes: "XR: Take without food or with light meal. Swallow whole.",
    monitoringParameters: ["Metabolic panel", "Weight", "Blood pressure", "Lipids", "A1c"],
    labsRequired: ["Fasting glucose", "Lipid panel", "A1c"],
    isControlled: false
  },
  {
    name: "Risperidone",
    genericName: "Risperidone",
    brandNames: ["Risperdal", "Risperdal Consta"],
    category: "Psychiatric - Atypical Antipsychotic",
    form: "Tablet, ODT, Solution, Long-acting injection",
    strength: "0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg; Soln: 1mg/mL; LAI: 12.5-50mg",
    route: "Oral, IM (LAI)",
    standardDoseAdult: "1-6mg/day in 1-2 doses",
    standardDosePediatric: "0.25-0.5mg/day initially",
    maxDailyDose: "8mg",
    dosingFrequency: "Once or twice daily",
    weightBasedDosing: false,
    renalAdjustment: "Start 0.5mg BID; titrate slowly",
    hepaticAdjustment: "Start 0.5mg BID; titrate slowly",
    contraindications: ["Hypersensitivity to risperidone or paliperidone"],
    drugInteractions: ["CYP2D6 inhibitors", "CNS depressants", "Antihypertensives", "Levodopa"],
    sideEffects: ["EPS", "Weight gain", "Hyperprolactinemia", "Sedation", "Metabolic syndrome"],
    blackBoxWarning: "Increased mortality in elderly patients with dementia-related psychosis.",
    pregnancyCategory: "C",
    administrationNotes: "May take with or without food. LAI requires 3-week oral overlap.",
    monitoringParameters: ["EPS", "Weight", "Prolactin", "Metabolic panel"],
    labsRequired: ["Fasting glucose", "Lipid panel", "Prolactin"],
    isControlled: false
  },
  {
    name: "Aripiprazole",
    genericName: "Aripiprazole",
    brandNames: ["Abilify", "Abilify Maintena"],
    category: "Psychiatric - Atypical Antipsychotic",
    form: "Tablet, ODT, Solution, Injection, Long-acting injection",
    strength: "2mg-30mg tablets; Solution: 1mg/mL; LAI: 300mg, 400mg",
    route: "Oral, IM",
    standardDoseAdult: "10-30mg once daily",
    standardDosePediatric: "2-10mg once daily",
    maxDailyDose: "30mg",
    dosingFrequency: "Once daily",
    weightBasedDosing: false,
    renalAdjustment: "No adjustment needed",
    hepaticAdjustment: "No adjustment needed",
    contraindications: ["Hypersensitivity to aripiprazole"],
    drugInteractions: ["CYP2D6/3A4 inhibitors/inducers", "CNS depressants"],
    sideEffects: ["Akathisia", "Insomnia", "Headache", "Nausea", "Weight gain (less than other antipsychotics)"],
    blackBoxWarning: "Increased mortality in elderly patients with dementia-related psychosis. Increased risk of suicidal thinking in young adults.",
    pregnancyCategory: "C",
    administrationNotes: "May take with or without food.",
    monitoringParameters: ["Akathisia", "Weight", "Metabolic panel"],
    labsRequired: ["Fasting glucose", "Lipid panel"],
    isControlled: false
  },
  {
    name: "Trazodone",
    genericName: "Trazodone Hydrochloride",
    brandNames: ["Desyrel", "Oleptro"],
    category: "Psychiatric - SARI",
    form: "Tablet, Extended-release tablet",
    strength: "50mg, 100mg, 150mg, 300mg; ER: 150mg, 300mg",
    route: "Oral",
    standardDoseAdult: "Depression: 150-400mg/day; Insomnia: 25-100mg at bedtime",
    maxDailyDose: "600mg (outpatient); 400mg (ER)",
    dosingFrequency: "One to three times daily with food",
    weightBasedDosing: false,
    renalAdjustment: "No adjustment needed",
    hepaticAdjustment: "Use with caution; may need lower doses",
    contraindications: ["MAOIs within 14 days", "Linezolid/IV methylene blue"],
    drugInteractions: ["MAOIs", "CYP3A4 inhibitors", "CNS depressants", "Warfarin"],
    sideEffects: ["Sedation", "Dizziness", "Dry mouth", "Priapism", "Orthostatic hypotension"],
    blackBoxWarning: "Increased risk of suicidal thinking and behavior in children, adolescents, and young adults.",
    pregnancyCategory: "C",
    administrationNotes: "Take with food. ER: Take in evening on empty stomach.",
    monitoringParameters: ["Mood", "Sedation", "Orthostatic BP", "Priapism"],
    labsRequired: ["None routinely"],
    isControlled: false
  },

  // THYROID MEDICATIONS
  {
    name: "Levothyroxine",
    genericName: "Levothyroxine Sodium",
    brandNames: ["Synthroid", "Levoxyl", "Unithroid"],
    category: "Endocrine - Thyroid Hormone",
    form: "Tablet, Capsule, Injection",
    strength: "25mcg-300mcg tablets",
    route: "Oral, IV",
    standardDoseAdult: "1.6mcg/kg/day; typically 50-200mcg/day",
    standardDosePediatric: "Varies by age: newborns 10-15mcg/kg/day",
    maxDailyDose: "Individualized",
    dosingFrequency: "Once daily",
    weightBasedDosing: true,
    weightBasedFormula: "1.6mcg/kg/day full replacement",
    renalAdjustment: "No adjustment needed",
    hepaticAdjustment: "No adjustment needed",
    contraindications: ["Untreated adrenal insufficiency", "Acute MI", "Thyrotoxicosis"],
    drugInteractions: ["Calcium", "Iron", "Antacids", "Warfarin", "Digoxin", "Cholestyramine"],
    sideEffects: ["Hyperthyroid symptoms", "Palpitations", "Weight loss", "Insomnia", "Hair loss"],
    pregnancyCategory: "A",
    administrationNotes: "Take on empty stomach 30-60 minutes before breakfast. Separate from other meds by 4 hours.",
    monitoringParameters: ["TSH", "Free T4", "Heart rate", "Weight"],
    labsRequired: ["TSH", "Free T4"],
    isControlled: false,
    marketStatus: "active",
    regulatoryApprovals: [
      { agency: "FDA", status: "approved", approvalDate: "1962-08-30", brandName: "Synthroid", indications: ["Hypothyroidism", "TSH Suppression", "Myxedema Coma"], riskCategory: "Pregnancy Category A" },
      { agency: "EMA", status: "approved", approvalDate: "1965-03-15", brandName: "Euthyrox", indications: ["Hypothyroidism", "Thyroid Cancer Suppression", "Goiter"] },
      { agency: "PMDA", status: "approved", approvalDate: "1963-11-20", brandName: "Thyradin-S", indications: ["Hypothyroidism", "Myxedema", "Cretinism"], riskCategory: "Safe in pregnancy when indicated" },
      { agency: "NMPA", status: "approved", approvalDate: "1990-07-10", brandName: "优甲乐", indications: ["Hypothyroidism", "Goiter", "Thyroid Cancer"] },
      { agency: "MFDS", status: "approved", approvalDate: "1985-05-25", brandName: "신지로이드", indications: ["Hypothyroidism", "Myxedema"] }
    ],
    regionalDosing: [
      { region: "USA", adultDose: "1.6mcg/kg/day; typically 50-200mcg", maxDose: "Individualized by TSH", notes: "Start 25-50mcg in elderly/cardiac patients" },
      { region: "EU", adultDose: "1.6-1.8mcg/kg/day", maxDose: "Individualized by TSH", notes: "Similar dosing to USA" },
      { region: "Japan", adultDose: "25-150mcg/day", maxDose: "Individualized", notes: "Often lower doses sufficient; start 25mcg" }
    ],
    internationalBrandNames: [
      { region: "Japan", names: ["Thyradin-S", "チラーヂン"] },
      { region: "China", names: ["优甲乐", "左甲状腺素"] },
      { region: "Korea", names: ["신지로이드", "Synthroid"] },
      { region: "Germany", names: ["Euthyrox", "L-Thyroxin"] },
      { region: "Spain", names: ["Eutirox", "Levotiroxina"] }
    ]
  },
  {
    name: "Methimazole",
    genericName: "Methimazole",
    brandNames: ["Tapazole"],
    category: "Endocrine - Antithyroid",
    form: "Tablet",
    strength: "5mg, 10mg",
    route: "Oral",
    standardDoseAdult: "Initial: 15-60mg/day in 3 divided doses",
    standardDosePediatric: "0.4mg/kg/day in 3 divided doses",
    maxDailyDose: "60mg",
    dosingFrequency: "One to three times daily",
    weightBasedDosing: true,
    weightBasedFormula: "0.4mg/kg/day initially",
    renalAdjustment: "No adjustment needed",
    hepaticAdjustment: "Use with caution",
    contraindications: ["Hypersensitivity to methimazole", "Breastfeeding (relative)"],
    drugInteractions: ["Warfarin", "Beta blockers", "Digoxin"],
    sideEffects: ["Agranulocytosis", "Rash", "GI upset", "Hepatotoxicity", "Hypothyroidism"],
    blackBoxWarning: "Agranulocytosis can occur. Monitor for signs of infection.",
    pregnancyCategory: "D",
    administrationNotes: "May take with or without food. Regular monitoring required.",
    monitoringParameters: ["TSH", "Free T4", "CBC", "LFTs"],
    labsRequired: ["TSH", "Free T4", "CBC", "LFTs"],
    isControlled: false
  },

  // ALLERGY MEDICATIONS
  {
    name: "Cetirizine",
    genericName: "Cetirizine Hydrochloride",
    brandNames: ["Zyrtec"],
    category: "Allergy - Antihistamine",
    form: "Tablet, Chewable, Liquid",
    strength: "5mg, 10mg; Liquid: 5mg/5mL",
    route: "Oral",
    standardDoseAdult: "5-10mg once daily",
    standardDosePediatric: "2.5-5mg once daily (2-5 years); 5-10mg once daily (6+)",
    maxDailyDose: "10mg",
    dosingFrequency: "Once daily",
    weightBasedDosing: false,
    renalAdjustment: "CrCl <31: 5mg once daily",
    hepaticAdjustment: "5mg once daily",
    contraindications: ["Hypersensitivity to cetirizine, hydroxyzine, or piperazine derivatives"],
    drugInteractions: ["CNS depressants", "Alcohol", "Theophylline"],
    sideEffects: ["Drowsiness", "Dry mouth", "Fatigue", "Headache"],
    pregnancyCategory: "B",
    administrationNotes: "May take with or without food. May cause drowsiness.",
    monitoringParameters: ["Symptom relief", "Drowsiness"],
    labsRequired: ["None routinely"],
    isControlled: false
  },
  {
    name: "Loratadine",
    genericName: "Loratadine",
    brandNames: ["Claritin"],
    category: "Allergy - Antihistamine",
    form: "Tablet, ODT, Syrup",
    strength: "10mg; Syrup: 5mg/5mL",
    route: "Oral",
    standardDoseAdult: "10mg once daily",
    standardDosePediatric: "5mg once daily (2-5 years); 10mg once daily (6+)",
    maxDailyDose: "10mg",
    dosingFrequency: "Once daily",
    weightBasedDosing: false,
    renalAdjustment: "CrCl <30: 10mg every other day",
    hepaticAdjustment: "10mg every other day",
    contraindications: ["Hypersensitivity to loratadine"],
    drugInteractions: ["Ketoconazole", "Erythromycin", "Cimetidine"],
    sideEffects: ["Headache", "Drowsiness (less than first-gen)", "Dry mouth", "Fatigue"],
    pregnancyCategory: "B",
    administrationNotes: "May take with or without food. Less sedating than first-generation antihistamines.",
    monitoringParameters: ["Symptom relief"],
    labsRequired: ["None routinely"],
    isControlled: false
  },
  {
    name: "Diphenhydramine",
    genericName: "Diphenhydramine Hydrochloride",
    brandNames: ["Benadryl"],
    category: "Allergy - Antihistamine (1st gen)",
    form: "Tablet, Capsule, Liquid, Injection",
    strength: "25mg, 50mg; Liquid: 12.5mg/5mL; IV: 50mg/mL",
    route: "Oral, IV, IM",
    standardDoseAdult: "25-50mg every 4-6 hours",
    standardDosePediatric: "1-1.25mg/kg every 4-6 hours",
    maxDailyDose: "300mg",
    dosingFrequency: "Every 4-6 hours",
    weightBasedDosing: true,
    weightBasedFormula: "1-1.25mg/kg/dose, max 50mg/dose",
    renalAdjustment: "Extend interval in renal impairment",
    hepaticAdjustment: "Use with caution",
    contraindications: ["Neonates", "Lower respiratory conditions", "Narrow-angle glaucoma", "Urinary retention"],
    drugInteractions: ["CNS depressants", "MAOIs", "Anticholinergics"],
    sideEffects: ["Sedation", "Dry mouth", "Urinary retention", "Confusion (elderly)", "Blurred vision"],
    pregnancyCategory: "B",
    administrationNotes: "Highly sedating. Avoid in elderly. IV: Give over at least 2 minutes.",
    monitoringParameters: ["Sedation", "Anticholinergic effects"],
    labsRequired: ["None routinely"],
    isControlled: false
  },
  {
    name: "Fexofenadine",
    genericName: "Fexofenadine Hydrochloride",
    brandNames: ["Allegra"],
    category: "Allergy - Antihistamine",
    form: "Tablet, ODT, Suspension",
    strength: "30mg, 60mg, 180mg; Susp: 30mg/5mL",
    route: "Oral",
    standardDoseAdult: "60mg twice daily or 180mg once daily",
    standardDosePediatric: "30mg twice daily (2-11 years)",
    maxDailyDose: "180mg",
    dosingFrequency: "Once or twice daily",
    weightBasedDosing: false,
    renalAdjustment: "CrCl <80: 60mg once daily",
    hepaticAdjustment: "No adjustment needed",
    contraindications: ["Hypersensitivity to fexofenadine"],
    drugInteractions: ["Antacids (aluminum/magnesium)", "Fruit juices (absorption)"],
    sideEffects: ["Headache", "Drowsiness (minimal)", "Nausea", "Dizziness"],
    pregnancyCategory: "C",
    administrationNotes: "Take with water. Avoid fruit juices within 1-2 hours.",
    monitoringParameters: ["Symptom relief"],
    labsRequired: ["None routinely"],
    isControlled: false
  },

  // OSTEOPOROSIS MEDICATIONS
  {
    name: "Alendronate",
    genericName: "Alendronate Sodium",
    brandNames: ["Fosamax"],
    category: "Bone Health - Bisphosphonate",
    form: "Tablet, Oral solution",
    strength: "5mg, 10mg, 35mg, 70mg; Solution: 70mg/75mL",
    route: "Oral",
    standardDoseAdult: "10mg daily or 70mg weekly",
    maxDailyDose: "10mg daily or 70mg weekly",
    dosingFrequency: "Once daily or once weekly",
    weightBasedDosing: false,
    renalAdjustment: "CrCl <35: Not recommended",
    hepaticAdjustment: "No adjustment needed",
    contraindications: ["Esophageal abnormalities", "Inability to stand/sit upright 30 min", "Hypocalcemia", "CrCl <35"],
    drugInteractions: ["Calcium supplements", "Antacids", "NSAIDs", "Aspirin"],
    sideEffects: ["Esophageal irritation", "Musculoskeletal pain", "Osteonecrosis of jaw", "Atypical femur fractures"],
    pregnancyCategory: "C",
    administrationNotes: "Take first thing in morning with full glass of water. Remain upright 30 min. Wait 30 min before eating.",
    monitoringParameters: ["Bone density", "Calcium", "Vitamin D", "Renal function"],
    labsRequired: ["Calcium", "Vitamin D", "BMP"],
    isControlled: false
  },
  {
    name: "Vitamin D3",
    genericName: "Cholecalciferol",
    brandNames: ["Drisdol", "D3"],
    category: "Bone Health - Vitamin Supplement",
    form: "Tablet, Capsule, Drops, Injection",
    strength: "400IU, 1000IU, 2000IU, 5000IU, 50000IU",
    route: "Oral, IM",
    standardDoseAdult: "600-800IU daily maintenance; up to 50000IU weekly for deficiency",
    standardDosePediatric: "400-600IU daily",
    maxDailyDose: "4000IU daily maintenance; higher for treatment",
    dosingFrequency: "Once daily or weekly",
    weightBasedDosing: false,
    renalAdjustment: "Use with caution; monitor calcium",
    hepaticAdjustment: "Use active form (calcitriol) in severe impairment",
    contraindications: ["Hypercalcemia", "Vitamin D toxicity", "Malabsorption syndromes"],
    drugInteractions: ["Thiazide diuretics", "Digoxin", "Orlistat", "Cholestyramine"],
    sideEffects: ["Hypercalcemia", "Hypercalciuria", "Nausea", "Weakness"],
    pregnancyCategory: "C (A at RDA)",
    administrationNotes: "May take with or without food. Fat aids absorption.",
    monitoringParameters: ["25-OH Vitamin D level", "Calcium"],
    labsRequired: ["25-OH Vitamin D", "Calcium"],
    isControlled: false
  },

  // ANTICOAGULANTS (additional)
  {
    name: "Apixaban",
    genericName: "Apixaban",
    brandNames: ["Eliquis"],
    category: "Cardiovascular - DOAC",
    form: "Tablet",
    strength: "2.5mg, 5mg",
    route: "Oral",
    standardDoseAdult: "5mg twice daily; 2.5mg twice daily if criteria met",
    maxDailyDose: "10mg",
    dosingFrequency: "Twice daily",
    weightBasedDosing: false,
    renalAdjustment: "2.5mg BID if 2+ criteria: age ≥80, weight ≤60kg, Cr ≥1.5",
    hepaticAdjustment: "Not recommended in severe hepatic impairment",
    contraindications: ["Active bleeding", "Severe hepatic impairment", "Prosthetic heart valves"],
    drugInteractions: ["Strong CYP3A4/P-gp inhibitors/inducers", "Anticoagulants", "NSAIDs"],
    sideEffects: ["Bleeding", "Bruising", "Anemia", "Nausea"],
    blackBoxWarning: "Spinal/epidural hematoma risk with neuraxial anesthesia. Premature discontinuation increases stroke risk.",
    pregnancyCategory: "B",
    administrationNotes: "May take with or without food. Crush and mix with apple juice if needed.",
    monitoringParameters: ["Signs of bleeding", "Renal function", "Hemoglobin"],
    labsRequired: ["CBC", "BMP", "LFTs"],
    isControlled: false
  },
  {
    name: "Rivaroxaban",
    genericName: "Rivaroxaban",
    brandNames: ["Xarelto"],
    category: "Cardiovascular - DOAC",
    form: "Tablet",
    strength: "2.5mg, 10mg, 15mg, 20mg",
    route: "Oral",
    standardDoseAdult: "AFib: 20mg daily with dinner; DVT/PE: 15mg BID x21 days, then 20mg daily",
    maxDailyDose: "20mg",
    dosingFrequency: "Once or twice daily depending on indication",
    weightBasedDosing: false,
    renalAdjustment: "CrCl 15-50: 15mg daily for AFib; avoid if CrCl <15",
    hepaticAdjustment: "Avoid in moderate-severe hepatic impairment",
    contraindications: ["Active bleeding", "Severe hepatic impairment", "CrCl <15"],
    drugInteractions: ["Strong CYP3A4/P-gp inhibitors/inducers", "Anticoagulants", "NSAIDs"],
    sideEffects: ["Bleeding", "Bruising", "Pruritus", "GI upset"],
    blackBoxWarning: "Spinal/epidural hematoma risk with neuraxial anesthesia. Premature discontinuation increases stroke risk.",
    pregnancyCategory: "C",
    administrationNotes: "15mg and 20mg tablets must be taken with food.",
    monitoringParameters: ["Signs of bleeding", "Renal function", "Hemoglobin"],
    labsRequired: ["CBC", "BMP", "LFTs"],
    isControlled: false
  },

  // MUSCLE RELAXANTS
  {
    name: "Cyclobenzaprine",
    genericName: "Cyclobenzaprine Hydrochloride",
    brandNames: ["Flexeril", "Amrix"],
    category: "Musculoskeletal - Muscle Relaxant",
    form: "Tablet, Extended-release capsule",
    strength: "5mg, 7.5mg, 10mg; ER: 15mg, 30mg",
    route: "Oral",
    standardDoseAdult: "IR: 5-10mg TID; ER: 15-30mg once daily",
    maxDailyDose: "30mg",
    dosingFrequency: "IR: Three times daily; ER: Once daily",
    weightBasedDosing: false,
    renalAdjustment: "No adjustment needed",
    hepaticAdjustment: "Start 5mg; avoid in moderate-severe impairment",
    contraindications: ["MAOIs within 14 days", "Hyperthyroidism", "Arrhythmias", "Heart failure", "Recent MI"],
    drugInteractions: ["MAOIs", "TCAs", "Tramadol", "CNS depressants", "SSRIs"],
    sideEffects: ["Drowsiness", "Dry mouth", "Dizziness", "Fatigue", "Anticholinergic effects"],
    pregnancyCategory: "B",
    administrationNotes: "Limit use to 2-3 weeks. May cause significant sedation.",
    monitoringParameters: ["Pain level", "Sedation", "Anticholinergic effects"],
    labsRequired: ["None routinely"],
    isControlled: false
  },
  {
    name: "Methocarbamol",
    genericName: "Methocarbamol",
    brandNames: ["Robaxin"],
    category: "Musculoskeletal - Muscle Relaxant",
    form: "Tablet, Injection",
    strength: "500mg, 750mg; IV: 100mg/mL",
    route: "Oral, IV, IM",
    standardDoseAdult: "Oral: 1500mg QID initially, then 750-1000mg QID; IV: 1-3g/day",
    maxDailyDose: "8g (oral); 3g (IV)",
    dosingFrequency: "Three to four times daily",
    weightBasedDosing: false,
    renalAdjustment: "Use with caution in renal impairment",
    hepaticAdjustment: "Use with caution in hepatic impairment",
    contraindications: ["Myasthenia gravis", "Renal impairment (injectable only)"],
    drugInteractions: ["CNS depressants", "Pyridostigmine"],
    sideEffects: ["Drowsiness", "Dizziness", "Nausea", "Blurred vision", "Headache"],
    pregnancyCategory: "C",
    administrationNotes: "May cause brown, black, or green urine. IV: Give slowly.",
    monitoringParameters: ["Pain level", "Sedation"],
    labsRequired: ["None routinely"],
    isControlled: false
  },
  {
    name: "Baclofen",
    genericName: "Baclofen",
    brandNames: ["Lioresal", "Gablofen"],
    category: "Musculoskeletal - Muscle Relaxant",
    form: "Tablet, Intrathecal injection",
    strength: "5mg, 10mg, 20mg; Intrathecal: various concentrations",
    route: "Oral, Intrathecal",
    standardDoseAdult: "5mg TID initially, increase to 40-80mg/day",
    standardDosePediatric: "2.5mg TID initially",
    maxDailyDose: "80mg oral",
    dosingFrequency: "Three times daily",
    weightBasedDosing: false,
    renalAdjustment: "Reduce dose in renal impairment",
    hepaticAdjustment: "No adjustment needed",
    contraindications: ["Hypersensitivity to baclofen"],
    drugInteractions: ["CNS depressants", "MAOIs", "TCAs", "Antihypertensives"],
    sideEffects: ["Drowsiness", "Dizziness", "Weakness", "Confusion", "Hypotension"],
    pregnancyCategory: "C",
    administrationNotes: "Do not discontinue abruptly - may cause hallucinations, seizures.",
    monitoringParameters: ["Spasticity", "Sedation", "Withdrawal symptoms"],
    labsRequired: ["BMP"],
    isControlled: false
  },

  // ERECTILE DYSFUNCTION
  {
    name: "Sildenafil",
    genericName: "Sildenafil Citrate",
    brandNames: ["Viagra", "Revatio"],
    category: "Genitourinary - PDE5 Inhibitor",
    form: "Tablet, Injection (Revatio)",
    strength: "25mg, 50mg, 100mg (ED); 20mg (PAH)",
    route: "Oral, IV",
    standardDoseAdult: "ED: 50mg 1 hour before activity; PAH: 20mg TID",
    maxDailyDose: "100mg (ED); 60mg (PAH)",
    dosingFrequency: "As needed for ED; TID for PAH",
    weightBasedDosing: false,
    renalAdjustment: "CrCl <30: Start 25mg",
    hepaticAdjustment: "Start 25mg",
    contraindications: ["Nitrates", "Riociguat", "Hypotension", "Recent stroke/MI"],
    drugInteractions: ["Nitrates", "Alpha blockers", "CYP3A4 inhibitors", "Riociguat"],
    sideEffects: ["Headache", "Flushing", "Dyspepsia", "Visual changes", "Priapism"],
    pregnancyCategory: "B",
    administrationNotes: "Take 30-60 minutes before activity. Avoid high-fat meals for ED use.",
    monitoringParameters: ["Efficacy", "Blood pressure", "Vision changes"],
    labsRequired: ["None routinely"],
    isControlled: false
  },

  // ANTIBIOTICS - Comprehensive International Coverage
  {
    name: "Azithromycin",
    genericName: "Azithromycin",
    brandNames: ["Zithromax", "Z-Pak", "Zmax"],
    category: "Antibiotic - Macrolide",
    form: "Tablet, Capsule, Suspension, Injection",
    strength: "250mg, 500mg, 600mg; Susp: 100mg/5mL, 200mg/5mL; IV: 500mg",
    route: "Oral, IV",
    standardDoseAdult: "500mg day 1, then 250mg days 2-5; or 500mg daily x3 days",
    standardDosePediatric: "10mg/kg day 1, then 5mg/kg days 2-5",
    maxDailyDose: "500mg",
    dosingFrequency: "Once daily",
    weightBasedDosing: true,
    weightBasedFormula: "10mg/kg day 1, then 5mg/kg days 2-5",
    renalAdjustment: "No adjustment needed",
    hepaticAdjustment: "Use with caution in severe hepatic impairment",
    contraindications: ["Hypersensitivity to macrolides", "History of cholestatic jaundice with azithromycin"],
    drugInteractions: ["Warfarin", "Digoxin", "Antacids", "Nelfinavir", "QT-prolonging drugs"],
    sideEffects: ["Diarrhea", "Nausea", "Abdominal pain", "QT prolongation", "Hearing changes"],
    blackBoxWarning: "QT prolongation and risk of potentially fatal cardiac arrhythmias.",
    pregnancyCategory: "B",
    administrationNotes: "May be taken with or without food. Complete full course.",
    monitoringParameters: ["Signs of infection", "QT interval in at-risk patients", "Liver function"],
    labsRequired: ["LFTs if prolonged use"],
    isControlled: false,
    marketStatus: "active",
    regulatoryApprovals: [
      { agency: "FDA", status: "approved", approvalDate: "1991-11-01", brandName: "Zithromax", indications: ["Community-Acquired Pneumonia", "Acute Bacterial Sinusitis", "Pharyngitis/Tonsillitis", "Skin Infections", "Chlamydia"], riskCategory: "Pregnancy Category B" },
      { agency: "EMA", status: "approved", approvalDate: "1992-03-15", brandName: "Zithromax", indications: ["Respiratory Tract Infections", "Skin Infections", "STIs"], restrictions: ["Monitor QT interval"] },
      { agency: "PMDA", status: "approved", approvalDate: "2000-09-22", brandName: "Zithromac", indications: ["Respiratory Infections", "Skin Infections", "Otitis Media"], riskCategory: "Use with caution in pregnancy" },
      { agency: "NMPA", status: "approved", approvalDate: "1996-08-10", brandName: "希舒美", indications: ["Respiratory Infections", "Skin Infections", "Urogenital Infections"] },
      { agency: "MFDS", status: "approved", approvalDate: "1995-04-20", brandName: "지스로맥스", indications: ["Respiratory Tract Infections", "Skin Infections"] },
      { agency: "MOHRU", status: "approved", approvalDate: "1998-06-15", brandName: "Сумамед", indications: ["Respiratory Infections", "Skin Infections", "STIs"] }
    ],
    regionalDosing: [
      { region: "USA", adultDose: "500mg day 1, then 250mg days 2-5", maxDose: "500mg/day", notes: "Z-Pak most common regimen" },
      { region: "EU", adultDose: "500mg daily for 3 days", maxDose: "500mg/day", notes: "Short-course therapy preferred" },
      { region: "Japan", adultDose: "500mg daily for 3 days", maxDose: "500mg/day", notes: "Single 2g dose for chlamydia" },
      { region: "Russia", adultDose: "500mg day 1, then 250mg days 2-5", maxDose: "500mg/day", notes: "Sumamed widely prescribed" }
    ],
    internationalBrandNames: [
      { region: "Japan", names: ["Zithromac", "ジスロマック"] },
      { region: "China", names: ["希舒美", "阿奇霉素"] },
      { region: "Korea", names: ["지스로맥스", "Zithromax"] },
      { region: "Russia", names: ["Сумамед", "Азитромицин"] },
      { region: "Germany", names: ["Zithromax", "Azithromycin"] },
      { region: "Spain", names: ["Zitromax", "Azitromicina"] }
    ]
  },
  {
    name: "Ciprofloxacin",
    genericName: "Ciprofloxacin",
    brandNames: ["Cipro", "Cipro XR"],
    category: "Antibiotic - Fluoroquinolone",
    form: "Tablet, Extended-release tablet, Suspension, Injection, Ophthalmic",
    strength: "250mg, 500mg, 750mg; XR: 500mg, 1000mg; IV: 200mg, 400mg",
    route: "Oral, IV, Ophthalmic, Otic",
    standardDoseAdult: "250-750mg every 12 hours; XR: 500-1000mg daily",
    standardDosePediatric: "10-20mg/kg/day divided every 12 hours (limited indications)",
    maxDailyDose: "1500mg oral; 1200mg IV",
    dosingFrequency: "Every 12 hours; XR once daily",
    weightBasedDosing: true,
    weightBasedFormula: "10-20mg/kg/day divided BID, max 1500mg/day",
    renalAdjustment: "CrCl 30-50: 250-500mg q12h; CrCl <30: 250-500mg q18h",
    hepaticAdjustment: "No adjustment needed",
    contraindications: ["Hypersensitivity to fluoroquinolones", "Concurrent tizanidine use", "Myasthenia gravis (relative)"],
    drugInteractions: ["Tizanidine", "Theophylline", "Warfarin", "Antacids", "Sucralfate", "NSAIDs"],
    sideEffects: ["Tendinitis", "Tendon rupture", "Nausea", "Diarrhea", "CNS effects", "Photosensitivity"],
    blackBoxWarning: "Disabling and potentially irreversible serious adverse reactions including tendinitis, tendon rupture, peripheral neuropathy, and CNS effects.",
    pregnancyCategory: "C",
    administrationNotes: "Take 2 hours before or 6 hours after antacids. Hydrate well.",
    monitoringParameters: ["Signs of tendinitis", "CNS symptoms", "Renal function"],
    labsRequired: ["BMP with prolonged use"],
    isControlled: false,
    marketStatus: "active",
    regulatoryApprovals: [
      { agency: "FDA", status: "approved", approvalDate: "1987-10-22", brandName: "Cipro", indications: ["UTI", "Respiratory Infections", "Skin Infections", "Bone/Joint Infections", "Anthrax Prophylaxis"], riskCategory: "Pregnancy Category C", additionalWarnings: ["Black box warning for tendon rupture"] },
      { agency: "EMA", status: "approved", approvalDate: "1987-05-10", brandName: "Ciproxin", indications: ["Respiratory Infections", "UTI", "GI Infections", "Bone Infections"] },
      { agency: "PMDA", status: "approved", approvalDate: "1988-03-25", brandName: "Ciproxan", indications: ["Respiratory Infections", "UTI", "Surgical Prophylaxis"], riskCategory: "Contraindicated in pregnancy" },
      { agency: "NMPA", status: "approved", approvalDate: "1990-11-20", brandName: "环丙沙星", indications: ["Respiratory Infections", "UTI", "GI Infections"] },
      { agency: "MFDS", status: "approved", approvalDate: "1989-08-15", brandName: "시프로", indications: ["UTI", "Respiratory Infections", "Skin Infections"] },
      { agency: "MOHRU", status: "approved", approvalDate: "1992-04-10", brandName: "Ципрофлоксацин", indications: ["Respiratory Infections", "UTI", "Skin Infections", "Bone Infections"] }
    ],
    regionalDosing: [
      { region: "USA", adultDose: "250-750mg every 12 hours", maxDose: "1500mg/day", notes: "Higher doses for severe infections" },
      { region: "EU", adultDose: "250-750mg every 12 hours", maxDose: "1500mg/day", notes: "Restricted use per EMA recommendations" },
      { region: "Japan", adultDose: "100-200mg every 12 hours", maxDose: "600mg/day", notes: "Lower doses typically used" },
      { region: "Russia", adultDose: "250-500mg every 12 hours", maxDose: "1500mg/day", notes: "Widely available as generic" }
    ],
    internationalBrandNames: [
      { region: "Japan", names: ["Ciproxan", "シプロキサン"] },
      { region: "China", names: ["环丙沙星", "拜复乐"] },
      { region: "Korea", names: ["시프로", "Cipro"] },
      { region: "Russia", names: ["Ципрофлоксацин", "Ципролет"] },
      { region: "Germany", names: ["Ciprobay", "Ciprofloxacin"] },
      { region: "Spain", names: ["Ciprofloxacino", "Baycip"] }
    ]
  },
  {
    name: "Amoxicillin",
    genericName: "Amoxicillin",
    brandNames: ["Amoxil", "Trimox", "Moxatag"],
    category: "Antibiotic - Penicillin",
    form: "Capsule, Tablet, Chewable tablet, Suspension",
    strength: "250mg, 500mg, 875mg; Chewable: 125mg, 250mg; Susp: 125mg/5mL, 250mg/5mL, 400mg/5mL",
    route: "Oral",
    standardDoseAdult: "250-500mg every 8 hours or 500-875mg every 12 hours",
    standardDosePediatric: "25-45mg/kg/day divided every 8-12 hours",
    maxDailyDose: "3g",
    dosingFrequency: "Every 8-12 hours",
    weightBasedDosing: true,
    weightBasedFormula: "25-45mg/kg/day divided every 8-12 hours",
    renalAdjustment: "CrCl 10-30: 250-500mg every 12 hours; CrCl <10: 250-500mg every 24 hours",
    hepaticAdjustment: "No adjustment needed",
    contraindications: ["Penicillin allergy", "History of amoxicillin-associated cholestatic jaundice"],
    drugInteractions: ["Warfarin", "Methotrexate", "Probenecid", "Allopurinol"],
    sideEffects: ["Diarrhea", "Nausea", "Rash", "Allergic reactions", "C. difficile colitis"],
    pregnancyCategory: "B",
    administrationNotes: "May be taken with or without food. Complete full course.",
    monitoringParameters: ["Signs of infection", "Allergic reactions", "GI symptoms"],
    labsRequired: ["None routinely"],
    isControlled: false,
    marketStatus: "active",
    regulatoryApprovals: [
      { agency: "FDA", status: "approved", approvalDate: "1974-02-03", brandName: "Amoxil", indications: ["Respiratory Infections", "UTI", "Skin Infections", "H. pylori Eradication", "Endocarditis Prophylaxis"], riskCategory: "Pregnancy Category B" },
      { agency: "EMA", status: "approved", approvalDate: "1972-06-15", brandName: "Amoxil", indications: ["Respiratory Infections", "UTI", "Skin Infections", "Dental Infections"] },
      { agency: "PMDA", status: "approved", approvalDate: "1975-09-10", brandName: "Sawacillin", indications: ["Respiratory Infections", "UTI", "Skin Infections"], riskCategory: "Use with caution in pregnancy" },
      { agency: "NMPA", status: "approved", approvalDate: "1985-03-20", brandName: "阿莫西林", indications: ["Respiratory Infections", "UTI", "Skin Infections", "GI Infections"] },
      { agency: "MFDS", status: "approved", approvalDate: "1980-11-25", brandName: "아목시실린", indications: ["Respiratory Infections", "UTI", "Dental Infections"] },
      { agency: "MOHRU", status: "approved", approvalDate: "1988-07-12", brandName: "Амоксициллин", indications: ["Respiratory Infections", "UTI", "Skin Infections", "GI Infections"] }
    ],
    regionalDosing: [
      { region: "USA", adultDose: "250-500mg every 8 hours", maxDose: "3g/day", notes: "High-dose for respiratory infections" },
      { region: "EU", adultDose: "250-500mg every 8 hours", maxDose: "3g/day", notes: "First-line for many infections" },
      { region: "Japan", adultDose: "250mg every 8 hours", maxDose: "1500mg/day", notes: "Lower doses typically sufficient" },
      { region: "Russia", adultDose: "250-500mg every 8 hours", maxDose: "3g/day", notes: "Widely used first-line antibiotic" }
    ],
    internationalBrandNames: [
      { region: "Japan", names: ["Sawacillin", "サワシリン", "Pasetocin", "パセトシン"] },
      { region: "China", names: ["阿莫西林", "阿莫仙"] },
      { region: "Korea", names: ["아목시실린", "Amoxicillin"] },
      { region: "Russia", names: ["Амоксициллин", "Флемоксин Солютаб"] },
      { region: "Germany", names: ["Amoxicillin", "Amoxypen"] },
      { region: "Spain", names: ["Clamoxyl", "Amoxicilina"] }
    ]
  },
  {
    name: "Ceftriaxone",
    genericName: "Ceftriaxone Sodium",
    brandNames: ["Rocephin"],
    category: "Antibiotic - Cephalosporin (3rd Generation)",
    form: "Injection",
    strength: "250mg, 500mg, 1g, 2g",
    route: "IV, IM",
    standardDoseAdult: "1-2g every 12-24 hours",
    standardDosePediatric: "50-100mg/kg/day divided every 12-24 hours",
    maxDailyDose: "4g",
    dosingFrequency: "Every 12-24 hours",
    weightBasedDosing: true,
    weightBasedFormula: "50-100mg/kg/day, max 4g/day",
    renalAdjustment: "No adjustment for renal impairment alone; reduce if combined hepatic/renal dysfunction",
    hepaticAdjustment: "Max 2g/day in severe hepatic impairment with renal dysfunction",
    contraindications: ["Cephalosporin allergy", "Neonates with hyperbilirubinemia", "Concomitant calcium-containing IV solutions in neonates"],
    drugInteractions: ["Calcium-containing products (in neonates)", "Warfarin", "Probenecid"],
    sideEffects: ["Diarrhea", "Rash", "Injection site reactions", "Biliary sludge", "Eosinophilia"],
    blackBoxWarning: "In neonates: Do not administer with calcium-containing IV products due to fatal reactions.",
    pregnancyCategory: "B",
    administrationNotes: "IM: Reconstitute with lidocaine 1% for less painful injection. IV: Infuse over 30 min.",
    monitoringParameters: ["Signs of infection", "Renal function", "Hepatic function", "CBC"],
    labsRequired: ["CBC", "BMP", "LFTs with prolonged use"],
    isControlled: false,
    marketStatus: "active",
    regulatoryApprovals: [
      { agency: "FDA", status: "approved", approvalDate: "1984-12-21", brandName: "Rocephin", indications: ["Lower Respiratory Infections", "UTI", "Meningitis", "Septicemia", "Gonorrhea", "Skin Infections"], riskCategory: "Pregnancy Category B" },
      { agency: "EMA", status: "approved", approvalDate: "1982-09-10", brandName: "Rocephin", indications: ["Severe Infections", "Meningitis", "Surgical Prophylaxis"] },
      { agency: "PMDA", status: "approved", approvalDate: "1986-06-20", brandName: "Rocephin", indications: ["Severe Infections", "Sepsis", "Meningitis"], riskCategory: "Use with caution in pregnancy" },
      { agency: "NMPA", status: "approved", approvalDate: "1992-04-15", brandName: "罗氏芬", indications: ["Severe Infections", "Meningitis", "Septicemia"] },
      { agency: "MFDS", status: "approved", approvalDate: "1988-10-30", brandName: "로세핀", indications: ["Severe Infections", "Surgical Prophylaxis", "Gonorrhea"] },
      { agency: "MOHRU", status: "approved", approvalDate: "1995-02-28", brandName: "Цефтриаксон", indications: ["Severe Infections", "Meningitis", "Sepsis", "Surgical Prophylaxis"] }
    ],
    regionalDosing: [
      { region: "USA", adultDose: "1-2g every 12-24 hours", maxDose: "4g/day", notes: "Once daily dosing for most indications" },
      { region: "EU", adultDose: "1-2g every 24 hours", maxDose: "4g/day", notes: "Once daily preferred" },
      { region: "Japan", adultDose: "1-2g every 12-24 hours", maxDose: "4g/day", notes: "Commonly used for severe infections" },
      { region: "Russia", adultDose: "1-2g every 24 hours", maxDose: "4g/day", notes: "First-line for many severe infections" }
    ],
    internationalBrandNames: [
      { region: "Japan", names: ["Rocephin", "ロセフィン"] },
      { region: "China", names: ["罗氏芬", "头孢曲松"] },
      { region: "Korea", names: ["로세핀", "Rocephin"] },
      { region: "Russia", names: ["Цефтриаксон", "Роцефин"] },
      { region: "Germany", names: ["Rocephin", "Ceftriaxon"] },
      { region: "Spain", names: ["Rocefalin", "Ceftriaxona"] }
    ]
  },
  {
    name: "Levofloxacin",
    genericName: "Levofloxacin",
    brandNames: ["Levaquin"],
    category: "Antibiotic - Fluoroquinolone",
    form: "Tablet, Injection, Ophthalmic",
    strength: "250mg, 500mg, 750mg; IV: 250mg, 500mg, 750mg",
    route: "Oral, IV, Ophthalmic",
    standardDoseAdult: "250-750mg once daily",
    standardDosePediatric: "8-10mg/kg/day (limited indications)",
    maxDailyDose: "750mg",
    dosingFrequency: "Once daily",
    weightBasedDosing: false,
    renalAdjustment: "CrCl 20-49: 750mg initially, then 500mg q48h; CrCl 10-19: 750mg initially, then 250mg q48h",
    hepaticAdjustment: "No adjustment needed",
    contraindications: ["Hypersensitivity to fluoroquinolones", "Myasthenia gravis"],
    drugInteractions: ["Theophylline", "Warfarin", "NSAIDs", "Antacids", "Sucralfate", "Iron"],
    sideEffects: ["Tendinitis", "Tendon rupture", "Nausea", "Diarrhea", "Headache", "Insomnia"],
    blackBoxWarning: "Disabling and potentially irreversible serious adverse reactions including tendinitis, tendon rupture, peripheral neuropathy, and CNS effects.",
    pregnancyCategory: "C",
    administrationNotes: "Take 2 hours before or 2 hours after antacids/iron. Hydrate well.",
    monitoringParameters: ["Signs of tendinitis", "CNS symptoms", "Glucose in diabetics"],
    labsRequired: ["BMP", "Blood glucose in diabetics"],
    isControlled: false,
    marketStatus: "active",
    regulatoryApprovals: [
      { agency: "FDA", status: "approved", approvalDate: "1996-12-20", brandName: "Levaquin", indications: ["Community-Acquired Pneumonia", "Nosocomial Pneumonia", "Chronic Bronchitis", "UTI", "Skin Infections", "Anthrax"], riskCategory: "Pregnancy Category C" },
      { agency: "EMA", status: "approved", approvalDate: "1997-06-27", brandName: "Tavanic", indications: ["Respiratory Infections", "UTI", "Skin Infections"], restrictions: ["Restricted use per EMA"] },
      { agency: "PMDA", status: "approved", approvalDate: "1993-12-01", brandName: "Cravit", indications: ["Respiratory Infections", "UTI", "Skin Infections"], riskCategory: "Contraindicated in pregnancy" },
      { agency: "NMPA", status: "approved", approvalDate: "1998-09-10", brandName: "可乐必妥", indications: ["Respiratory Infections", "UTI", "Skin Infections"] },
      { agency: "MFDS", status: "approved", approvalDate: "1997-03-25", brandName: "레바퀸", indications: ["Respiratory Infections", "UTI", "Skin Infections"] },
      { agency: "MOHRU", status: "approved", approvalDate: "2000-08-15", brandName: "Левофлоксацин", indications: ["Respiratory Infections", "UTI", "Skin Infections", "Prostatitis"] }
    ],
    regionalDosing: [
      { region: "USA", adultDose: "250-750mg once daily", maxDose: "750mg/day", notes: "5-14 day course typical" },
      { region: "EU", adultDose: "250-500mg once daily", maxDose: "500mg/day", notes: "Restricted to serious infections" },
      { region: "Japan", adultDose: "500mg once daily", maxDose: "500mg/day", notes: "Lower doses typical" },
      { region: "Russia", adultDose: "250-500mg once daily", maxDose: "750mg/day", notes: "Widely used respiratory quinolone" }
    ],
    internationalBrandNames: [
      { region: "Japan", names: ["Cravit", "クラビット"] },
      { region: "China", names: ["可乐必妥", "左氧氟沙星"] },
      { region: "Korea", names: ["레바퀸", "Levaquin"] },
      { region: "Russia", names: ["Левофлоксацин", "Таваник"] },
      { region: "Germany", names: ["Tavanic", "Levofloxacin"] },
      { region: "Spain", names: ["Tavanic", "Levofloxacino"] }
    ]
  },
  {
    name: "Doxycycline",
    genericName: "Doxycycline",
    brandNames: ["Vibramycin", "Doryx", "Oracea"],
    category: "Antibiotic - Tetracycline",
    form: "Capsule, Tablet, Delayed-release tablet, Suspension, Injection",
    strength: "50mg, 75mg, 100mg, 150mg; DR: 40mg, 75mg, 100mg, 150mg",
    route: "Oral, IV",
    standardDoseAdult: "100mg every 12 hours on day 1, then 100mg once daily or 50mg every 12 hours",
    standardDosePediatric: "4.4mg/kg/day divided every 12 hours day 1, then 2.2-4.4mg/kg/day (>8 years)",
    maxDailyDose: "200mg (acute); 100mg (maintenance)",
    dosingFrequency: "Once or twice daily",
    weightBasedDosing: true,
    weightBasedFormula: "2.2-4.4mg/kg/day divided BID",
    renalAdjustment: "No adjustment needed",
    hepaticAdjustment: "Use with caution",
    contraindications: ["Hypersensitivity to tetracyclines", "Children under 8 years (tooth discoloration)", "Pregnancy"],
    drugInteractions: ["Antacids", "Iron", "Calcium", "Warfarin", "Barbiturates", "Phenytoin", "Isotretinoin"],
    sideEffects: ["Photosensitivity", "Nausea", "Esophageal ulceration", "Tooth discoloration (children)", "Pseudotumor cerebri"],
    pregnancyCategory: "D",
    administrationNotes: "Take with full glass of water. Avoid lying down 30 min after dose. Take with food if GI upset.",
    monitoringParameters: ["Signs of infection", "GI symptoms", "Photosensitivity"],
    labsRequired: ["None routinely"],
    isControlled: false,
    marketStatus: "active",
    regulatoryApprovals: [
      { agency: "FDA", status: "approved", approvalDate: "1967-02-04", brandName: "Vibramycin", indications: ["Respiratory Infections", "UTI", "Acne", "Lyme Disease", "Malaria Prophylaxis", "STIs"], riskCategory: "Pregnancy Category D" },
      { agency: "EMA", status: "approved", approvalDate: "1967-09-15", brandName: "Vibramycin", indications: ["Respiratory Infections", "Acne", "Lyme Disease", "Malaria Prophylaxis"] },
      { agency: "PMDA", status: "approved", approvalDate: "1969-06-20", brandName: "Vibramycin", indications: ["Respiratory Infections", "Acne", "STIs"], riskCategory: "Contraindicated in pregnancy" },
      { agency: "NMPA", status: "approved", approvalDate: "1985-10-15", brandName: "多西环素", indications: ["Respiratory Infections", "Acne", "Lyme Disease"] },
      { agency: "MFDS", status: "approved", approvalDate: "1980-06-10", brandName: "독시사이클린", indications: ["Respiratory Infections", "Acne", "Lyme Disease"] },
      { agency: "MOHRU", status: "approved", approvalDate: "1990-03-25", brandName: "Доксициклин", indications: ["Respiratory Infections", "Acne", "Lyme Disease", "STIs"] }
    ],
    regionalDosing: [
      { region: "USA", adultDose: "100mg every 12 hours or 200mg once daily", maxDose: "200mg/day", notes: "Loading dose on day 1" },
      { region: "EU", adultDose: "100-200mg once daily", maxDose: "200mg/day", notes: "Take with food" },
      { region: "Japan", adultDose: "100mg once or twice daily", maxDose: "200mg/day", notes: "Similar dosing to Western countries" },
      { region: "Russia", adultDose: "100mg every 12 hours", maxDose: "200mg/day", notes: "Widely used for various infections" }
    ],
    internationalBrandNames: [
      { region: "Japan", names: ["Vibramycin", "ビブラマイシン"] },
      { region: "China", names: ["多西环素", "强力霉素"] },
      { region: "Korea", names: ["독시사이클린", "Doxycycline"] },
      { region: "Russia", names: ["Доксициклин", "Юнидокс Солютаб"] },
      { region: "Germany", names: ["Doxycyclin", "Vibramycin"] },
      { region: "Spain", names: ["Vibravenosa", "Doxiciclina"] }
    ]
  },
  {
    name: "Metronidazole",
    genericName: "Metronidazole",
    brandNames: ["Flagyl", "Flagyl ER", "MetroGel"],
    category: "Antibiotic - Nitroimidazole",
    form: "Tablet, Capsule, Extended-release tablet, Injection, Topical gel/cream",
    strength: "250mg, 500mg; ER: 750mg; IV: 500mg",
    route: "Oral, IV, Topical, Vaginal",
    standardDoseAdult: "250-500mg every 8 hours or 500-750mg every 12 hours",
    standardDosePediatric: "30-50mg/kg/day divided every 8 hours",
    maxDailyDose: "4g",
    dosingFrequency: "Every 8-12 hours",
    weightBasedDosing: true,
    weightBasedFormula: "30-50mg/kg/day divided TID",
    renalAdjustment: "No adjustment needed for renal impairment",
    hepaticAdjustment: "Reduce dose 50% in severe hepatic impairment",
    contraindications: ["First trimester pregnancy", "Alcohol use during and 3 days after treatment", "Disulfiram within 2 weeks"],
    drugInteractions: ["Alcohol", "Warfarin", "Lithium", "Phenytoin", "Phenobarbital"],
    sideEffects: ["Metallic taste", "Nausea", "Headache", "Dark urine", "Disulfiram-like reaction with alcohol"],
    blackBoxWarning: "Carcinogenic in rodents. Use only for approved indications.",
    pregnancyCategory: "B (avoid first trimester)",
    administrationNotes: "Avoid alcohol during treatment and 3 days after. Take with food to reduce GI upset.",
    monitoringParameters: ["Signs of infection", "Neurologic symptoms with prolonged use", "CBC"],
    labsRequired: ["CBC with prolonged use"],
    isControlled: false,
    marketStatus: "active",
    regulatoryApprovals: [
      { agency: "FDA", status: "approved", approvalDate: "1963-08-08", brandName: "Flagyl", indications: ["Trichomoniasis", "Bacterial Vaginosis", "C. difficile Infection", "Anaerobic Infections", "H. pylori"], riskCategory: "Pregnancy Category B" },
      { agency: "EMA", status: "approved", approvalDate: "1960-05-20", brandName: "Flagyl", indications: ["Anaerobic Infections", "Protozoal Infections", "C. difficile"] },
      { agency: "PMDA", status: "approved", approvalDate: "1961-09-10", brandName: "Flagyl", indications: ["Trichomoniasis", "Giardiasis", "Anaerobic Infections"], riskCategory: "Use with caution in pregnancy" },
      { agency: "NMPA", status: "approved", approvalDate: "1980-06-15", brandName: "甲硝唑", indications: ["Anaerobic Infections", "Protozoal Infections", "H. pylori"] },
      { agency: "MFDS", status: "approved", approvalDate: "1975-04-20", brandName: "메트로니다졸", indications: ["Anaerobic Infections", "Protozoal Infections"] },
      { agency: "MOHRU", status: "approved", approvalDate: "1985-11-30", brandName: "Метронидазол", indications: ["Anaerobic Infections", "Protozoal Infections", "H. pylori"] }
    ],
    regionalDosing: [
      { region: "USA", adultDose: "250-500mg TID or 500mg BID", maxDose: "4g/day", notes: "7-14 day courses typical" },
      { region: "EU", adultDose: "400-500mg every 8 hours", maxDose: "4g/day", notes: "Avoid alcohol strictly" },
      { region: "Japan", adultDose: "250mg every 8 hours", maxDose: "2250mg/day", notes: "Similar indications" },
      { region: "Russia", adultDose: "250-500mg every 8 hours", maxDose: "4g/day", notes: "Widely used for anaerobic infections" }
    ],
    internationalBrandNames: [
      { region: "Japan", names: ["Flagyl", "フラジール"] },
      { region: "China", names: ["甲硝唑", "灭滴灵"] },
      { region: "Korea", names: ["메트로니다졸", "Metronidazole"] },
      { region: "Russia", names: ["Метронидазол", "Трихопол"] },
      { region: "Germany", names: ["Clont", "Metronidazol"] },
      { region: "Spain", names: ["Flagyl", "Metronidazol"] }
    ]
  },
  {
    name: "Vancomycin",
    genericName: "Vancomycin Hydrochloride",
    brandNames: ["Vancocin", "Firvanq"],
    category: "Antibiotic - Glycopeptide",
    form: "Injection, Capsule (oral for C. diff)",
    strength: "IV: 500mg, 750mg, 1g, 1.25g, 1.5g; Oral: 125mg, 250mg",
    route: "IV, Oral (for C. difficile only)",
    standardDoseAdult: "IV: 15-20mg/kg every 8-12 hours; Oral: 125mg every 6 hours",
    standardDosePediatric: "IV: 10-15mg/kg every 6 hours; Oral: 10mg/kg every 6 hours",
    maxDailyDose: "IV: 4g; Oral: 2g",
    dosingFrequency: "IV: Every 8-12 hours; Oral: Every 6 hours",
    weightBasedDosing: true,
    weightBasedFormula: "IV: 15-20mg/kg/dose; Oral: 10mg/kg/dose",
    renalAdjustment: "Adjust based on trough levels and renal function; CrCl <30: extend interval",
    hepaticAdjustment: "No adjustment needed",
    contraindications: ["Hypersensitivity to vancomycin"],
    drugInteractions: ["Aminoglycosides", "NSAIDs", "Loop diuretics", "Other nephrotoxic/ototoxic drugs"],
    sideEffects: ["Red man syndrome", "Nephrotoxicity", "Ototoxicity", "Thrombophlebitis", "Neutropenia"],
    pregnancyCategory: "B (IV); C (Oral)",
    administrationNotes: "IV: Infuse over at least 1 hour. Monitor trough levels. Oral only for C. diff.",
    monitoringParameters: ["Trough levels (IV)", "Renal function", "Hearing", "CBC", "Signs of infection"],
    labsRequired: ["Vancomycin trough", "BMP", "CBC"],
    isControlled: false,
    marketStatus: "active",
    regulatoryApprovals: [
      { agency: "FDA", status: "approved", approvalDate: "1958-11-01", brandName: "Vancocin", indications: ["MRSA Infections", "C. difficile Infection", "Endocarditis", "Osteomyelitis", "Pneumonia"], riskCategory: "Pregnancy Category B/C" },
      { agency: "EMA", status: "approved", approvalDate: "1958-06-15", brandName: "Vancomycin", indications: ["Serious Gram-positive Infections", "C. difficile Colitis", "MRSA"] },
      { agency: "PMDA", status: "approved", approvalDate: "1981-07-01", brandName: "Vancomycin", indications: ["MRSA Infections", "Sepsis", "Endocarditis"], riskCategory: "Use with caution in pregnancy" },
      { agency: "NMPA", status: "approved", approvalDate: "1995-08-20", brandName: "万古霉素", indications: ["MRSA Infections", "C. difficile", "Severe Gram-positive Infections"] },
      { agency: "MFDS", status: "approved", approvalDate: "1990-03-15", brandName: "반코마이신", indications: ["MRSA Infections", "C. difficile", "Endocarditis"] },
      { agency: "MOHRU", status: "approved", approvalDate: "1998-12-10", brandName: "Ванкомицин", indications: ["MRSA Infections", "C. difficile", "Severe Gram-positive Infections"] }
    ],
    regionalDosing: [
      { region: "USA", adultDose: "15-20mg/kg every 8-12 hours IV", maxDose: "4g/day", notes: "Target trough 15-20 mcg/mL for serious infections" },
      { region: "EU", adultDose: "15-20mg/kg every 8-12 hours IV", maxDose: "4g/day", notes: "AUC/MIC dosing increasingly used" },
      { region: "Japan", adultDose: "10-15mg/kg every 6-12 hours IV", maxDose: "2g/day", notes: "Lower doses typically used" },
      { region: "Russia", adultDose: "1g every 12 hours IV", maxDose: "4g/day", notes: "Reserved for resistant organisms" }
    ],
    internationalBrandNames: [
      { region: "Japan", names: ["Vancomycin", "バンコマイシン"] },
      { region: "China", names: ["万古霉素", "稳可信"] },
      { region: "Korea", names: ["반코마이신", "Vancomycin"] },
      { region: "Russia", names: ["Ванкомицин", "Эдицин"] },
      { region: "Germany", names: ["Vancomycin", "Vanco"] },
      { region: "Spain", names: ["Vancomicina", "Vancocin"] }
    ]
  },

  // ANTIVIRAL MEDICATIONS
  {
    name: "Oseltamivir",
    genericName: "Oseltamivir Phosphate",
    brandNames: ["Tamiflu"],
    category: "Antiviral - Neuraminidase Inhibitor",
    form: "Capsule, Oral suspension",
    strength: "30mg, 45mg, 75mg; Susp: 6mg/mL",
    route: "Oral",
    standardDoseAdult: "Treatment: 75mg twice daily x5 days; Prophylaxis: 75mg once daily x10 days",
    standardDosePediatric: "Treatment: ≤15kg: 30mg BID; >15-23kg: 45mg BID; >23-40kg: 60mg BID; >40kg: 75mg BID",
    maxDailyDose: "150mg",
    dosingFrequency: "Once or twice daily",
    weightBasedDosing: true,
    weightBasedFormula: "Weight-banded dosing for pediatrics",
    renalAdjustment: "CrCl 30-60: 30mg BID treatment, 30mg daily prophylaxis; CrCl 10-30: 30mg daily treatment, 30mg every other day prophylaxis",
    hepaticAdjustment: "No adjustment needed",
    contraindications: ["Hypersensitivity to oseltamivir"],
    drugInteractions: ["Live attenuated influenza vaccine (avoid 2 weeks before to 48 hours after)"],
    sideEffects: ["Nausea", "Vomiting", "Headache", "Neuropsychiatric events (rare)"],
    pregnancyCategory: "C",
    administrationNotes: "Start within 48 hours of symptom onset for best efficacy. May take with food to reduce GI upset.",
    monitoringParameters: ["Symptom improvement", "Neuropsychiatric symptoms", "Renal function"],
    labsRequired: ["BMP if renal impairment suspected"],
    isControlled: false,
    marketStatus: "active",
    regulatoryApprovals: [
      { agency: "FDA", status: "approved", approvalDate: "1999-10-27", brandName: "Tamiflu", indications: ["Influenza Treatment", "Influenza Prophylaxis"], riskCategory: "Pregnancy Category C" },
      { agency: "EMA", status: "approved", approvalDate: "2002-06-20", brandName: "Tamiflu", indications: ["Influenza A and B Treatment and Prophylaxis"] },
      { agency: "PMDA", status: "approved", approvalDate: "2001-02-01", brandName: "Tamiflu", indications: ["Influenza Treatment and Prophylaxis"], riskCategory: "Use with caution in pregnancy", additionalWarnings: ["Monitor for neuropsychiatric events in adolescents"] },
      { agency: "NMPA", status: "approved", approvalDate: "2002-11-15", brandName: "达菲", indications: ["Influenza Treatment and Prophylaxis"] },
      { agency: "MFDS", status: "approved", approvalDate: "2002-05-20", brandName: "타미플루", indications: ["Influenza Treatment and Prophylaxis"] },
      { agency: "MOHRU", status: "approved", approvalDate: "2005-09-10", brandName: "Тамифлю", indications: ["Influenza Treatment and Prophylaxis"] }
    ],
    regionalDosing: [
      { region: "USA", adultDose: "75mg BID x5 days treatment", maxDose: "150mg/day", notes: "Start within 48 hours of symptoms" },
      { region: "EU", adultDose: "75mg BID x5 days treatment", maxDose: "150mg/day", notes: "Prophylaxis 75mg once daily" },
      { region: "Japan", adultDose: "75mg BID x5 days", maxDose: "150mg/day", notes: "Extensive use; monitor neuropsychiatric events" },
      { region: "Russia", adultDose: "75mg BID x5 days", maxDose: "150mg/day", notes: "Strategic reserve medication" }
    ],
    internationalBrandNames: [
      { region: "Japan", names: ["Tamiflu", "タミフル"] },
      { region: "China", names: ["达菲", "奥司他韦"] },
      { region: "Korea", names: ["타미플루", "Tamiflu"] },
      { region: "Russia", names: ["Тамифлю", "Осельтамивир"] },
      { region: "Germany", names: ["Tamiflu", "Oseltamivir"] },
      { region: "Spain", names: ["Tamiflu", "Oseltamivir"] }
    ]
  },
  {
    name: "Acyclovir",
    genericName: "Acyclovir",
    brandNames: ["Zovirax"],
    category: "Antiviral - Nucleoside Analog",
    form: "Tablet, Capsule, Suspension, Injection, Topical cream/ointment",
    strength: "200mg, 400mg, 800mg; IV: 500mg, 1g; Cream: 5%",
    route: "Oral, IV, Topical",
    standardDoseAdult: "Genital herpes: 400mg TID or 200mg 5x/day; Zoster: 800mg 5x/day; IV: 5-10mg/kg every 8 hours",
    standardDosePediatric: "HSV: 20mg/kg/dose TID; Varicella: 20mg/kg/dose QID (max 800mg/dose)",
    maxDailyDose: "4g oral; 30mg/kg IV",
    dosingFrequency: "Three to five times daily oral; every 8 hours IV",
    weightBasedDosing: true,
    weightBasedFormula: "20mg/kg/dose TID for HSV; 5-10mg/kg/dose every 8 hours IV",
    renalAdjustment: "CrCl 25-50: normal dose every 12 hours; CrCl 10-25: normal dose every 24 hours; CrCl <10: 50% dose every 24 hours",
    hepaticAdjustment: "No adjustment needed",
    contraindications: ["Hypersensitivity to acyclovir or valacyclovir"],
    drugInteractions: ["Probenecid", "Nephrotoxic drugs", "Mycophenolate", "Theophylline"],
    sideEffects: ["Nausea", "Headache", "Nephrotoxicity (IV)", "Neurotoxicity (rare)", "Crystalluria"],
    pregnancyCategory: "B",
    administrationNotes: "IV: Infuse over 1 hour with adequate hydration. Oral: maintain hydration.",
    monitoringParameters: ["Renal function", "Hydration status", "Signs of neurotoxicity"],
    labsRequired: ["BMP"],
    isControlled: false,
    marketStatus: "active",
    regulatoryApprovals: [
      { agency: "FDA", status: "approved", approvalDate: "1982-03-29", brandName: "Zovirax", indications: ["Herpes Simplex", "Herpes Zoster", "Varicella", "HSV Encephalitis"], riskCategory: "Pregnancy Category B" },
      { agency: "EMA", status: "approved", approvalDate: "1981-09-15", brandName: "Zovirax", indications: ["HSV Infections", "VZV Infections", "CMV Prophylaxis"] },
      { agency: "PMDA", status: "approved", approvalDate: "1985-10-25", brandName: "Zovirax", indications: ["HSV Infections", "VZV Infections"], riskCategory: "Use with caution in pregnancy" },
      { agency: "NMPA", status: "approved", approvalDate: "1990-07-10", brandName: "阿昔洛韦", indications: ["HSV Infections", "VZV Infections"] },
      { agency: "MFDS", status: "approved", approvalDate: "1988-04-15", brandName: "아시클로버", indications: ["HSV Infections", "VZV Infections"] },
      { agency: "MOHRU", status: "approved", approvalDate: "1992-06-20", brandName: "Ацикловир", indications: ["HSV Infections", "VZV Infections", "CMV Prevention"] }
    ],
    regionalDosing: [
      { region: "USA", adultDose: "200-800mg 3-5 times daily", maxDose: "4g/day oral", notes: "Higher doses for zoster" },
      { region: "EU", adultDose: "200-800mg 3-5 times daily", maxDose: "4g/day oral", notes: "IV for severe infections" },
      { region: "Japan", adultDose: "200-400mg 5 times daily", maxDose: "4g/day", notes: "Similar dosing regimens" },
      { region: "Russia", adultDose: "200-400mg 5 times daily", maxDose: "4g/day", notes: "Widely available generic" }
    ],
    internationalBrandNames: [
      { region: "Japan", names: ["Zovirax", "ゾビラックス"] },
      { region: "China", names: ["阿昔洛韦", "无环鸟苷"] },
      { region: "Korea", names: ["아시클로버", "Acyclovir"] },
      { region: "Russia", names: ["Ацикловир", "Зовиракс"] },
      { region: "Germany", names: ["Zovirax", "Aciclovir"] },
      { region: "Spain", names: ["Zovirax", "Aciclovir"] }
    ]
  },
  {
    name: "Remdesivir",
    genericName: "Remdesivir",
    brandNames: ["Veklury"],
    category: "Antiviral - Nucleotide Analog",
    form: "Injection",
    strength: "100mg lyophilized powder; 100mg/20mL solution",
    route: "IV",
    standardDoseAdult: "200mg IV day 1, then 100mg IV daily for 4 days (total 5 days); up to 10 days for severe COVID-19",
    standardDosePediatric: "≥3.5kg to <40kg: 5mg/kg day 1, then 2.5mg/kg daily; ≥40kg: adult dosing",
    maxDailyDose: "200mg day 1; 100mg thereafter",
    dosingFrequency: "Once daily",
    weightBasedDosing: true,
    weightBasedFormula: "<40kg: 5mg/kg day 1, then 2.5mg/kg daily",
    renalAdjustment: "Not recommended if eGFR <30 (formulation contains sulfobutylether-β-cyclodextrin)",
    hepaticAdjustment: "Not studied in hepatic impairment",
    contraindications: ["Hypersensitivity to remdesivir", "eGFR <30 mL/min (due to excipient)"],
    drugInteractions: ["Chloroquine (antagonism)", "Hydroxychloroquine (antagonism)"],
    sideEffects: ["Nausea", "Elevated transaminases", "Bradycardia", "Infusion-related reactions", "Renal impairment"],
    pregnancyCategory: "Not established (insufficient data)",
    administrationNotes: "Infuse over 30-120 minutes. Monitor LFTs and renal function.",
    monitoringParameters: ["LFTs", "Renal function", "Heart rate", "Infusion reactions"],
    labsRequired: ["LFTs", "BMP", "eGFR"],
    isControlled: false,
    marketStatus: "active",
    regulatoryApprovals: [
      { agency: "FDA", status: "approved", approvalDate: "2020-10-22", brandName: "Veklury", indications: ["COVID-19 requiring hospitalization"], riskCategory: "Insufficient pregnancy data", additionalWarnings: ["EUA initially, then full approval"] },
      { agency: "EMA", status: "approved", approvalDate: "2020-07-03", brandName: "Veklury", indications: ["COVID-19 with pneumonia requiring supplemental oxygen"], restrictions: ["Hospital use only"] },
      { agency: "PMDA", status: "approved", approvalDate: "2020-05-07", brandName: "Veklury", indications: ["COVID-19 requiring oxygen or mechanical ventilation"], riskCategory: "Special approval pathway" },
      { agency: "NMPA", status: "approved", approvalDate: "2021-05-20", brandName: "瑞德西韦", indications: ["COVID-19 requiring hospitalization"] },
      { agency: "MFDS", status: "approved", approvalDate: "2020-07-24", brandName: "베클루리", indications: ["COVID-19 with pneumonia"] },
      { agency: "MOHRU", status: "approved", approvalDate: "2020-11-19", brandName: "Ремдесивир", indications: ["COVID-19 requiring hospitalization"] }
    ],
    regionalDosing: [
      { region: "USA", adultDose: "200mg day 1, then 100mg daily", maxDose: "200mg/day", notes: "5 days typical; 10 days if on ventilator" },
      { region: "EU", adultDose: "200mg day 1, then 100mg daily", maxDose: "200mg/day", notes: "5-10 day course" },
      { region: "Japan", adultDose: "200mg day 1, then 100mg daily", maxDose: "200mg/day", notes: "Special approval for COVID-19" },
      { region: "Russia", adultDose: "200mg day 1, then 100mg daily", maxDose: "200mg/day", notes: "5-10 day course" }
    ],
    internationalBrandNames: [
      { region: "Japan", names: ["Veklury", "ベクルリー"] },
      { region: "China", names: ["瑞德西韦", "Veklury"] },
      { region: "Korea", names: ["베클루리", "Veklury"] },
      { region: "Russia", names: ["Ремдесивир", "Веклури"] },
      { region: "Germany", names: ["Veklury", "Remdesivir"] },
      { region: "Spain", names: ["Veklury", "Remdesivir"] }
    ]
  },
  {
    name: "Valacyclovir",
    genericName: "Valacyclovir Hydrochloride",
    brandNames: ["Valtrex"],
    category: "Antiviral - Prodrug of Acyclovir",
    form: "Tablet, Caplet",
    strength: "500mg, 1g",
    route: "Oral",
    standardDoseAdult: "Genital herpes initial: 1g BID x10 days; Recurrent: 500mg BID x3 days; Zoster: 1g TID x7 days; Suppression: 500mg-1g daily",
    standardDosePediatric: "Cold sores ≥12 years: 2g every 12 hours x1 day; Chickenpox 2-17 years: 20mg/kg TID x5 days",
    maxDailyDose: "4g",
    dosingFrequency: "One to three times daily",
    weightBasedDosing: false,
    renalAdjustment: "CrCl 30-49: reduce dose by 50%; CrCl 10-29: reduce dose by 50-75%; CrCl <10: 500mg every 24 hours",
    hepaticAdjustment: "No adjustment for mild-moderate; caution in severe",
    contraindications: ["Hypersensitivity to valacyclovir or acyclovir"],
    drugInteractions: ["Cimetidine", "Probenecid", "Nephrotoxic drugs"],
    sideEffects: ["Headache", "Nausea", "Abdominal pain", "TTP/HUS (high doses in immunocompromised)"],
    pregnancyCategory: "B",
    administrationNotes: "May take with or without food. Maintain adequate hydration.",
    monitoringParameters: ["Renal function", "Symptom improvement", "Signs of TTP/HUS"],
    labsRequired: ["BMP with prolonged use"],
    isControlled: false,
    marketStatus: "active",
    regulatoryApprovals: [
      { agency: "FDA", status: "approved", approvalDate: "1995-06-29", brandName: "Valtrex", indications: ["Genital Herpes", "Herpes Zoster", "Cold Sores", "Chickenpox"], riskCategory: "Pregnancy Category B" },
      { agency: "EMA", status: "approved", approvalDate: "1995-08-10", brandName: "Valtrex", indications: ["HSV Infections", "VZV Infections", "CMV Prophylaxis"] },
      { agency: "PMDA", status: "approved", approvalDate: "2000-07-14", brandName: "Valtrex", indications: ["HSV Infections", "VZV Infections"], riskCategory: "Use with caution in pregnancy" },
      { agency: "NMPA", status: "approved", approvalDate: "2001-03-25", brandName: "万乃洛韦", indications: ["HSV Infections", "VZV Infections"] },
      { agency: "MFDS", status: "approved", approvalDate: "1999-09-15", brandName: "발트렉스", indications: ["HSV Infections", "VZV Infections"] },
      { agency: "MOHRU", status: "approved", approvalDate: "2003-05-20", brandName: "Валацикловир", indications: ["HSV Infections", "VZV Infections"] }
    ],
    regionalDosing: [
      { region: "USA", adultDose: "500mg-1g BID-TID depending on indication", maxDose: "4g/day", notes: "Better bioavailability than acyclovir" },
      { region: "EU", adultDose: "500mg-1g BID-TID", maxDose: "4g/day", notes: "Once daily for suppression" },
      { region: "Japan", adultDose: "500mg-1g BID-TID", maxDose: "3g/day", notes: "Similar to Western dosing" },
      { region: "Russia", adultDose: "500mg-1g BID-TID", maxDose: "4g/day", notes: "Preferred over acyclovir for convenience" }
    ],
    internationalBrandNames: [
      { region: "Japan", names: ["Valtrex", "バルトレックス"] },
      { region: "China", names: ["万乃洛韦", "伐昔洛韦"] },
      { region: "Korea", names: ["발트렉스", "Valtrex"] },
      { region: "Russia", names: ["Валацикловир", "Валтрекс"] },
      { region: "Germany", names: ["Valtrex", "Valaciclovir"] },
      { region: "Spain", names: ["Valtrex", "Valaciclovir"] }
    ]
  },

  // PSYCHIATRIC MEDICATIONS
  {
    name: "Sertraline",
    genericName: "Sertraline Hydrochloride",
    brandNames: ["Zoloft"],
    category: "Psychiatric - SSRI Antidepressant",
    form: "Tablet, Oral concentrate",
    strength: "25mg, 50mg, 100mg; Concentrate: 20mg/mL",
    route: "Oral",
    standardDoseAdult: "50mg once daily; may increase to 200mg/day",
    standardDosePediatric: "OCD 6-12 years: 25mg once daily; 13-17 years: 50mg once daily",
    maxDailyDose: "200mg",
    dosingFrequency: "Once daily",
    weightBasedDosing: false,
    renalAdjustment: "No adjustment needed",
    hepaticAdjustment: "Reduce dose or dosing frequency",
    contraindications: ["MAOIs within 14 days", "Concurrent pimozide", "Disulfiram (with oral concentrate)", "Hypersensitivity"],
    drugInteractions: ["MAOIs", "Pimozide", "Warfarin", "NSAIDs", "TCAs", "Triptans", "Serotonergic drugs"],
    sideEffects: ["Nausea", "Diarrhea", "Insomnia", "Sexual dysfunction", "Dry mouth", "Headache"],
    blackBoxWarning: "Increased risk of suicidal thinking and behavior in children, adolescents, and young adults.",
    pregnancyCategory: "C",
    administrationNotes: "May take with or without food. Oral concentrate must be diluted before use.",
    monitoringParameters: ["Depression/anxiety symptoms", "Suicidal ideation", "Mania", "Bleeding"],
    labsRequired: ["None routinely"],
    isControlled: false,
    marketStatus: "active",
    regulatoryApprovals: [
      { agency: "FDA", status: "approved", approvalDate: "1991-12-30", brandName: "Zoloft", indications: ["Major Depressive Disorder", "OCD", "Panic Disorder", "PTSD", "Social Anxiety Disorder", "PMDD"], riskCategory: "Pregnancy Category C" },
      { agency: "EMA", status: "approved", approvalDate: "1990-09-25", brandName: "Zoloft", indications: ["Depression", "OCD", "Panic Disorder", "PTSD", "Social Anxiety"] },
      { agency: "PMDA", status: "approved", approvalDate: "2006-04-21", brandName: "Zoloft", indications: ["Depression", "Panic Disorder", "PTSD"], riskCategory: "Use with caution in pregnancy" },
      { agency: "NMPA", status: "approved", approvalDate: "1998-06-15", brandName: "左洛复", indications: ["Depression", "OCD", "Panic Disorder"] },
      { agency: "MFDS", status: "approved", approvalDate: "1996-11-20", brandName: "졸로프트", indications: ["Depression", "OCD", "Panic Disorder", "PTSD"] },
      { agency: "MOHRU", status: "approved", approvalDate: "2000-03-10", brandName: "Золофт", indications: ["Depression", "OCD", "Panic Disorder", "PTSD"] }
    ],
    regionalDosing: [
      { region: "USA", adultDose: "50-200mg once daily", maxDose: "200mg/day", notes: "Start 50mg; increase by 50mg weekly if needed" },
      { region: "EU", adultDose: "50-200mg once daily", maxDose: "200mg/day", notes: "Titrate slowly" },
      { region: "Japan", adultDose: "25-100mg once daily", maxDose: "100mg/day", notes: "Lower maximum dose approved" },
      { region: "Russia", adultDose: "50-200mg once daily", maxDose: "200mg/day", notes: "Similar to Western dosing" }
    ],
    internationalBrandNames: [
      { region: "Japan", names: ["Zoloft", "ジェイゾロフト"] },
      { region: "China", names: ["左洛复", "舍曲林"] },
      { region: "Korea", names: ["졸로프트", "Zoloft"] },
      { region: "Russia", names: ["Золофт", "Сертралин"] },
      { region: "Germany", names: ["Zoloft", "Sertralin"] },
      { region: "Spain", names: ["Besitran", "Sertralina"] }
    ]
  },
  {
    name: "Fluoxetine",
    genericName: "Fluoxetine Hydrochloride",
    brandNames: ["Prozac", "Sarafem"],
    category: "Psychiatric - SSRI Antidepressant",
    form: "Capsule, Tablet, Oral solution, Delayed-release capsule",
    strength: "10mg, 20mg, 40mg; DR: 90mg; Solution: 20mg/5mL",
    route: "Oral",
    standardDoseAdult: "20mg once daily in morning; may increase to 80mg/day",
    standardDosePediatric: "MDD 8-17 years: 10-20mg/day; OCD 7-17 years: 10-60mg/day",
    maxDailyDose: "80mg (MDD); 60mg (OCD, bulimia)",
    dosingFrequency: "Once daily or divided; weekly for DR capsule",
    weightBasedDosing: false,
    renalAdjustment: "Lower dose or less frequent dosing",
    hepaticAdjustment: "Lower dose; increase interval",
    contraindications: ["MAOIs within 14 days (5 weeks after stopping fluoxetine)", "Concurrent pimozide or thioridazine", "Hypersensitivity"],
    drugInteractions: ["MAOIs", "Pimozide", "Thioridazine", "Warfarin", "Phenytoin", "TCAs"],
    sideEffects: ["Nausea", "Headache", "Insomnia", "Anxiety", "Sexual dysfunction", "Decreased appetite"],
    blackBoxWarning: "Increased risk of suicidal thinking and behavior in children, adolescents, and young adults.",
    pregnancyCategory: "C",
    administrationNotes: "Take in morning to minimize insomnia. Long half-life allows missed dose flexibility.",
    monitoringParameters: ["Depression symptoms", "Suicidal ideation", "Weight", "Mania"],
    labsRequired: ["None routinely"],
    isControlled: false,
    marketStatus: "active",
    regulatoryApprovals: [
      { agency: "FDA", status: "approved", approvalDate: "1987-12-29", brandName: "Prozac", indications: ["Major Depressive Disorder", "OCD", "Panic Disorder", "Bulimia Nervosa", "PMDD"], riskCategory: "Pregnancy Category C" },
      { agency: "EMA", status: "approved", approvalDate: "1988-03-15", brandName: "Prozac", indications: ["Depression", "OCD", "Bulimia Nervosa"] },
      { agency: "PMDA", status: "approved", approvalDate: "1999-06-18", brandName: "Prozac", indications: ["Depression", "OCD", "Bulimia"], riskCategory: "Use with caution in pregnancy" },
      { agency: "NMPA", status: "approved", approvalDate: "1995-10-20", brandName: "百忧解", indications: ["Depression", "OCD", "Bulimia"] },
      { agency: "MFDS", status: "approved", approvalDate: "1993-07-15", brandName: "프로작", indications: ["Depression", "OCD", "Panic Disorder"] },
      { agency: "MOHRU", status: "approved", approvalDate: "1997-11-25", brandName: "Прозак", indications: ["Depression", "OCD", "Bulimia"] }
    ],
    regionalDosing: [
      { region: "USA", adultDose: "20-80mg once daily", maxDose: "80mg/day", notes: "Weekly 90mg DR for maintenance" },
      { region: "EU", adultDose: "20-60mg once daily", maxDose: "60mg/day", notes: "Lower max dose in EU" },
      { region: "Japan", adultDose: "20-60mg once daily", maxDose: "60mg/day", notes: "Titrate from 20mg" },
      { region: "Russia", adultDose: "20-60mg once daily", maxDose: "80mg/day", notes: "First SSRI widely used" }
    ],
    internationalBrandNames: [
      { region: "Japan", names: ["Prozac", "プロザック"] },
      { region: "China", names: ["百忧解", "氟西汀"] },
      { region: "Korea", names: ["프로작", "Prozac"] },
      { region: "Russia", names: ["Прозак", "Флуоксетин"] },
      { region: "Germany", names: ["Fluctin", "Fluoxetin"] },
      { region: "Spain", names: ["Prozac", "Fluoxetina"] }
    ]
  },
  {
    name: "Quetiapine",
    genericName: "Quetiapine Fumarate",
    brandNames: ["Seroquel", "Seroquel XR"],
    category: "Psychiatric - Atypical Antipsychotic",
    form: "Tablet, Extended-release tablet",
    strength: "IR: 25mg, 50mg, 100mg, 200mg, 300mg, 400mg; XR: 50mg, 150mg, 200mg, 300mg, 400mg",
    route: "Oral",
    standardDoseAdult: "Schizophrenia: 150-750mg/day divided; Bipolar: 400-800mg/day; Depression (adjunct): 150-300mg/day",
    standardDosePediatric: "Schizophrenia 13-17 years: 400-800mg/day; Bipolar 10-17 years: 400-600mg/day",
    maxDailyDose: "800mg",
    dosingFrequency: "IR: Two to three times daily; XR: Once daily",
    weightBasedDosing: false,
    renalAdjustment: "No adjustment needed",
    hepaticAdjustment: "Start 25mg/day; titrate slowly",
    contraindications: ["Hypersensitivity to quetiapine"],
    drugInteractions: ["CYP3A4 inhibitors/inducers", "Antihypertensives", "CNS depressants", "Levodopa"],
    sideEffects: ["Sedation", "Weight gain", "Metabolic changes", "Orthostatic hypotension", "Dry mouth", "Constipation"],
    blackBoxWarning: "Increased mortality in elderly patients with dementia-related psychosis. Suicidality risk in children/young adults.",
    pregnancyCategory: "C",
    administrationNotes: "Take without food or with light meal (<300 cal). XR: Swallow whole.",
    monitoringParameters: ["Mental status", "Weight", "Metabolic panel", "Lipids", "Blood pressure"],
    labsRequired: ["Fasting glucose", "Lipid panel", "A1c"],
    isControlled: false,
    marketStatus: "active",
    regulatoryApprovals: [
      { agency: "FDA", status: "approved", approvalDate: "1997-09-26", brandName: "Seroquel", indications: ["Schizophrenia", "Bipolar Disorder", "MDD Adjunct"], riskCategory: "Pregnancy Category C" },
      { agency: "EMA", status: "approved", approvalDate: "1997-04-01", brandName: "Seroquel", indications: ["Schizophrenia", "Bipolar Disorder", "MDD Adjunct"] },
      { agency: "PMDA", status: "approved", approvalDate: "2001-09-21", brandName: "Seroquel", indications: ["Schizophrenia"], riskCategory: "Use with caution in pregnancy" },
      { agency: "NMPA", status: "approved", approvalDate: "2000-11-15", brandName: "思瑞康", indications: ["Schizophrenia", "Bipolar Disorder"] },
      { agency: "MFDS", status: "approved", approvalDate: "1999-06-20", brandName: "쎄로퀄", indications: ["Schizophrenia", "Bipolar Disorder"] },
      { agency: "MOHRU", status: "approved", approvalDate: "2002-04-10", brandName: "Сероквель", indications: ["Schizophrenia", "Bipolar Disorder"] }
    ],
    regionalDosing: [
      { region: "USA", adultDose: "150-800mg/day", maxDose: "800mg/day", notes: "Lower doses for depression adjunct" },
      { region: "EU", adultDose: "150-800mg/day", maxDose: "800mg/day", notes: "XR once daily at bedtime" },
      { region: "Japan", adultDose: "50-750mg/day", maxDose: "750mg/day", notes: "Often lower doses used" },
      { region: "Russia", adultDose: "150-750mg/day", maxDose: "800mg/day", notes: "Commonly used atypical antipsychotic" }
    ],
    internationalBrandNames: [
      { region: "Japan", names: ["Seroquel", "セロクエル"] },
      { region: "China", names: ["思瑞康", "喹硫平"] },
      { region: "Korea", names: ["쎄로퀄", "Seroquel"] },
      { region: "Russia", names: ["Сероквель", "Кветиапин"] },
      { region: "Germany", names: ["Seroquel", "Quetiapin"] },
      { region: "Spain", names: ["Seroquel", "Quetiapina"] }
    ]
  },
  {
    name: "Escitalopram",
    genericName: "Escitalopram Oxalate",
    brandNames: ["Lexapro"],
    category: "Psychiatric - SSRI Antidepressant",
    form: "Tablet, Oral solution",
    strength: "5mg, 10mg, 20mg; Solution: 5mg/5mL",
    route: "Oral",
    standardDoseAdult: "10mg once daily; may increase to 20mg/day after 1 week",
    standardDosePediatric: "MDD 12-17 years: 10mg once daily; may increase to 20mg after 3 weeks",
    maxDailyDose: "20mg (10mg in elderly or hepatic impairment)",
    dosingFrequency: "Once daily",
    weightBasedDosing: false,
    renalAdjustment: "No adjustment for mild-moderate; caution in severe",
    hepaticAdjustment: "Max 10mg/day",
    contraindications: ["MAOIs within 14 days", "Concurrent pimozide", "Hypersensitivity"],
    drugInteractions: ["MAOIs", "Pimozide", "Linezolid", "IV methylene blue", "NSAIDs", "Warfarin"],
    sideEffects: ["Nausea", "Insomnia", "Ejaculation disorder", "Fatigue", "Dry mouth", "Sweating"],
    blackBoxWarning: "Increased risk of suicidal thinking and behavior in children, adolescents, and young adults.",
    pregnancyCategory: "C",
    administrationNotes: "May take with or without food. May take in morning or evening.",
    monitoringParameters: ["Depression symptoms", "Suicidal ideation", "Mania", "Sexual function"],
    labsRequired: ["None routinely"],
    isControlled: false,
    marketStatus: "active",
    regulatoryApprovals: [
      { agency: "FDA", status: "approved", approvalDate: "2002-08-14", brandName: "Lexapro", indications: ["Major Depressive Disorder", "Generalized Anxiety Disorder"], riskCategory: "Pregnancy Category C" },
      { agency: "EMA", status: "approved", approvalDate: "2002-02-28", brandName: "Cipralex", indications: ["Depression", "Panic Disorder", "Social Anxiety", "GAD", "OCD"] },
      { agency: "PMDA", status: "approved", approvalDate: "2011-07-01", brandName: "Lexapro", indications: ["Depression", "Social Anxiety Disorder"], riskCategory: "Use with caution in pregnancy" },
      { agency: "NMPA", status: "approved", approvalDate: "2006-09-15", brandName: "来士普", indications: ["Depression", "Anxiety Disorders"] },
      { agency: "MFDS", status: "approved", approvalDate: "2004-03-20", brandName: "렉사프로", indications: ["Depression", "Panic Disorder", "GAD"] },
      { agency: "MOHRU", status: "approved", approvalDate: "2006-07-10", brandName: "Ципралекс", indications: ["Depression", "Panic Disorder", "GAD", "OCD"] }
    ],
    regionalDosing: [
      { region: "USA", adultDose: "10-20mg once daily", maxDose: "20mg/day", notes: "10mg often sufficient" },
      { region: "EU", adultDose: "10-20mg once daily", maxDose: "20mg/day", notes: "Start at 10mg" },
      { region: "Japan", adultDose: "10-20mg once daily", maxDose: "20mg/day", notes: "Start at 10mg" },
      { region: "Russia", adultDose: "10-20mg once daily", maxDose: "20mg/day", notes: "Popular SSRI choice" }
    ],
    internationalBrandNames: [
      { region: "Japan", names: ["Lexapro", "レクサプロ"] },
      { region: "China", names: ["来士普", "艾司西酞普兰"] },
      { region: "Korea", names: ["렉사프로", "Lexapro"] },
      { region: "Russia", names: ["Ципралекс", "Эсциталопрам"] },
      { region: "Germany", names: ["Cipralex", "Escitalopram"] },
      { region: "Spain", names: ["Cipralex", "Escitalopram"] }
    ]
  },
  {
    name: "Olanzapine",
    genericName: "Olanzapine",
    brandNames: ["Zyprexa", "Zyprexa Zydis"],
    category: "Psychiatric - Atypical Antipsychotic",
    form: "Tablet, Orally disintegrating tablet, Injection",
    strength: "2.5mg, 5mg, 7.5mg, 10mg, 15mg, 20mg; ODT: 5mg, 10mg, 15mg, 20mg; IM: 10mg",
    route: "Oral, IM",
    standardDoseAdult: "Schizophrenia: 5-20mg/day; Bipolar: 10-15mg/day; Agitation IM: 10mg",
    standardDosePediatric: "Schizophrenia/Bipolar 13-17 years: 2.5-20mg/day",
    maxDailyDose: "20mg oral; 30mg IM/day",
    dosingFrequency: "Once daily oral; IM as needed",
    weightBasedDosing: false,
    renalAdjustment: "No adjustment needed",
    hepaticAdjustment: "Start 5mg; use with caution",
    contraindications: ["Hypersensitivity to olanzapine", "IM with parenteral benzodiazepines (risk of hypotension)"],
    drugInteractions: ["Fluvoxamine", "Carbamazepine", "CNS depressants", "Anticholinergics", "Levodopa"],
    sideEffects: ["Weight gain", "Sedation", "Metabolic syndrome", "Orthostatic hypotension", "Anticholinergic effects"],
    blackBoxWarning: "Increased mortality in elderly patients with dementia-related psychosis. Post-injection delirium/sedation syndrome with long-acting injection.",
    pregnancyCategory: "C",
    administrationNotes: "May take with or without food. ODT: Place on tongue, dissolves in seconds.",
    monitoringParameters: ["Mental status", "Weight", "Metabolic panel", "Lipids", "Blood pressure"],
    labsRequired: ["Fasting glucose", "Lipid panel", "A1c"],
    isControlled: false,
    marketStatus: "active",
    regulatoryApprovals: [
      { agency: "FDA", status: "approved", approvalDate: "1996-09-30", brandName: "Zyprexa", indications: ["Schizophrenia", "Bipolar Disorder", "Acute Agitation"], riskCategory: "Pregnancy Category C" },
      { agency: "EMA", status: "approved", approvalDate: "1996-09-27", brandName: "Zyprexa", indications: ["Schizophrenia", "Bipolar Disorder"] },
      { agency: "PMDA", status: "approved", approvalDate: "2001-06-08", brandName: "Zyprexa", indications: ["Schizophrenia", "Bipolar Disorder"], riskCategory: "Use with caution in pregnancy" },
      { agency: "NMPA", status: "approved", approvalDate: "1999-04-20", brandName: "再普乐", indications: ["Schizophrenia", "Bipolar Disorder"] },
      { agency: "MFDS", status: "approved", approvalDate: "1998-08-15", brandName: "자이프렉사", indications: ["Schizophrenia", "Bipolar Disorder"] },
      { agency: "MOHRU", status: "approved", approvalDate: "2001-02-28", brandName: "Зипрекса", indications: ["Schizophrenia", "Bipolar Disorder", "Acute Agitation"] }
    ],
    regionalDosing: [
      { region: "USA", adultDose: "5-20mg once daily", maxDose: "20mg/day", notes: "Start 5-10mg" },
      { region: "EU", adultDose: "5-20mg once daily", maxDose: "20mg/day", notes: "Monitor metabolic parameters" },
      { region: "Japan", adultDose: "5-20mg once daily", maxDose: "20mg/day", notes: "Start at lower doses" },
      { region: "Russia", adultDose: "5-20mg once daily", maxDose: "20mg/day", notes: "Widely used antipsychotic" }
    ],
    internationalBrandNames: [
      { region: "Japan", names: ["Zyprexa", "ジプレキサ"] },
      { region: "China", names: ["再普乐", "奥氮平"] },
      { region: "Korea", names: ["자이프렉사", "Zyprexa"] },
      { region: "Russia", names: ["Зипрекса", "Оланзапин"] },
      { region: "Germany", names: ["Zyprexa", "Olanzapin"] },
      { region: "Spain", names: ["Zyprexa", "Olanzapina"] }
    ]
  },
  {
    name: "Risperidone",
    genericName: "Risperidone",
    brandNames: ["Risperdal", "Risperdal Consta"],
    category: "Psychiatric - Atypical Antipsychotic",
    form: "Tablet, Orally disintegrating tablet, Solution, Long-acting injection",
    strength: "0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg; ODT: same; Solution: 1mg/mL; LAI: 12.5mg, 25mg, 37.5mg, 50mg",
    route: "Oral, IM (long-acting)",
    standardDoseAdult: "Schizophrenia: 2-8mg/day; Bipolar: 1-6mg/day; LAI: 25-50mg every 2 weeks",
    standardDosePediatric: "Irritability in autism 5-16 years: 0.25-3mg/day; Bipolar/Schizophrenia 10-17 years: 0.5-6mg/day",
    maxDailyDose: "16mg (oral); 50mg biweekly (LAI)",
    dosingFrequency: "Once or twice daily oral; every 2 weeks for LAI",
    weightBasedDosing: true,
    weightBasedFormula: "0.25-0.5mg/day starting dose in pediatrics, titrate slowly",
    renalAdjustment: "Start 0.5mg BID; max 4mg/day",
    hepaticAdjustment: "Start 0.5mg BID; max 4mg/day",
    contraindications: ["Hypersensitivity to risperidone or paliperidone"],
    drugInteractions: ["CYP2D6 inhibitors", "Carbamazepine", "CNS depressants", "Levodopa"],
    sideEffects: ["EPS", "Weight gain", "Hyperprolactinemia", "Sedation", "Orthostatic hypotension"],
    blackBoxWarning: "Increased mortality in elderly patients with dementia-related psychosis.",
    pregnancyCategory: "C",
    administrationNotes: "May take with or without food. ODT: Place on tongue without water.",
    monitoringParameters: ["Mental status", "EPS", "Prolactin", "Weight", "Metabolic panel"],
    labsRequired: ["Fasting glucose", "Lipid panel", "Prolactin if indicated"],
    isControlled: false,
    marketStatus: "active",
    regulatoryApprovals: [
      { agency: "FDA", status: "approved", approvalDate: "1993-12-29", brandName: "Risperdal", indications: ["Schizophrenia", "Bipolar Disorder", "Irritability in Autism"], riskCategory: "Pregnancy Category C" },
      { agency: "EMA", status: "approved", approvalDate: "1994-02-15", brandName: "Risperdal", indications: ["Schizophrenia", "Bipolar Disorder", "Behavioral Problems"] },
      { agency: "PMDA", status: "approved", approvalDate: "1996-04-17", brandName: "Risperdal", indications: ["Schizophrenia"], riskCategory: "Use with caution in pregnancy" },
      { agency: "NMPA", status: "approved", approvalDate: "1997-09-10", brandName: "维思通", indications: ["Schizophrenia", "Bipolar Disorder"] },
      { agency: "MFDS", status: "approved", approvalDate: "1995-11-20", brandName: "리스페달", indications: ["Schizophrenia", "Bipolar Disorder"] },
      { agency: "MOHRU", status: "approved", approvalDate: "1999-05-15", brandName: "Рисполепт", indications: ["Schizophrenia", "Bipolar Disorder", "Behavioral Disorders"] }
    ],
    regionalDosing: [
      { region: "USA", adultDose: "2-8mg/day", maxDose: "16mg/day", notes: "Titrate over days" },
      { region: "EU", adultDose: "2-6mg/day", maxDose: "16mg/day", notes: "Start 2mg/day" },
      { region: "Japan", adultDose: "2-6mg/day", maxDose: "12mg/day", notes: "Lower max dose" },
      { region: "Russia", adultDose: "2-6mg/day", maxDose: "16mg/day", notes: "Commonly prescribed antipsychotic" }
    ],
    internationalBrandNames: [
      { region: "Japan", names: ["Risperdal", "リスパダール"] },
      { region: "China", names: ["维思通", "利培酮"] },
      { region: "Korea", names: ["리스페달", "Risperdal"] },
      { region: "Russia", names: ["Рисполепт", "Рисперидон"] },
      { region: "Germany", names: ["Risperdal", "Risperidon"] },
      { region: "Spain", names: ["Risperdal", "Risperidona"] }
    ]
  },
  {
    name: "Aripiprazole",
    genericName: "Aripiprazole",
    brandNames: ["Abilify", "Abilify Maintena"],
    category: "Psychiatric - Atypical Antipsychotic",
    form: "Tablet, Orally disintegrating tablet, Solution, Injection, Long-acting injection",
    strength: "2mg, 5mg, 10mg, 15mg, 20mg, 30mg; ODT: 10mg, 15mg; Solution: 1mg/mL; LAI: 300mg, 400mg",
    route: "Oral, IM",
    standardDoseAdult: "Schizophrenia: 10-15mg/day; Bipolar: 15-30mg/day; MDD adjunct: 2-15mg/day; LAI: 400mg monthly",
    standardDosePediatric: "Schizophrenia 13-17 years: 10mg/day; Bipolar 10-17 years: 10mg/day; Irritability/Autism 6-17 years: 5-15mg/day",
    maxDailyDose: "30mg",
    dosingFrequency: "Once daily oral; monthly for LAI",
    weightBasedDosing: false,
    renalAdjustment: "No adjustment needed",
    hepaticAdjustment: "No adjustment needed",
    contraindications: ["Hypersensitivity to aripiprazole"],
    drugInteractions: ["CYP2D6 inhibitors", "CYP3A4 inhibitors/inducers", "Carbamazepine", "CNS depressants"],
    sideEffects: ["Akathisia", "Headache", "Insomnia", "Anxiety", "Nausea", "Constipation"],
    blackBoxWarning: "Increased mortality in elderly patients with dementia-related psychosis. Suicidality risk in children/young adults (MDD adjunct).",
    pregnancyCategory: "C",
    administrationNotes: "May take with or without food. Less weight gain than other atypicals.",
    monitoringParameters: ["Mental status", "Akathisia", "Weight", "Metabolic panel"],
    labsRequired: ["Fasting glucose", "Lipid panel"],
    isControlled: false,
    marketStatus: "active",
    regulatoryApprovals: [
      { agency: "FDA", status: "approved", approvalDate: "2002-11-15", brandName: "Abilify", indications: ["Schizophrenia", "Bipolar Disorder", "MDD Adjunct", "Irritability in Autism", "Tourette's"], riskCategory: "Pregnancy Category C" },
      { agency: "EMA", status: "approved", approvalDate: "2004-06-04", brandName: "Abilify", indications: ["Schizophrenia", "Bipolar Disorder"] },
      { agency: "PMDA", status: "approved", approvalDate: "2006-01-13", brandName: "Abilify", indications: ["Schizophrenia", "Bipolar Disorder", "Depression Adjunct"], riskCategory: "Use with caution in pregnancy" },
      { agency: "NMPA", status: "approved", approvalDate: "2006-10-20", brandName: "安律凡", indications: ["Schizophrenia", "Bipolar Disorder"] },
      { agency: "MFDS", status: "approved", approvalDate: "2004-09-15", brandName: "아빌리파이", indications: ["Schizophrenia", "Bipolar Disorder"] },
      { agency: "MOHRU", status: "approved", approvalDate: "2007-03-25", brandName: "Абилифай", indications: ["Schizophrenia", "Bipolar Disorder"] }
    ],
    regionalDosing: [
      { region: "USA", adultDose: "10-30mg once daily", maxDose: "30mg/day", notes: "Lower doses for MDD adjunct" },
      { region: "EU", adultDose: "10-30mg once daily", maxDose: "30mg/day", notes: "Start 10-15mg" },
      { region: "Japan", adultDose: "6-24mg once daily", maxDose: "30mg/day", notes: "Often start lower" },
      { region: "Russia", adultDose: "10-30mg once daily", maxDose: "30mg/day", notes: "Newer atypical antipsychotic" }
    ],
    internationalBrandNames: [
      { region: "Japan", names: ["Abilify", "エビリファイ"] },
      { region: "China", names: ["安律凡", "阿立哌唑"] },
      { region: "Korea", names: ["아빌리파이", "Abilify"] },
      { region: "Russia", names: ["Абилифай", "Арипипразол"] },
      { region: "Germany", names: ["Abilify", "Aripiprazol"] },
      { region: "Spain", names: ["Abilify", "Aripiprazol"] }
    ]
  },

  // BLOOD THINNERS/ANTICOAGULANTS
  {
    name: "Heparin",
    genericName: "Heparin Sodium",
    brandNames: ["Heparin Sodium"],
    category: "Cardiovascular - Anticoagulant",
    form: "Injection",
    strength: "1000 units/mL, 5000 units/mL, 10000 units/mL, 20000 units/mL; Flush: 10 units/mL, 100 units/mL",
    route: "IV, SC",
    standardDoseAdult: "DVT/PE: 80 units/kg bolus, then 18 units/kg/hr; Prophylaxis: 5000 units SC every 8-12 hours",
    standardDosePediatric: "Varies by indication and protocol",
    maxDailyDose: "Individualized to aPTT",
    dosingFrequency: "Continuous IV or SC every 8-12 hours",
    weightBasedDosing: true,
    weightBasedFormula: "80 units/kg bolus, 18 units/kg/hr infusion",
    renalAdjustment: "Use with caution; may need dose reduction",
    hepaticAdjustment: "Use with caution; may need dose reduction",
    contraindications: ["Uncontrolled active bleeding", "Severe thrombocytopenia", "History of HIT", "Hypersensitivity"],
    drugInteractions: ["Antiplatelets", "Thrombolytics", "NSAIDs", "Warfarin"],
    sideEffects: ["Bleeding", "HIT", "Osteoporosis (long-term)", "Hyperkalemia", "Alopecia"],
    blackBoxWarning: "Epidural or spinal hematomas may occur with neuraxial anesthesia or spinal puncture.",
    pregnancyCategory: "C",
    administrationNotes: "Monitor aPTT closely. Have protamine available for reversal. Avoid IM injections.",
    monitoringParameters: ["aPTT", "Platelet count", "Signs of bleeding", "Anti-Xa levels if indicated"],
    labsRequired: ["aPTT", "CBC", "Platelet count"],
    isControlled: false,
    marketStatus: "active",
    regulatoryApprovals: [
      { agency: "FDA", status: "approved", approvalDate: "1939-01-01", brandName: "Heparin Sodium", indications: ["DVT", "PE", "Anticoagulation for Procedures", "VTE Prophylaxis"], riskCategory: "Pregnancy Category C" },
      { agency: "EMA", status: "approved", approvalDate: "1940-06-15", brandName: "Heparin", indications: ["Thromboembolism", "Anticoagulation", "DIC"] },
      { agency: "PMDA", status: "approved", approvalDate: "1952-04-20", brandName: "Heparin", indications: ["Thromboembolism", "DIC", "Anticoagulation"], riskCategory: "Use with caution in pregnancy" },
      { agency: "NMPA", status: "approved", approvalDate: "1960-08-10", brandName: "肝素钠", indications: ["Thromboembolism", "Anticoagulation"] },
      { agency: "MFDS", status: "approved", approvalDate: "1958-03-25", brandName: "헤파린", indications: ["Thromboembolism", "Anticoagulation"] },
      { agency: "MOHRU", status: "approved", approvalDate: "1962-11-15", brandName: "Гепарин", indications: ["Thromboembolism", "DIC", "Anticoagulation"] }
    ],
    regionalDosing: [
      { region: "USA", adultDose: "80 units/kg bolus, 18 units/kg/hr", maxDose: "Per protocol/aPTT", notes: "Weight-based protocols common" },
      { region: "EU", adultDose: "75-80 units/kg bolus, 18 units/kg/hr", maxDose: "Per protocol", notes: "Similar protocols" },
      { region: "Japan", adultDose: "10000-20000 units/day continuous", maxDose: "Per aPTT", notes: "Often fixed-dose protocols" },
      { region: "Russia", adultDose: "5000 units bolus, 1000 units/hr", maxDose: "Per aPTT", notes: "Unit-based dosing common" }
    ],
    internationalBrandNames: [
      { region: "Japan", names: ["Heparin", "ヘパリン"] },
      { region: "China", names: ["肝素钠", "普通肝素"] },
      { region: "Korea", names: ["헤파린", "Heparin"] },
      { region: "Russia", names: ["Гепарин", "Heparin"] },
      { region: "Germany", names: ["Heparin", "Liquemin"] },
      { region: "Spain", names: ["Heparina", "Fragmin"] }
    ]
  },
  {
    name: "Enoxaparin",
    genericName: "Enoxaparin Sodium",
    brandNames: ["Lovenox"],
    category: "Cardiovascular - Low Molecular Weight Heparin",
    form: "Injection",
    strength: "30mg/0.3mL, 40mg/0.4mL, 60mg/0.6mL, 80mg/0.8mL, 100mg/mL, 120mg/0.8mL, 150mg/mL",
    route: "SC, IV",
    standardDoseAdult: "DVT/PE treatment: 1mg/kg every 12 hours or 1.5mg/kg once daily; Prophylaxis: 40mg once daily or 30mg every 12 hours",
    standardDosePediatric: "1mg/kg every 12 hours; adjust based on anti-Xa levels",
    maxDailyDose: "Individualized",
    dosingFrequency: "Once or twice daily",
    weightBasedDosing: true,
    weightBasedFormula: "1mg/kg every 12 hours or 1.5mg/kg once daily for treatment",
    renalAdjustment: "CrCl <30: 1mg/kg once daily for treatment; 30mg once daily for prophylaxis",
    hepaticAdjustment: "Use with caution",
    contraindications: ["Active major bleeding", "History of HIT", "Hypersensitivity to heparin or pork products"],
    drugInteractions: ["Antiplatelets", "Thrombolytics", "NSAIDs", "Warfarin"],
    sideEffects: ["Bleeding", "Injection site reactions", "HIT", "Thrombocytopenia", "Osteoporosis (long-term)"],
    blackBoxWarning: "Epidural or spinal hematomas may occur with neuraxial anesthesia or spinal puncture.",
    pregnancyCategory: "B",
    administrationNotes: "Inject SC in abdominal wall. Do not expel air bubble before injection. Rotate sites.",
    monitoringParameters: ["Anti-Xa levels (if indicated)", "Platelet count", "Renal function", "Signs of bleeding"],
    labsRequired: ["CBC", "BMP", "Anti-Xa if monitoring needed"],
    isControlled: false,
    marketStatus: "active",
    regulatoryApprovals: [
      { agency: "FDA", status: "approved", approvalDate: "1993-03-29", brandName: "Lovenox", indications: ["DVT/PE Treatment", "VTE Prophylaxis", "UA/NSTEMI", "STEMI"], riskCategory: "Pregnancy Category B" },
      { agency: "EMA", status: "approved", approvalDate: "1987-06-15", brandName: "Clexane", indications: ["Thromboprophylaxis", "DVT/PE Treatment", "Acute Coronary Syndrome"] },
      { agency: "PMDA", status: "approved", approvalDate: "2008-04-16", brandName: "Clexane", indications: ["VTE Prophylaxis", "DVT/PE Treatment"], riskCategory: "Use with caution in pregnancy" },
      { agency: "NMPA", status: "approved", approvalDate: "1998-10-20", brandName: "克赛", indications: ["DVT/PE", "VTE Prophylaxis", "ACS"] },
      { agency: "MFDS", status: "approved", approvalDate: "1996-05-15", brandName: "클렉산", indications: ["DVT/PE", "VTE Prophylaxis"] },
      { agency: "MOHRU", status: "approved", approvalDate: "2000-09-10", brandName: "Клексан", indications: ["DVT/PE", "VTE Prophylaxis", "ACS"] }
    ],
    regionalDosing: [
      { region: "USA", adultDose: "1mg/kg every 12 hours treatment", maxDose: "Per anti-Xa levels", notes: "Renal adjustment critical" },
      { region: "EU", adultDose: "1mg/kg every 12 hours or 1.5mg/kg once daily", maxDose: "Per protocol", notes: "Once daily option available" },
      { region: "Japan", adultDose: "1mg/kg every 12 hours", maxDose: "Per protocol", notes: "Anti-Xa monitoring often used" },
      { region: "Russia", adultDose: "1mg/kg every 12 hours", maxDose: "Per protocol", notes: "Commonly used LMWH" }
    ],
    internationalBrandNames: [
      { region: "Japan", names: ["Clexane", "クレキサン"] },
      { region: "China", names: ["克赛", "依诺肝素"] },
      { region: "Korea", names: ["클렉산", "Clexane"] },
      { region: "Russia", names: ["Клексан", "Эноксапарин"] },
      { region: "Germany", names: ["Clexane", "Lovenox"] },
      { region: "Spain", names: ["Clexane", "Enoxaparina"] }
    ]
  },
  {
    name: "Dabigatran",
    genericName: "Dabigatran Etexilate",
    brandNames: ["Pradaxa"],
    category: "Cardiovascular - Direct Thrombin Inhibitor (DOAC)",
    form: "Capsule",
    strength: "75mg, 110mg, 150mg",
    route: "Oral",
    standardDoseAdult: "AFib: 150mg twice daily; DVT/PE: 150mg twice daily after parenteral anticoagulation; Prophylaxis post-hip: 110mg then 220mg daily",
    maxDailyDose: "300mg",
    dosingFrequency: "Twice daily",
    weightBasedDosing: false,
    renalAdjustment: "CrCl 30-50: 150mg BID (AFib), 75mg BID if on P-gp inhibitors; CrCl 15-30: 75mg BID; CrCl <15: Avoid",
    hepaticAdjustment: "Avoid in moderate-severe hepatic impairment",
    contraindications: ["Active pathological bleeding", "Severe renal impairment", "Mechanical prosthetic heart valve", "Hypersensitivity"],
    drugInteractions: ["P-gp inhibitors/inducers", "Anticoagulants", "Antiplatelets", "NSAIDs"],
    sideEffects: ["Bleeding", "Dyspepsia", "GI upset", "Gastritis-like symptoms"],
    blackBoxWarning: "Spinal/epidural hematoma risk with neuraxial anesthesia. Premature discontinuation increases stroke risk.",
    pregnancyCategory: "C",
    administrationNotes: "Swallow whole; do not open capsules. Store in original bottle/blister. Take with or without food.",
    monitoringParameters: ["Signs of bleeding", "Renal function", "Hemoglobin"],
    labsRequired: ["BMP", "CBC"],
    isControlled: false,
    marketStatus: "active",
    regulatoryApprovals: [
      { agency: "FDA", status: "approved", approvalDate: "2010-10-19", brandName: "Pradaxa", indications: ["Stroke Prevention in AFib", "DVT/PE Treatment", "VTE Prophylaxis Post-Hip"], riskCategory: "Pregnancy Category C" },
      { agency: "EMA", status: "approved", approvalDate: "2008-03-18", brandName: "Pradaxa", indications: ["Stroke Prevention in AFib", "VTE Treatment", "VTE Prophylaxis"] },
      { agency: "PMDA", status: "approved", approvalDate: "2011-01-21", brandName: "Prazaxa", indications: ["Stroke Prevention in AFib", "VTE Prevention"], riskCategory: "Use with caution in pregnancy" },
      { agency: "NMPA", status: "approved", approvalDate: "2013-05-15", brandName: "泰毕全", indications: ["Stroke Prevention in AFib", "VTE"] },
      { agency: "MFDS", status: "approved", approvalDate: "2011-06-20", brandName: "프라닥사", indications: ["Stroke Prevention in AFib", "VTE Treatment"] },
      { agency: "MOHRU", status: "approved", approvalDate: "2012-09-10", brandName: "Прадакса", indications: ["Stroke Prevention in AFib", "VTE Prevention/Treatment"] }
    ],
    regionalDosing: [
      { region: "USA", adultDose: "150mg twice daily", maxDose: "300mg/day", notes: "75mg BID for renal impairment" },
      { region: "EU", adultDose: "150mg twice daily; 110mg BID for elderly/renal", maxDose: "300mg/day", notes: "110mg option available" },
      { region: "Japan", adultDose: "110-150mg twice daily", maxDose: "300mg/day", notes: "Lower doses for elderly" },
      { region: "Russia", adultDose: "150mg twice daily", maxDose: "300mg/day", notes: "Similar to EU guidelines" }
    ],
    internationalBrandNames: [
      { region: "Japan", names: ["Prazaxa", "プラザキサ"] },
      { region: "China", names: ["泰毕全", "达比加群"] },
      { region: "Korea", names: ["프라닥사", "Pradaxa"] },
      { region: "Russia", names: ["Прадакса", "Дабигатран"] },
      { region: "Germany", names: ["Pradaxa", "Dabigatran"] },
      { region: "Spain", names: ["Pradaxa", "Dabigatrán"] }
    ]
  },

  // IMMUNOSUPPRESSANTS AND CANCER MEDICATIONS
  {
    name: "Tacrolimus",
    genericName: "Tacrolimus",
    brandNames: ["Prograf", "Astagraf XL", "Envarsus XR"],
    category: "Immunosuppressant - Calcineurin Inhibitor",
    form: "Capsule, Extended-release capsule, Injection",
    strength: "0.5mg, 1mg, 5mg; XL/XR: 0.5mg, 1mg, 4mg; IV: 5mg/mL",
    route: "Oral, IV",
    standardDoseAdult: "Kidney transplant: 0.1-0.15mg/kg/day divided BID; Liver: 0.1-0.15mg/kg/day divided BID",
    standardDosePediatric: "0.15-0.2mg/kg/day divided every 12 hours",
    maxDailyDose: "Individualized to trough levels",
    dosingFrequency: "IR: Twice daily; XR/XL: Once daily",
    weightBasedDosing: true,
    weightBasedFormula: "0.1-0.2mg/kg/day divided BID (organ-specific)",
    renalAdjustment: "No initial adjustment; monitor levels closely",
    hepaticAdjustment: "Reduce dose; slower metabolism",
    contraindications: ["Hypersensitivity to tacrolimus or HCO-60 (IV only)"],
    drugInteractions: ["CYP3A4 inhibitors/inducers", "Potassium-sparing diuretics", "ACE inhibitors", "NSAIDs", "Grapefruit"],
    sideEffects: ["Nephrotoxicity", "Neurotoxicity", "Hyperglycemia", "Hypertension", "Hyperkalemia", "Tremor"],
    blackBoxWarning: "Increased susceptibility to infection and possible development of lymphoma. Should only be used by physicians experienced in immunosuppressive therapy.",
    pregnancyCategory: "C",
    administrationNotes: "Take consistently with or without food. Do not use with grapefruit. Monitor trough levels.",
    monitoringParameters: ["Tacrolimus trough levels", "Renal function", "Blood glucose", "Potassium", "Blood pressure"],
    labsRequired: ["Tacrolimus level", "BMP", "Fasting glucose", "LFTs"],
    isControlled: false,
    marketStatus: "active",
    riskEvaluationProgram: "REMS required",
    regulatoryApprovals: [
      { agency: "FDA", status: "approved", approvalDate: "1994-04-08", brandName: "Prograf", indications: ["Organ Transplant Prophylaxis", "Kidney/Liver/Heart Rejection Prevention"], riskCategory: "Pregnancy Category C" },
      { agency: "EMA", status: "approved", approvalDate: "1994-06-10", brandName: "Prograf", indications: ["Transplant Rejection Prophylaxis"] },
      { agency: "PMDA", status: "approved", approvalDate: "1993-06-24", brandName: "Prograf", indications: ["Transplant Rejection", "Atopic Dermatitis (topical)"], riskCategory: "Use with caution in pregnancy" },
      { agency: "NMPA", status: "approved", approvalDate: "1998-07-15", brandName: "普乐可复", indications: ["Transplant Rejection Prophylaxis"] },
      { agency: "MFDS", status: "approved", approvalDate: "1996-09-20", brandName: "프로그라프", indications: ["Transplant Rejection Prophylaxis"] },
      { agency: "MOHRU", status: "approved", approvalDate: "2000-11-25", brandName: "Програф", indications: ["Transplant Rejection Prophylaxis"] }
    ],
    regionalDosing: [
      { region: "USA", adultDose: "0.1-0.15mg/kg/day divided BID", maxDose: "Per trough levels", notes: "Target trough varies by organ/time post-transplant" },
      { region: "EU", adultDose: "0.1-0.3mg/kg/day divided BID", maxDose: "Per trough levels", notes: "Protocol-dependent" },
      { region: "Japan", adultDose: "0.15-0.3mg/kg/day", maxDose: "Per trough levels", notes: "Often higher starting doses" },
      { region: "Russia", adultDose: "0.1-0.15mg/kg/day divided BID", maxDose: "Per trough levels", notes: "Standard transplant protocols" }
    ],
    internationalBrandNames: [
      { region: "Japan", names: ["Prograf", "プログラフ"] },
      { region: "China", names: ["普乐可复", "他克莫司"] },
      { region: "Korea", names: ["프로그라프", "Prograf"] },
      { region: "Russia", names: ["Програф", "Такролимус"] },
      { region: "Germany", names: ["Prograf", "Advagraf"] },
      { region: "Spain", names: ["Prograf", "Tacrolimus"] }
    ]
  },
  {
    name: "Methotrexate",
    genericName: "Methotrexate",
    brandNames: ["Rheumatrex", "Trexall", "Otrexup", "Rasuvo"],
    category: "Immunosuppressant/Antineoplastic - Antimetabolite",
    form: "Tablet, Injection, Auto-injector",
    strength: "2.5mg, 5mg, 7.5mg, 10mg, 15mg tablets; Various injection strengths",
    route: "Oral, SC, IM, IV, Intrathecal",
    standardDoseAdult: "RA/Psoriasis: 7.5-25mg weekly; Oncology: Protocol-dependent (high doses)",
    standardDosePediatric: "JIA: 10-15mg/m2 weekly; Oncology: Protocol-dependent",
    maxDailyDose: "Weekly dosing for RA/psoriasis; protocol-specific for oncology",
    dosingFrequency: "Once weekly (RA/psoriasis); varies for oncology",
    weightBasedDosing: true,
    weightBasedFormula: "10-15mg/m2 weekly for JIA; varies by indication",
    renalAdjustment: "CrCl 30-50: reduce by 50%; CrCl <30: avoid or use with extreme caution",
    hepaticAdjustment: "Use with caution; reduce dose",
    contraindications: ["Pregnancy", "Breastfeeding", "Severe renal impairment", "Alcoholism", "Immunodeficiency", "Blood dyscrasias"],
    drugInteractions: ["NSAIDs", "Penicillins", "Probenecid", "Trimethoprim", "PPIs", "Live vaccines"],
    sideEffects: ["Myelosuppression", "Hepatotoxicity", "Pulmonary toxicity", "Mucositis", "Nausea", "Infections"],
    blackBoxWarning: "Serious toxicity including death. Monitor closely. Should only be used by physicians experienced with antimetabolite therapy.",
    pregnancyCategory: "X",
    administrationNotes: "Take folic acid supplementation. Weekly dosing only for RA/psoriasis - NOT daily. Avoid live vaccines.",
    storageRequirements: "Store at room temperature, protect from light",
    monitoringParameters: ["CBC", "LFTs", "Renal function", "Pulmonary symptoms", "Mucositis"],
    labsRequired: ["CBC", "LFTs", "BMP", "Albumin"],
    isControlled: false,
    marketStatus: "active",
    regulatoryApprovals: [
      { agency: "FDA", status: "approved", approvalDate: "1953-12-07", brandName: "Methotrexate", indications: ["Rheumatoid Arthritis", "Psoriasis", "Various Cancers", "Ectopic Pregnancy"], riskCategory: "Pregnancy Category X" },
      { agency: "EMA", status: "approved", approvalDate: "1960-03-15", brandName: "Methotrexate", indications: ["RA", "Psoriasis", "JIA", "Various Cancers"] },
      { agency: "PMDA", status: "approved", approvalDate: "1963-08-20", brandName: "Rheumatrex", indications: ["RA", "Psoriasis", "Various Cancers"], riskCategory: "Contraindicated in pregnancy" },
      { agency: "NMPA", status: "approved", approvalDate: "1975-04-10", brandName: "甲氨蝶呤", indications: ["RA", "Psoriasis", "Various Cancers"] },
      { agency: "MFDS", status: "approved", approvalDate: "1970-11-15", brandName: "메토트렉세이트", indications: ["RA", "Psoriasis", "Various Cancers"] },
      { agency: "MOHRU", status: "approved", approvalDate: "1978-06-25", brandName: "Метотрексат", indications: ["RA", "Psoriasis", "Various Cancers"] }
    ],
    regionalDosing: [
      { region: "USA", adultDose: "RA: 7.5-25mg weekly", maxDose: "25mg weekly for RA", notes: "Always with folic acid" },
      { region: "EU", adultDose: "RA: 7.5-25mg weekly", maxDose: "30mg weekly for some protocols", notes: "SC may be preferred for higher doses" },
      { region: "Japan", adultDose: "RA: 6-16mg weekly", maxDose: "16mg weekly", notes: "Lower max dose in Japan" },
      { region: "Russia", adultDose: "RA: 7.5-20mg weekly", maxDose: "25mg weekly", notes: "Standard DMARD" }
    ],
    internationalBrandNames: [
      { region: "Japan", names: ["Rheumatrex", "メトトレキサート"] },
      { region: "China", names: ["甲氨蝶呤", "氨甲蝶呤"] },
      { region: "Korea", names: ["메토트렉세이트", "Methotrexate"] },
      { region: "Russia", names: ["Метотрексат", "Методжект"] },
      { region: "Germany", names: ["Metex", "Lantarel"] },
      { region: "Spain", names: ["Metoject", "Metotrexato"] }
    ]
  },
  {
    name: "Imatinib",
    genericName: "Imatinib Mesylate",
    brandNames: ["Gleevec", "Glivec"],
    category: "Antineoplastic - Tyrosine Kinase Inhibitor",
    form: "Tablet",
    strength: "100mg, 400mg",
    route: "Oral",
    standardDoseAdult: "CML: 400-800mg/day; GIST: 400mg/day; may increase to 800mg if inadequate response",
    standardDosePediatric: "CML: 340mg/m2/day (max 600mg); Ph+ ALL: 340mg/m2/day",
    maxDailyDose: "800mg",
    dosingFrequency: "Once daily or divided twice daily",
    weightBasedDosing: true,
    weightBasedFormula: "340mg/m2/day for pediatrics",
    renalAdjustment: "CrCl 20-39: Max 400mg; CrCl <20: 50% dose reduction",
    hepaticAdjustment: "Reduce dose by 25% in mild-moderate; avoid in severe",
    contraindications: ["Hypersensitivity to imatinib"],
    drugInteractions: ["CYP3A4 inhibitors/inducers", "Warfarin", "Acetaminophen"],
    sideEffects: ["Edema", "Nausea", "Muscle cramps", "Diarrhea", "Fatigue", "Myelosuppression"],
    pregnancyCategory: "D",
    administrationNotes: "Take with food and large glass of water to minimize GI upset. May dissolve in water/apple juice if unable to swallow.",
    monitoringParameters: ["CBC", "LFTs", "Renal function", "Weight", "Edema", "Tumor response"],
    labsRequired: ["CBC", "CMP", "LFTs"],
    isControlled: false,
    marketStatus: "active",
    regulatoryApprovals: [
      { agency: "FDA", status: "approved", approvalDate: "2001-05-10", brandName: "Gleevec", indications: ["CML", "GIST", "Ph+ ALL", "Dermatofibrosarcoma", "Mastocytosis"], riskCategory: "Pregnancy Category D" },
      { agency: "EMA", status: "approved", approvalDate: "2001-11-07", brandName: "Glivec", indications: ["CML", "GIST", "Ph+ ALL", "Various Rare Tumors"] },
      { agency: "PMDA", status: "approved", approvalDate: "2001-11-02", brandName: "Glivec", indications: ["CML", "GIST", "Ph+ ALL"], riskCategory: "Contraindicated in pregnancy" },
      { agency: "NMPA", status: "approved", approvalDate: "2002-04-20", brandName: "格列卫", indications: ["CML", "GIST"] },
      { agency: "MFDS", status: "approved", approvalDate: "2001-12-15", brandName: "글리벡", indications: ["CML", "GIST"] },
      { agency: "MOHRU", status: "approved", approvalDate: "2003-06-10", brandName: "Гливек", indications: ["CML", "GIST"] }
    ],
    regionalDosing: [
      { region: "USA", adultDose: "400-800mg once daily", maxDose: "800mg/day", notes: "Divide doses >400mg" },
      { region: "EU", adultDose: "400-800mg once daily", maxDose: "800mg/day", notes: "Standard CML therapy" },
      { region: "Japan", adultDose: "400mg once daily", maxDose: "800mg/day", notes: "Start at standard dose" },
      { region: "Russia", adultDose: "400-600mg once daily", maxDose: "800mg/day", notes: "First-line CML treatment" }
    ],
    internationalBrandNames: [
      { region: "Japan", names: ["Glivec", "グリベック"] },
      { region: "China", names: ["格列卫", "伊马替尼"] },
      { region: "Korea", names: ["글리벡", "Glivec"] },
      { region: "Russia", names: ["Гливек", "Иматиниб"] },
      { region: "Germany", names: ["Glivec", "Imatinib"] },
      { region: "Spain", names: ["Glivec", "Imatinib"] }
    ]
  },

  // MORE CARDIOVASCULAR MEDICATIONS
  {
    name: "Carvedilol",
    genericName: "Carvedilol",
    brandNames: ["Coreg", "Coreg CR"],
    category: "Cardiovascular - Beta Blocker (with alpha-blocking activity)",
    form: "Tablet, Extended-release capsule",
    strength: "IR: 3.125mg, 6.25mg, 12.5mg, 25mg; CR: 10mg, 20mg, 40mg, 80mg",
    route: "Oral",
    standardDoseAdult: "Heart failure: Start 3.125mg BID, titrate to 25mg BID; Hypertension: 6.25mg BID to 25mg BID",
    maxDailyDose: "100mg",
    dosingFrequency: "IR: Twice daily; CR: Once daily",
    weightBasedDosing: false,
    renalAdjustment: "No adjustment needed",
    hepaticAdjustment: "Contraindicated in severe hepatic impairment",
    contraindications: ["Severe hepatic impairment", "Bronchial asthma", "2nd/3rd degree AV block", "Severe bradycardia", "Cardiogenic shock"],
    drugInteractions: ["Insulin", "Digoxin", "Cyclosporine", "Rifampin", "Cimetidine", "Other antihypertensives"],
    sideEffects: ["Dizziness", "Fatigue", "Hypotension", "Diarrhea", "Weight gain", "Bradycardia"],
    pregnancyCategory: "C",
    administrationNotes: "Take with food to slow absorption. Titrate slowly. Do not crush CR capsules.",
    monitoringParameters: ["Heart rate", "Blood pressure", "Weight", "Signs of heart failure worsening"],
    labsRequired: ["LFTs periodically", "BMP"],
    isControlled: false,
    marketStatus: "active",
    regulatoryApprovals: [
      { agency: "FDA", status: "approved", approvalDate: "1995-09-14", brandName: "Coreg", indications: ["Heart Failure", "Hypertension", "LV Dysfunction Post-MI"], riskCategory: "Pregnancy Category C" },
      { agency: "EMA", status: "approved", approvalDate: "1992-03-20", brandName: "Dilatrend", indications: ["Heart Failure", "Hypertension", "Angina"] },
      { agency: "PMDA", status: "approved", approvalDate: "1993-11-12", brandName: "Artist", indications: ["Chronic Heart Failure", "Hypertension"], riskCategory: "Use with caution in pregnancy" },
      { agency: "NMPA", status: "approved", approvalDate: "1999-08-15", brandName: "达利全", indications: ["Heart Failure", "Hypertension"] },
      { agency: "MFDS", status: "approved", approvalDate: "1997-05-20", brandName: "딜라트렌드", indications: ["Heart Failure", "Hypertension"] },
      { agency: "MOHRU", status: "approved", approvalDate: "2000-12-10", brandName: "Дилатренд", indications: ["Heart Failure", "Hypertension", "Angina"] }
    ],
    regionalDosing: [
      { region: "USA", adultDose: "3.125-25mg BID", maxDose: "50mg BID (100mg/day)", notes: "Titrate slowly every 2 weeks" },
      { region: "EU", adultDose: "3.125-25mg BID", maxDose: "50mg BID", notes: "Start low, go slow" },
      { region: "Japan", adultDose: "1.25-10mg BID", maxDose: "20mg BID", notes: "Lower doses typically used" },
      { region: "Russia", adultDose: "6.25-25mg BID", maxDose: "50mg BID", notes: "Standard heart failure therapy" }
    ],
    internationalBrandNames: [
      { region: "Japan", names: ["Artist", "アーチスト"] },
      { region: "China", names: ["达利全", "卡维地洛"] },
      { region: "Korea", names: ["딜라트렌드", "Dilatrend"] },
      { region: "Russia", names: ["Дилатренд", "Карведилол"] },
      { region: "Germany", names: ["Dilatrend", "Carvedilol"] },
      { region: "Spain", names: ["Coropres", "Carvedilol"] }
    ]
  },
  {
    name: "Spironolactone",
    genericName: "Spironolactone",
    brandNames: ["Aldactone", "CaroSpir"],
    category: "Cardiovascular - Potassium-Sparing Diuretic/Aldosterone Antagonist",
    form: "Tablet, Suspension",
    strength: "25mg, 50mg, 100mg; Suspension: 25mg/5mL",
    route: "Oral",
    standardDoseAdult: "Heart failure: 12.5-25mg daily; Edema/Ascites: 25-200mg daily; Hypertension: 25-50mg daily",
    standardDosePediatric: "1-3.3mg/kg/day divided once or twice daily",
    maxDailyDose: "400mg (edema); 50mg (heart failure)",
    dosingFrequency: "Once or twice daily",
    weightBasedDosing: true,
    weightBasedFormula: "1-3.3mg/kg/day",
    renalAdjustment: "CrCl <30: Avoid; CrCl 30-50: use with caution, lower doses",
    hepaticAdjustment: "May need higher doses in cirrhosis for ascites",
    contraindications: ["Anuria", "Hyperkalemia", "Addison's disease", "Concurrent use with eplerenone"],
    drugInteractions: ["ACE inhibitors", "ARBs", "Potassium supplements", "NSAIDs", "Lithium", "Digoxin"],
    sideEffects: ["Hyperkalemia", "Gynecomastia", "Menstrual irregularities", "GI upset", "Dizziness"],
    pregnancyCategory: "C",
    administrationNotes: "Take with food. Monitor potassium closely. Antiandrogenic effects more common at higher doses.",
    monitoringParameters: ["Potassium", "Renal function", "Blood pressure", "Signs of endocrine effects"],
    labsRequired: ["BMP", "Potassium", "Creatinine"],
    isControlled: false,
    marketStatus: "active",
    regulatoryApprovals: [
      { agency: "FDA", status: "approved", approvalDate: "1960-05-18", brandName: "Aldactone", indications: ["Heart Failure", "Edema", "Hypertension", "Primary Hyperaldosteronism", "Ascites"], riskCategory: "Pregnancy Category C" },
      { agency: "EMA", status: "approved", approvalDate: "1961-03-15", brandName: "Aldactone", indications: ["Heart Failure", "Edema", "Hypertension", "Hyperaldosteronism"] },
      { agency: "PMDA", status: "approved", approvalDate: "1963-10-25", brandName: "Aldactone A", indications: ["Edema", "Heart Failure", "Hyperaldosteronism"], riskCategory: "Use with caution in pregnancy" },
      { agency: "NMPA", status: "approved", approvalDate: "1975-07-10", brandName: "安体舒通", indications: ["Edema", "Heart Failure", "Hypertension"] },
      { agency: "MFDS", status: "approved", approvalDate: "1970-04-20", brandName: "알닥톤", indications: ["Edema", "Heart Failure", "Hypertension"] },
      { agency: "MOHRU", status: "approved", approvalDate: "1978-09-15", brandName: "Верошпирон", indications: ["Edema", "Heart Failure", "Hypertension", "Hyperaldosteronism"] }
    ],
    regionalDosing: [
      { region: "USA", adultDose: "25-100mg once daily", maxDose: "400mg/day for edema", notes: "25mg for heart failure" },
      { region: "EU", adultDose: "25-200mg daily", maxDose: "400mg/day", notes: "Titrate based on response" },
      { region: "Japan", adultDose: "25-100mg daily", maxDose: "200mg/day", notes: "Lower max doses" },
      { region: "Russia", adultDose: "25-200mg daily", maxDose: "400mg/day", notes: "Veroshpiron widely used" }
    ],
    internationalBrandNames: [
      { region: "Japan", names: ["Aldactone A", "アルダクトンA"] },
      { region: "China", names: ["安体舒通", "螺内酯"] },
      { region: "Korea", names: ["알닥톤", "Aldactone"] },
      { region: "Russia", names: ["Верошпирон", "Спиронолактон"] },
      { region: "Germany", names: ["Aldactone", "Spironolacton"] },
      { region: "Spain", names: ["Aldactone", "Espironolactona"] }
    ]
  },

  // MORE DIABETES MEDICATIONS
  {
    name: "Empagliflozin",
    genericName: "Empagliflozin",
    brandNames: ["Jardiance"],
    category: "Endocrine - SGLT2 Inhibitor",
    form: "Tablet",
    strength: "10mg, 25mg",
    route: "Oral",
    standardDoseAdult: "10mg once daily; may increase to 25mg",
    maxDailyDose: "25mg",
    dosingFrequency: "Once daily",
    weightBasedDosing: false,
    renalAdjustment: "eGFR 30-45: Avoid initiation; eGFR <30: Contraindicated for glycemic control",
    hepaticAdjustment: "No adjustment needed",
    contraindications: ["Severe renal impairment", "Dialysis", "Type 1 diabetes", "Diabetic ketoacidosis"],
    drugInteractions: ["Insulin", "Sulfonylureas (hypoglycemia risk)", "Diuretics (volume depletion)"],
    sideEffects: ["Genital mycotic infections", "UTI", "Increased urination", "Hypotension", "DKA (rare)"],
    blackBoxWarning: "None (but euglycemic DKA risk communicated)",
    pregnancyCategory: "C",
    administrationNotes: "Take in morning with or without food. Maintain hydration. Monitor for ketoacidosis.",
    monitoringParameters: ["A1c", "Renal function", "Blood pressure", "LDL", "Signs of genital infections"],
    labsRequired: ["A1c", "eGFR", "Lipid panel"],
    isControlled: false,
    marketStatus: "active",
    regulatoryApprovals: [
      { agency: "FDA", status: "approved", approvalDate: "2014-08-01", brandName: "Jardiance", indications: ["Type 2 Diabetes", "Heart Failure", "CV Risk Reduction"], riskCategory: "Pregnancy Category C" },
      { agency: "EMA", status: "approved", approvalDate: "2014-05-22", brandName: "Jardiance", indications: ["Type 2 Diabetes", "Heart Failure"] },
      { agency: "PMDA", status: "approved", approvalDate: "2014-12-26", brandName: "Jardiance", indications: ["Type 2 Diabetes"], riskCategory: "Use with caution in pregnancy" },
      { agency: "NMPA", status: "approved", approvalDate: "2017-09-15", brandName: "欧唐静", indications: ["Type 2 Diabetes"] },
      { agency: "MFDS", status: "approved", approvalDate: "2014-11-20", brandName: "자디앙", indications: ["Type 2 Diabetes"] },
      { agency: "MOHRU", status: "approved", approvalDate: "2016-04-10", brandName: "Джардинс", indications: ["Type 2 Diabetes"] }
    ],
    regionalDosing: [
      { region: "USA", adultDose: "10-25mg once daily", maxDose: "25mg/day", notes: "Heart failure dosing: 10mg" },
      { region: "EU", adultDose: "10-25mg once daily", maxDose: "25mg/day", notes: "Similar to US" },
      { region: "Japan", adultDose: "10-25mg once daily", maxDose: "25mg/day", notes: "Monitor renal function" },
      { region: "Russia", adultDose: "10-25mg once daily", maxDose: "25mg/day", notes: "Newer diabetes medication" }
    ],
    internationalBrandNames: [
      { region: "Japan", names: ["Jardiance", "ジャディアンス"] },
      { region: "China", names: ["欧唐静", "恩格列净"] },
      { region: "Korea", names: ["자디앙", "Jardiance"] },
      { region: "Russia", names: ["Джардинс", "Эмпаглифлозин"] },
      { region: "Germany", names: ["Jardiance", "Empagliflozin"] },
      { region: "Spain", names: ["Jardiance", "Empagliflozina"] }
    ]
  },
  {
    name: "Liraglutide",
    genericName: "Liraglutide",
    brandNames: ["Victoza", "Saxenda"],
    category: "Endocrine - GLP-1 Receptor Agonist",
    form: "Injection (prefilled pen)",
    strength: "6mg/mL (Victoza: 3mL pen; Saxenda: 3mL pen)",
    route: "Subcutaneous",
    standardDoseAdult: "Diabetes: Start 0.6mg daily x1 week, then 1.2mg, may increase to 1.8mg; Weight management: Up to 3mg daily",
    standardDosePediatric: "Type 2 diabetes ≥10 years: 0.6-1.8mg daily",
    maxDailyDose: "1.8mg (diabetes); 3mg (weight management)",
    dosingFrequency: "Once daily",
    weightBasedDosing: false,
    renalAdjustment: "No adjustment; use caution in renal impairment due to GI effects",
    hepaticAdjustment: "No adjustment; limited data",
    contraindications: ["Personal/family history of MTC", "MEN 2 syndrome", "Hypersensitivity"],
    drugInteractions: ["Insulin", "Sulfonylureas (hypoglycemia risk)", "Oral medications (delayed absorption)"],
    sideEffects: ["Nausea", "Vomiting", "Diarrhea", "Constipation", "Injection site reactions", "Pancreatitis"],
    blackBoxWarning: "Thyroid C-cell tumors in rodents. Contraindicated in patients with personal/family history of MTC or MEN 2.",
    pregnancyCategory: "C",
    administrationNotes: "Inject SC in abdomen, thigh, or upper arm. May be given at any time of day. Titrate slowly to reduce GI effects.",
    storageRequirements: "Refrigerate before first use. Room temperature up to 30 days after first use.",
    monitoringParameters: ["A1c", "Weight", "Signs of pancreatitis", "Thyroid nodules"],
    labsRequired: ["A1c", "Renal function", "Lipase if pancreatitis suspected"],
    isControlled: false,
    marketStatus: "active",
    regulatoryApprovals: [
      { agency: "FDA", status: "approved", approvalDate: "2010-01-25", brandName: "Victoza", indications: ["Type 2 Diabetes", "CV Risk Reduction"], riskCategory: "Pregnancy Category C", additionalWarnings: ["Black box for thyroid tumors"] },
      { agency: "EMA", status: "approved", approvalDate: "2009-07-03", brandName: "Victoza", indications: ["Type 2 Diabetes"] },
      { agency: "PMDA", status: "approved", approvalDate: "2010-06-17", brandName: "Victoza", indications: ["Type 2 Diabetes"], riskCategory: "Use with caution in pregnancy" },
      { agency: "NMPA", status: "approved", approvalDate: "2011-05-20", brandName: "诺和力", indications: ["Type 2 Diabetes"] },
      { agency: "MFDS", status: "approved", approvalDate: "2010-09-15", brandName: "빅토자", indications: ["Type 2 Diabetes"] },
      { agency: "MOHRU", status: "approved", approvalDate: "2012-11-10", brandName: "Виктоза", indications: ["Type 2 Diabetes"] }
    ],
    regionalDosing: [
      { region: "USA", adultDose: "0.6-1.8mg daily (diabetes)", maxDose: "1.8mg (diabetes); 3mg (weight)", notes: "Titrate weekly" },
      { region: "EU", adultDose: "0.6-1.8mg daily", maxDose: "1.8mg/day", notes: "Similar titration" },
      { region: "Japan", adultDose: "0.3-0.9mg daily", maxDose: "0.9mg/day", notes: "Lower approved doses" },
      { region: "Russia", adultDose: "0.6-1.8mg daily", maxDose: "1.8mg/day", notes: "Standard GLP-1 RA" }
    ],
    internationalBrandNames: [
      { region: "Japan", names: ["Victoza", "ビクトーザ"] },
      { region: "China", names: ["诺和力", "利拉鲁肽"] },
      { region: "Korea", names: ["빅토자", "Victoza"] },
      { region: "Russia", names: ["Виктоза", "Лираглутид"] },
      { region: "Germany", names: ["Victoza", "Liraglutid"] },
      { region: "Spain", names: ["Victoza", "Liraglutida"] }
    ]
  },
  {
    name: "Dapagliflozin",
    genericName: "Dapagliflozin",
    brandNames: ["Farxiga", "Forxiga"],
    category: "Endocrine - SGLT2 Inhibitor",
    form: "Tablet",
    strength: "5mg, 10mg",
    route: "Oral",
    standardDoseAdult: "Type 2 diabetes: 5mg once daily, may increase to 10mg; Heart failure/CKD: 10mg once daily",
    maxDailyDose: "10mg",
    dosingFrequency: "Once daily",
    weightBasedDosing: false,
    renalAdjustment: "eGFR <25: Not recommended for diabetes; Heart failure: no lower limit",
    hepaticAdjustment: "Use caution in severe impairment",
    contraindications: ["Type 1 diabetes", "Diabetic ketoacidosis", "Dialysis"],
    drugInteractions: ["Insulin", "Sulfonylureas", "Diuretics"],
    sideEffects: ["Genital mycotic infections", "UTI", "Increased urination", "Hypotension", "Ketoacidosis"],
    pregnancyCategory: "C",
    administrationNotes: "Take in morning with or without food. Monitor for signs of ketoacidosis and volume depletion.",
    monitoringParameters: ["A1c", "eGFR", "Blood pressure", "Signs of genital/urinary infections"],
    labsRequired: ["A1c", "eGFR", "BMP"],
    isControlled: false,
    marketStatus: "active",
    regulatoryApprovals: [
      { agency: "FDA", status: "approved", approvalDate: "2014-01-08", brandName: "Farxiga", indications: ["Type 2 Diabetes", "Heart Failure", "Chronic Kidney Disease"], riskCategory: "Pregnancy Category C" },
      { agency: "EMA", status: "approved", approvalDate: "2012-11-12", brandName: "Forxiga", indications: ["Type 2 Diabetes", "Heart Failure", "CKD"] },
      { agency: "PMDA", status: "approved", approvalDate: "2014-03-24", brandName: "Forxiga", indications: ["Type 2 Diabetes", "Heart Failure", "CKD"], riskCategory: "Use with caution in pregnancy" },
      { agency: "NMPA", status: "approved", approvalDate: "2017-03-15", brandName: "安达唐", indications: ["Type 2 Diabetes", "Heart Failure"] },
      { agency: "MFDS", status: "approved", approvalDate: "2014-06-20", brandName: "포시가", indications: ["Type 2 Diabetes", "Heart Failure"] },
      { agency: "MOHRU", status: "approved", approvalDate: "2015-09-10", brandName: "Форсига", indications: ["Type 2 Diabetes", "Heart Failure", "CKD"] }
    ],
    regionalDosing: [
      { region: "USA", adultDose: "5-10mg once daily", maxDose: "10mg/day", notes: "10mg for HF regardless of diabetes" },
      { region: "EU", adultDose: "5-10mg once daily", maxDose: "10mg/day", notes: "Approved for CKD" },
      { region: "Japan", adultDose: "5-10mg once daily", maxDose: "10mg/day", notes: "Expanding indications" },
      { region: "Russia", adultDose: "5-10mg once daily", maxDose: "10mg/day", notes: "SGLT2i class expanding" }
    ],
    internationalBrandNames: [
      { region: "Japan", names: ["Forxiga", "フォシーガ"] },
      { region: "China", names: ["安达唐", "达格列净"] },
      { region: "Korea", names: ["포시가", "Forxiga"] },
      { region: "Russia", names: ["Форсига", "Дапаглифлозин"] },
      { region: "Germany", names: ["Forxiga", "Dapagliflozin"] },
      { region: "Spain", names: ["Forxiga", "Dapagliflozina"] }
    ]
  },

  // PAIN MEDICATIONS
  {
    name: "Tramadol",
    genericName: "Tramadol Hydrochloride",
    brandNames: ["Ultram", "Ultram ER", "ConZip"],
    category: "Analgesic - Centrally Acting",
    form: "Tablet, Extended-release tablet/capsule, ODT",
    strength: "IR: 50mg; ER: 100mg, 200mg, 300mg; ODT: 50mg",
    route: "Oral",
    standardDoseAdult: "IR: 50-100mg every 4-6 hours as needed; ER: 100mg once daily, titrate to 300mg",
    standardDosePediatric: "Not recommended under 12 years",
    maxDailyDose: "400mg IR; 300mg ER",
    dosingFrequency: "IR: Every 4-6 hours; ER: Once daily",
    weightBasedDosing: false,
    renalAdjustment: "CrCl <30: Max 200mg/day, increase interval to every 12 hours",
    hepaticAdjustment: "Cirrhosis: 50mg every 12 hours",
    contraindications: ["Severe respiratory depression", "MAOIs within 14 days", "Acute intoxication", "Children <12", "Post-tonsillectomy in children"],
    drugInteractions: ["MAOIs", "SSRIs", "TCAs", "Carbamazepine", "CNS depressants", "Serotonergic drugs"],
    sideEffects: ["Nausea", "Dizziness", "Constipation", "Headache", "Seizures", "Serotonin syndrome"],
    blackBoxWarning: "Risk of addiction, abuse, and misuse. Respiratory depression. Not for children <12 or post-tonsillectomy pain.",
    pregnancyCategory: "C",
    administrationNotes: "May take with or without food. Do not crush ER formulations. Taper to discontinue.",
    monitoringParameters: ["Pain level", "Respiratory status", "CNS effects", "Signs of serotonin syndrome"],
    labsRequired: ["LFTs", "BMP periodically"],
    isControlled: true,
    controlledSchedule: "Schedule IV",
    marketStatus: "active",
    regulatoryApprovals: [
      { agency: "FDA", status: "approved", approvalDate: "1995-03-03", brandName: "Ultram", indications: ["Moderate to Moderately Severe Pain"], riskCategory: "Pregnancy Category C" },
      { agency: "EMA", status: "approved", approvalDate: "1977-09-15", brandName: "Tramal", indications: ["Moderate to Severe Pain"] },
      { agency: "PMDA", status: "approved", approvalDate: "2010-04-16", brandName: "Tramal", indications: ["Chronic Pain", "Cancer Pain"], riskCategory: "Use with caution in pregnancy" },
      { agency: "NMPA", status: "approved", approvalDate: "1995-06-10", brandName: "曲马多", indications: ["Moderate to Severe Pain"] },
      { agency: "MFDS", status: "approved", approvalDate: "1992-11-20", brandName: "트라마돌", indications: ["Moderate to Severe Pain"] },
      { agency: "MOHRU", status: "approved", approvalDate: "1998-08-15", brandName: "Трамадол", indications: ["Moderate to Severe Pain"] }
    ],
    regionalDosing: [
      { region: "USA", adultDose: "50-100mg every 4-6 hours", maxDose: "400mg/day", notes: "Schedule IV controlled" },
      { region: "EU", adultDose: "50-100mg every 4-6 hours", maxDose: "400mg/day", notes: "Long history of use" },
      { region: "Japan", adultDose: "25-100mg every 4-6 hours", maxDose: "300mg/day", notes: "Lower starting doses" },
      { region: "Russia", adultDose: "50-100mg every 4-6 hours", maxDose: "400mg/day", notes: "Commonly used analgesic" }
    ],
    internationalBrandNames: [
      { region: "Japan", names: ["Tramal", "トラマール"] },
      { region: "China", names: ["曲马多", "奇曼丁"] },
      { region: "Korea", names: ["트라마돌", "Tramadol"] },
      { region: "Russia", names: ["Трамадол", "Трамал"] },
      { region: "Germany", names: ["Tramal", "Tramadol"] },
      { region: "Spain", names: ["Adolonta", "Tramadol"] }
    ]
  },
  {
    name: "Celecoxib",
    genericName: "Celecoxib",
    brandNames: ["Celebrex"],
    category: "Analgesic - COX-2 Inhibitor (NSAID)",
    form: "Capsule",
    strength: "50mg, 100mg, 200mg, 400mg",
    route: "Oral",
    standardDoseAdult: "OA: 200mg once daily or 100mg BID; RA: 100-200mg BID; Pain: 400mg then 200mg on day 1, then 200mg BID",
    standardDosePediatric: "JRA ≥2 years: 10-25kg: 50mg BID; >25kg: 100mg BID",
    maxDailyDose: "400mg (OA/RA); 800mg day 1 then 400mg (acute pain)",
    dosingFrequency: "Once or twice daily",
    weightBasedDosing: false,
    renalAdjustment: "Avoid in advanced renal disease",
    hepaticAdjustment: "Reduce dose by 50% in moderate impairment; avoid in severe",
    contraindications: ["Sulfonamide allergy", "NSAID allergy", "CABG surgery", "Active GI bleeding"],
    drugInteractions: ["Warfarin", "ACE inhibitors", "ARBs", "Lithium", "Methotrexate", "Fluconazole"],
    sideEffects: ["Abdominal pain", "Diarrhea", "Dyspepsia", "Cardiovascular events", "Renal effects"],
    blackBoxWarning: "Increased risk of serious cardiovascular and GI events. Contraindicated for CABG surgery.",
    pregnancyCategory: "C (D in 3rd trimester)",
    administrationNotes: "May take with or without food. Capsule may be opened and sprinkled on applesauce.",
    monitoringParameters: ["GI symptoms", "Blood pressure", "Renal function", "Signs of cardiovascular events"],
    labsRequired: ["BMP", "CBC periodically"],
    isControlled: false,
    marketStatus: "active",
    regulatoryApprovals: [
      { agency: "FDA", status: "approved", approvalDate: "1998-12-31", brandName: "Celebrex", indications: ["OA", "RA", "Acute Pain", "Dysmenorrhea", "JRA", "Ankylosing Spondylitis"], riskCategory: "Pregnancy Category C/D" },
      { agency: "EMA", status: "approved", approvalDate: "2000-06-15", brandName: "Celebrex", indications: ["OA", "RA", "Ankylosing Spondylitis", "Pain"] },
      { agency: "PMDA", status: "approved", approvalDate: "2007-06-21", brandName: "Celecox", indications: ["OA", "RA", "Pain"], riskCategory: "Contraindicated in pregnancy" },
      { agency: "NMPA", status: "approved", approvalDate: "2001-09-15", brandName: "西乐葆", indications: ["OA", "RA", "Pain"] },
      { agency: "MFDS", status: "approved", approvalDate: "2000-03-20", brandName: "세레콕시브", indications: ["OA", "RA", "Pain"] },
      { agency: "MOHRU", status: "approved", approvalDate: "2002-11-10", brandName: "Целебрекс", indications: ["OA", "RA", "Pain", "Ankylosing Spondylitis"] }
    ],
    regionalDosing: [
      { region: "USA", adultDose: "100-200mg BID", maxDose: "400mg/day maintenance", notes: "Lower CV risk than non-selective NSAIDs" },
      { region: "EU", adultDose: "100-200mg BID", maxDose: "400mg/day", notes: "Similar to US" },
      { region: "Japan", adultDose: "100mg BID", maxDose: "400mg/day", notes: "Standard dosing" },
      { region: "Russia", adultDose: "100-200mg BID", maxDose: "400mg/day", notes: "COX-2 selective" }
    ],
    internationalBrandNames: [
      { region: "Japan", names: ["Celecox", "セレコックス"] },
      { region: "China", names: ["西乐葆", "塞来昔布"] },
      { region: "Korea", names: ["세레콕시브", "Celebrex"] },
      { region: "Russia", names: ["Целебрекс", "Целекоксиб"] },
      { region: "Germany", names: ["Celebrex", "Celecoxib"] },
      { region: "Spain", names: ["Celebrex", "Celecoxib"] }
    ]
  },
  {
    name: "Ketorolac",
    genericName: "Ketorolac Tromethamine",
    brandNames: ["Toradol", "Sprix"],
    category: "Analgesic - NSAID",
    form: "Tablet, Injection, Nasal spray",
    strength: "Oral: 10mg; IM/IV: 15mg/mL, 30mg/mL; Nasal: 15.75mg/spray",
    route: "Oral, IM, IV, Intranasal",
    standardDoseAdult: "IM/IV: 30mg single dose or 30mg q6h (max 5 days); Oral: 10mg q4-6h (max 40mg/day, 5 days); Nasal: 1 spray each nostril q6-8h",
    standardDosePediatric: "2-16 years: 0.5mg/kg IV single dose (max 15mg); 1mg/kg IM single dose (max 30mg)",
    maxDailyDose: "120mg/day parenteral; 40mg/day oral (max 5 days total)",
    dosingFrequency: "Every 4-6 hours",
    weightBasedDosing: true,
    weightBasedFormula: "0.5mg/kg IV, 1mg/kg IM for pediatrics",
    renalAdjustment: "Reduce dose 50%; avoid if CrCl <30",
    hepaticAdjustment: "Use with caution",
    contraindications: ["Active GI bleeding", "Renal impairment", "CABG surgery", "Cerebrovascular bleeding", "Labor and delivery", "Concurrent NSAIDs"],
    drugInteractions: ["Anticoagulants", "ACE inhibitors", "Lithium", "Methotrexate", "Probenecid"],
    sideEffects: ["GI bleeding", "Nausea", "Headache", "Drowsiness", "Renal impairment"],
    blackBoxWarning: "Increased risk of serious cardiovascular and GI events. Limited to 5 days. Contraindicated for perioperative CABG pain.",
    pregnancyCategory: "C (D in 3rd trimester)",
    administrationNotes: "Maximum 5 days combined therapy (all routes). Use lowest effective dose.",
    monitoringParameters: ["GI symptoms", "Renal function", "Blood pressure", "Signs of bleeding"],
    labsRequired: ["BMP", "CBC"],
    isControlled: false,
    marketStatus: "active",
    regulatoryApprovals: [
      { agency: "FDA", status: "approved", approvalDate: "1989-11-30", brandName: "Toradol", indications: ["Short-term Moderate to Severe Pain"], riskCategory: "Pregnancy Category C/D", additionalWarnings: ["Maximum 5 days use"] },
      { agency: "EMA", status: "approved", approvalDate: "1991-06-15", brandName: "Toradol", indications: ["Short-term Pain Management"] },
      { agency: "PMDA", status: "approved", approvalDate: "1995-03-24", brandName: "Toradol", indications: ["Postoperative Pain"], riskCategory: "Contraindicated in pregnancy" },
      { agency: "NMPA", status: "approved", approvalDate: "1997-10-20", brandName: "酮咯酸", indications: ["Short-term Pain Management"] },
      { agency: "MFDS", status: "approved", approvalDate: "1994-05-15", brandName: "케토롤락", indications: ["Short-term Pain Management"] },
      { agency: "MOHRU", status: "approved", approvalDate: "1999-08-10", brandName: "Кеторолак", indications: ["Short-term Pain Management"] }
    ],
    regionalDosing: [
      { region: "USA", adultDose: "30mg IV/IM q6h or 10mg PO q4-6h", maxDose: "120mg/day IV; 40mg/day PO", notes: "5 day maximum" },
      { region: "EU", adultDose: "10-30mg every 4-6 hours", maxDose: "90mg/day IV", notes: "Short-term only" },
      { region: "Japan", adultDose: "30mg IV single or q6h", maxDose: "90mg/day", notes: "Postoperative use" },
      { region: "Russia", adultDose: "10-30mg every 4-6 hours", maxDose: "90mg/day", notes: "5 day limit" }
    ],
    internationalBrandNames: [
      { region: "Japan", names: ["Toradol", "トラドール"] },
      { region: "China", names: ["酮咯酸", "托拉多"] },
      { region: "Korea", names: ["케토롤락", "Ketorolac"] },
      { region: "Russia", names: ["Кеторолак", "Кеторол"] },
      { region: "Germany", names: ["Toradol", "Ketorolac"] },
      { region: "Spain", names: ["Toradol", "Ketorolaco"] }
    ]
  },

  // RESPIRATORY MEDICATIONS
  {
    name: "Budesonide",
    genericName: "Budesonide",
    brandNames: ["Pulmicort", "Rhinocort", "Entocort", "Uceris"],
    category: "Respiratory/GI - Corticosteroid",
    form: "Nebulizer suspension, Nasal spray, Capsule, Rectal foam",
    strength: "Neb: 0.25mg, 0.5mg, 1mg; Nasal: 32mcg/spray; Oral: 3mg, 9mg",
    route: "Inhalation, Intranasal, Oral, Rectal",
    standardDoseAdult: "Asthma (Neb): 1-2mg BID; Nasal: 1-4 sprays per nostril daily; Crohn's: 9mg daily x8 weeks",
    standardDosePediatric: "Neb 1-8 years: 0.25-0.5mg BID; 8+ years: 0.5-1mg BID",
    maxDailyDose: "4mg/day nebulized; Oral: 9mg",
    dosingFrequency: "Once or twice daily",
    weightBasedDosing: false,
    renalAdjustment: "No adjustment needed",
    hepaticAdjustment: "Oral: Reduce dose in moderate-severe impairment",
    contraindications: ["Primary treatment of status asthmaticus", "Hypersensitivity to budesonide"],
    drugInteractions: ["CYP3A4 inhibitors", "Ketoconazole", "Ritonavir", "Itraconazole"],
    sideEffects: ["Oral candidiasis (inhaled)", "Dysphonia", "Headache", "Adrenal suppression (high doses)"],
    pregnancyCategory: "B (inhaled); C (oral)",
    administrationNotes: "Rinse mouth after inhaled use. Oral: Take in morning with or without food.",
    monitoringParameters: ["Symptom control", "Growth in children", "Adrenal function (high doses)", "Bone density (long-term)"],
    labsRequired: ["None routinely"],
    isControlled: false,
    marketStatus: "active",
    regulatoryApprovals: [
      { agency: "FDA", status: "approved", approvalDate: "1994-02-02", brandName: "Pulmicort", indications: ["Asthma", "Allergic Rhinitis", "Crohn's Disease", "Ulcerative Colitis"], riskCategory: "Pregnancy Category B/C" },
      { agency: "EMA", status: "approved", approvalDate: "1981-05-20", brandName: "Pulmicort", indications: ["Asthma", "COPD", "Allergic Rhinitis", "Crohn's Disease"] },
      { agency: "PMDA", status: "approved", approvalDate: "1998-09-25", brandName: "Pulmicort", indications: ["Asthma", "COPD"], riskCategory: "Use with caution in pregnancy" },
      { agency: "NMPA", status: "approved", approvalDate: "2001-04-15", brandName: "普米克", indications: ["Asthma", "Allergic Rhinitis"] },
      { agency: "MFDS", status: "approved", approvalDate: "1997-11-20", brandName: "풀미코트", indications: ["Asthma", "Allergic Rhinitis"] },
      { agency: "MOHRU", status: "approved", approvalDate: "2000-06-10", brandName: "Пульмикорт", indications: ["Asthma", "COPD", "Allergic Rhinitis"] }
    ],
    regionalDosing: [
      { region: "USA", adultDose: "Neb 1-2mg BID; Nasal 1-4 sprays/nostril daily", maxDose: "4mg/day nebulized", notes: "Titrate to lowest effective dose" },
      { region: "EU", adultDose: "Similar to US", maxDose: "4mg/day", notes: "First-choice ICS in many guidelines" },
      { region: "Japan", adultDose: "0.5-2mg/day nebulized", maxDose: "2mg/day", notes: "Lower doses often sufficient" },
      { region: "Russia", adultDose: "1-2mg BID nebulized", maxDose: "4mg/day", notes: "Pulmicort widely used" }
    ],
    internationalBrandNames: [
      { region: "Japan", names: ["Pulmicort", "パルミコート"] },
      { region: "China", names: ["普米克", "布地奈德"] },
      { region: "Korea", names: ["풀미코트", "Pulmicort"] },
      { region: "Russia", names: ["Пульмикорт", "Будесонид"] },
      { region: "Germany", names: ["Pulmicort", "Budesonid"] },
      { region: "Spain", names: ["Pulmicort", "Budesonida"] }
    ]
  },
  {
    name: "Tiotropium",
    genericName: "Tiotropium Bromide",
    brandNames: ["Spiriva", "Spiriva Respimat"],
    category: "Respiratory - Long-Acting Anticholinergic (LAMA)",
    form: "Dry powder inhaler (HandiHaler), Soft mist inhaler (Respimat)",
    strength: "HandiHaler: 18mcg capsules; Respimat: 1.25mcg/actuation, 2.5mcg/actuation",
    route: "Inhalation",
    standardDoseAdult: "HandiHaler: 18mcg (1 capsule) once daily; Respimat: 2 puffs (2.5mcg or 5mcg total) once daily",
    standardDosePediatric: "Asthma ≥6 years: Respimat 2.5mcg (2 puffs) once daily",
    maxDailyDose: "18mcg HandiHaler; 5mcg Respimat",
    dosingFrequency: "Once daily",
    weightBasedDosing: false,
    renalAdjustment: "CrCl <60: Monitor closely",
    hepaticAdjustment: "No adjustment needed",
    contraindications: ["Hypersensitivity to tiotropium, ipratropium, or atropine derivatives"],
    drugInteractions: ["Other anticholinergics", "Potassium chloride (esophageal injury risk)"],
    sideEffects: ["Dry mouth", "Constipation", "Urinary retention", "Pharyngitis", "Sinusitis"],
    pregnancyCategory: "C",
    administrationNotes: "HandiHaler capsules for oral inhalation only (not for swallowing). Rinse mouth after use. Use at same time daily.",
    monitoringParameters: ["Lung function (FEV1)", "Symptom control", "Anticholinergic effects"],
    labsRequired: ["None routinely"],
    isControlled: false,
    marketStatus: "active",
    regulatoryApprovals: [
      { agency: "FDA", status: "approved", approvalDate: "2004-01-30", brandName: "Spiriva", indications: ["COPD Maintenance", "Asthma Maintenance"], riskCategory: "Pregnancy Category C" },
      { agency: "EMA", status: "approved", approvalDate: "2002-04-15", brandName: "Spiriva", indications: ["COPD Maintenance", "Asthma"] },
      { agency: "PMDA", status: "approved", approvalDate: "2004-12-17", brandName: "Spiriva", indications: ["COPD", "Asthma"], riskCategory: "Use with caution in pregnancy" },
      { agency: "NMPA", status: "approved", approvalDate: "2006-08-20", brandName: "思力华", indications: ["COPD Maintenance"] },
      { agency: "MFDS", status: "approved", approvalDate: "2005-03-15", brandName: "스피리바", indications: ["COPD Maintenance", "Asthma"] },
      { agency: "MOHRU", status: "approved", approvalDate: "2007-11-10", brandName: "Спирива", indications: ["COPD Maintenance"] }
    ],
    regionalDosing: [
      { region: "USA", adultDose: "18mcg once daily (HandiHaler) or 5mcg once daily (Respimat)", maxDose: "18mcg/day", notes: "Once daily dosing convenient" },
      { region: "EU", adultDose: "18mcg or 5mcg once daily", maxDose: "18mcg/day", notes: "First-choice LAMA" },
      { region: "Japan", adultDose: "18mcg once daily", maxDose: "18mcg/day", notes: "Standard COPD therapy" },
      { region: "Russia", adultDose: "18mcg once daily", maxDose: "18mcg/day", notes: "Widely used for COPD" }
    ],
    internationalBrandNames: [
      { region: "Japan", names: ["Spiriva", "スピリーバ"] },
      { region: "China", names: ["思力华", "噻托溴铵"] },
      { region: "Korea", names: ["스피리바", "Spiriva"] },
      { region: "Russia", names: ["Спирива", "Тиотропий"] },
      { region: "Germany", names: ["Spiriva", "Tiotropium"] },
      { region: "Spain", names: ["Spiriva", "Tiotropio"] }
    ]
  },
  {
    name: "Salmeterol",
    genericName: "Salmeterol Xinafoate",
    brandNames: ["Serevent Diskus"],
    category: "Respiratory - Long-Acting Beta-2 Agonist (LABA)",
    form: "Dry powder inhaler (Diskus)",
    strength: "50mcg/inhalation",
    route: "Inhalation",
    standardDoseAdult: "1 inhalation (50mcg) twice daily, approximately 12 hours apart",
    standardDosePediatric: "≥4 years: 1 inhalation (50mcg) twice daily",
    maxDailyDose: "100mcg (2 inhalations)",
    dosingFrequency: "Twice daily",
    weightBasedDosing: false,
    renalAdjustment: "No adjustment needed",
    hepaticAdjustment: "Use with caution in severe impairment",
    contraindications: ["Monotherapy in asthma (must use with ICS)", "Acute bronchospasm", "Hypersensitivity"],
    drugInteractions: ["Beta blockers", "MAOIs", "TCAs", "QT-prolonging drugs"],
    sideEffects: ["Headache", "Tremor", "Palpitations", "Throat irritation", "Upper respiratory infection"],
    blackBoxWarning: "LABAs increase the risk of asthma-related death. Use only with an ICS for asthma.",
    pregnancyCategory: "C",
    administrationNotes: "Not for acute symptoms. Always use with inhaled corticosteroid for asthma. Use every 12 hours.",
    monitoringParameters: ["Peak flow", "Symptom control", "Heart rate", "Tremor"],
    labsRequired: ["None routinely"],
    isControlled: false,
    marketStatus: "active",
    regulatoryApprovals: [
      { agency: "FDA", status: "approved", approvalDate: "1994-02-04", brandName: "Serevent", indications: ["Asthma (with ICS)", "COPD", "Exercise-Induced Bronchospasm"], riskCategory: "Pregnancy Category C", additionalWarnings: ["Black box for asthma mortality"] },
      { agency: "EMA", status: "approved", approvalDate: "1990-12-15", brandName: "Serevent", indications: ["Asthma", "COPD", "Exercise-Induced Bronchospasm"] },
      { agency: "PMDA", status: "approved", approvalDate: "1998-03-27", brandName: "Serevent", indications: ["Asthma", "COPD"], riskCategory: "Use with caution in pregnancy" },
      { agency: "NMPA", status: "approved", approvalDate: "2000-09-15", brandName: "施立稳", indications: ["Asthma", "COPD"] },
      { agency: "MFDS", status: "approved", approvalDate: "1997-06-20", brandName: "세레벤트", indications: ["Asthma", "COPD"] },
      { agency: "MOHRU", status: "approved", approvalDate: "2001-04-10", brandName: "Серевент", indications: ["Asthma", "COPD"] }
    ],
    regionalDosing: [
      { region: "USA", adultDose: "50mcg twice daily", maxDose: "100mcg/day", notes: "Must combine with ICS for asthma" },
      { region: "EU", adultDose: "50mcg twice daily", maxDose: "100mcg/day", notes: "Often in combination products" },
      { region: "Japan", adultDose: "50mcg twice daily", maxDose: "100mcg/day", notes: "Use with ICS" },
      { region: "Russia", adultDose: "50mcg twice daily", maxDose: "100mcg/day", notes: "Often combined with fluticasone" }
    ],
    internationalBrandNames: [
      { region: "Japan", names: ["Serevent", "セレベント"] },
      { region: "China", names: ["施立稳", "沙美特罗"] },
      { region: "Korea", names: ["세레벤트", "Serevent"] },
      { region: "Russia", names: ["Серевент", "Салметерол"] },
      { region: "Germany", names: ["Serevent", "Salmeterol"] },
      { region: "Spain", names: ["Serevent", "Salmeterol"] }
    ]
  },

  // MORE PSYCHIATRIC MEDICATIONS
  {
    name: "Venlafaxine",
    genericName: "Venlafaxine Hydrochloride",
    brandNames: ["Effexor", "Effexor XR"],
    category: "Psychiatric - SNRI Antidepressant",
    form: "Tablet, Extended-release capsule",
    strength: "IR: 25mg, 37.5mg, 50mg, 75mg, 100mg; XR: 37.5mg, 75mg, 150mg, 225mg",
    route: "Oral",
    standardDoseAdult: "IR: Start 75mg/day divided BID-TID; XR: Start 37.5-75mg once daily; max 225mg/day (depression), 375mg/day (some conditions)",
    standardDosePediatric: "Not approved for children",
    maxDailyDose: "375mg",
    dosingFrequency: "IR: Two to three times daily; XR: Once daily",
    weightBasedDosing: false,
    renalAdjustment: "CrCl 10-70: Reduce dose by 25-50%; Dialysis: Reduce by 50%",
    hepaticAdjustment: "Mild-moderate: Reduce by 50%; Severe: Reduce by 50% or more",
    contraindications: ["MAOIs within 14 days", "Concurrent linezolid or IV methylene blue", "Hypersensitivity"],
    drugInteractions: ["MAOIs", "SSRIs", "Triptans", "Tramadol", "CYP2D6 inhibitors", "CYP3A4 inhibitors"],
    sideEffects: ["Nausea", "Headache", "Dizziness", "Insomnia", "Sexual dysfunction", "Hypertension"],
    blackBoxWarning: "Increased risk of suicidal thinking and behavior in children, adolescents, and young adults.",
    pregnancyCategory: "C",
    administrationNotes: "Take with food. XR: Swallow whole, do not crush. Taper when discontinuing.",
    monitoringParameters: ["Depression symptoms", "Blood pressure", "Suicidal ideation", "Serotonin syndrome"],
    labsRequired: ["Blood pressure monitoring"],
    isControlled: false,
    marketStatus: "active",
    regulatoryApprovals: [
      { agency: "FDA", status: "approved", approvalDate: "1993-12-28", brandName: "Effexor", indications: ["MDD", "GAD", "Social Anxiety", "Panic Disorder"], riskCategory: "Pregnancy Category C" },
      { agency: "EMA", status: "approved", approvalDate: "1994-06-15", brandName: "Efexor", indications: ["Depression", "GAD", "Social Phobia", "Panic Disorder"] },
      { agency: "PMDA", status: "approved", approvalDate: "2000-10-27", brandName: "Effexor", indications: ["Depression", "GAD"], riskCategory: "Use with caution in pregnancy" },
      { agency: "NMPA", status: "approved", approvalDate: "1998-09-20", brandName: "怡诺思", indications: ["Depression", "Anxiety Disorders"] },
      { agency: "MFDS", status: "approved", approvalDate: "1997-05-15", brandName: "이펙사", indications: ["Depression", "GAD", "Panic Disorder"] },
      { agency: "MOHRU", status: "approved", approvalDate: "2001-03-10", brandName: "Велаксин", indications: ["Depression", "GAD"] }
    ],
    regionalDosing: [
      { region: "USA", adultDose: "75-225mg/day (XR once daily)", maxDose: "375mg/day", notes: "Start 37.5-75mg XR" },
      { region: "EU", adultDose: "75-225mg/day", maxDose: "375mg/day", notes: "Titrate slowly" },
      { region: "Japan", adultDose: "37.5-225mg/day", maxDose: "225mg/day", notes: "Lower max in some cases" },
      { region: "Russia", adultDose: "75-225mg/day", maxDose: "375mg/day", notes: "SNRI antidepressant" }
    ],
    internationalBrandNames: [
      { region: "Japan", names: ["Effexor", "イフェクサー"] },
      { region: "China", names: ["怡诺思", "文拉法辛"] },
      { region: "Korea", names: ["이펙사", "Effexor"] },
      { region: "Russia", names: ["Велаксин", "Венлафаксин"] },
      { region: "Germany", names: ["Trevilor", "Venlafaxin"] },
      { region: "Spain", names: ["Vandral", "Venlafaxina"] }
    ]
  },
  {
    name: "Duloxetine",
    genericName: "Duloxetine Hydrochloride",
    brandNames: ["Cymbalta", "Irenka"],
    category: "Psychiatric - SNRI Antidepressant",
    form: "Delayed-release capsule",
    strength: "20mg, 30mg, 40mg, 60mg",
    route: "Oral",
    standardDoseAdult: "Depression/GAD: 60mg once daily; Fibromyalgia/Neuropathy: 60mg once daily; Chronic pain: 30mg daily x1 week, then 60mg",
    standardDosePediatric: "GAD 7-17 years: 30-60mg once daily",
    maxDailyDose: "120mg (divided doses for some conditions)",
    dosingFrequency: "Once or twice daily",
    weightBasedDosing: false,
    renalAdjustment: "CrCl <30 or ESRD: Avoid",
    hepaticAdjustment: "Avoid in hepatic impairment",
    contraindications: ["MAOIs within 14 days", "Uncontrolled narrow-angle glaucoma", "Chronic liver disease", "Severe renal impairment"],
    drugInteractions: ["MAOIs", "Thioridazine", "CYP1A2 inhibitors", "CYP2D6 inhibitors", "Serotonergic drugs"],
    sideEffects: ["Nausea", "Dry mouth", "Constipation", "Fatigue", "Dizziness", "Decreased appetite"],
    blackBoxWarning: "Increased risk of suicidal thinking and behavior in children, adolescents, and young adults.",
    pregnancyCategory: "C",
    administrationNotes: "Swallow whole; do not crush or chew. Taper when discontinuing.",
    monitoringParameters: ["Depression symptoms", "Blood pressure", "LFTs", "Suicidal ideation"],
    labsRequired: ["LFTs", "BMP"],
    isControlled: false,
    marketStatus: "active",
    regulatoryApprovals: [
      { agency: "FDA", status: "approved", approvalDate: "2004-08-03", brandName: "Cymbalta", indications: ["MDD", "GAD", "Diabetic Neuropathy", "Fibromyalgia", "Chronic Musculoskeletal Pain"], riskCategory: "Pregnancy Category C" },
      { agency: "EMA", status: "approved", approvalDate: "2004-12-17", brandName: "Cymbalta", indications: ["MDD", "GAD", "Diabetic Neuropathy", "Stress Urinary Incontinence"] },
      { agency: "PMDA", status: "approved", approvalDate: "2010-01-20", brandName: "Cymbalta", indications: ["Depression", "Diabetic Neuropathy", "Fibromyalgia"], riskCategory: "Use with caution in pregnancy" },
      { agency: "NMPA", status: "approved", approvalDate: "2007-06-15", brandName: "欣百达", indications: ["Depression", "Diabetic Neuropathy"] },
      { agency: "MFDS", status: "approved", approvalDate: "2005-11-20", brandName: "심발타", indications: ["Depression", "GAD", "Diabetic Neuropathy"] },
      { agency: "MOHRU", status: "approved", approvalDate: "2008-04-10", brandName: "Симбалта", indications: ["Depression", "GAD", "Diabetic Neuropathy"] }
    ],
    regionalDosing: [
      { region: "USA", adultDose: "60mg once daily", maxDose: "120mg/day", notes: "Start 30mg for some conditions" },
      { region: "EU", adultDose: "60mg once daily", maxDose: "120mg/day", notes: "Once daily dosing" },
      { region: "Japan", adultDose: "40-60mg once daily", maxDose: "60mg/day", notes: "Lower max dose" },
      { region: "Russia", adultDose: "60mg once daily", maxDose: "120mg/day", notes: "SNRI for depression and pain" }
    ],
    internationalBrandNames: [
      { region: "Japan", names: ["Cymbalta", "サインバルタ"] },
      { region: "China", names: ["欣百达", "度洛西汀"] },
      { region: "Korea", names: ["심발타", "Cymbalta"] },
      { region: "Russia", names: ["Симбалта", "Дулоксетин"] },
      { region: "Germany", names: ["Cymbalta", "Duloxetin"] },
      { region: "Spain", names: ["Cymbalta", "Duloxetina"] }
    ]
  },
  {
    name: "Bupropion",
    genericName: "Bupropion Hydrochloride",
    brandNames: ["Wellbutrin", "Wellbutrin SR", "Wellbutrin XL", "Zyban"],
    category: "Psychiatric - NDRI Antidepressant",
    form: "Tablet, Sustained-release tablet, Extended-release tablet",
    strength: "IR: 75mg, 100mg; SR: 100mg, 150mg, 200mg; XL: 150mg, 300mg, 450mg",
    route: "Oral",
    standardDoseAdult: "Depression: Start 150mg SR once daily, may increase to 150mg SR BID or 300mg XL daily; Smoking cessation: 150mg SR daily x3 days, then 150mg SR BID",
    standardDosePediatric: "Not recommended under 18 years",
    maxDailyDose: "450mg",
    dosingFrequency: "IR: Two to three times daily; SR: Twice daily; XL: Once daily",
    weightBasedDosing: false,
    renalAdjustment: "Reduce dose frequency and amount",
    hepaticAdjustment: "Mild-moderate: Reduce dose; Severe: Max 75mg IR daily or 150mg SR every other day",
    contraindications: ["Seizure disorder", "Eating disorders", "MAOIs within 14 days", "Abrupt alcohol/sedative withdrawal"],
    drugInteractions: ["MAOIs", "CYP2B6 substrates", "Dopaminergic drugs", "Drugs lowering seizure threshold"],
    sideEffects: ["Insomnia", "Dry mouth", "Headache", "Nausea", "Weight loss", "Seizures (dose-related)"],
    blackBoxWarning: "Serious neuropsychiatric events have been reported with smoking cessation. Suicidality risk in young adults.",
    pregnancyCategory: "C",
    administrationNotes: "Do not crush SR/XL. Allow at least 8 hours between doses (SR). Take morning dose early to avoid insomnia.",
    monitoringParameters: ["Depression symptoms", "Blood pressure", "Seizures", "Weight"],
    labsRequired: ["None routinely"],
    isControlled: false,
    marketStatus: "active",
    regulatoryApprovals: [
      { agency: "FDA", status: "approved", approvalDate: "1985-12-30", brandName: "Wellbutrin", indications: ["MDD", "Seasonal Affective Disorder", "Smoking Cessation"], riskCategory: "Pregnancy Category C" },
      { agency: "EMA", status: "approved", approvalDate: "2000-06-15", brandName: "Zyban", indications: ["Smoking Cessation", "Depression"] },
      { agency: "PMDA", status: "approved", approvalDate: "2007-04-20", brandName: "Zyban", indications: ["Smoking Cessation"], riskCategory: "Use with caution in pregnancy" },
      { agency: "NMPA", status: "approved", approvalDate: "2001-08-15", brandName: "安非他酮", indications: ["Smoking Cessation"] },
      { agency: "MFDS", status: "approved", approvalDate: "2000-09-20", brandName: "웰부트린", indications: ["Depression", "Smoking Cessation"] },
      { agency: "MOHRU", status: "approved", approvalDate: "2003-12-10", brandName: "Зибан", indications: ["Smoking Cessation"] }
    ],
    regionalDosing: [
      { region: "USA", adultDose: "150-450mg/day (XL once daily)", maxDose: "450mg/day", notes: "Dose-dependent seizure risk" },
      { region: "EU", adultDose: "150-300mg/day", maxDose: "300mg/day", notes: "Lower max in EU for smoking cessation" },
      { region: "Japan", adultDose: "150-300mg/day", maxDose: "300mg/day", notes: "Primarily for smoking cessation" },
      { region: "Russia", adultDose: "150-300mg/day", maxDose: "300mg/day", notes: "Smoking cessation indication" }
    ],
    internationalBrandNames: [
      { region: "Japan", names: ["Zyban", "ザイバン"] },
      { region: "China", names: ["安非他酮", "悦亭"] },
      { region: "Korea", names: ["웰부트린", "Wellbutrin"] },
      { region: "Russia", names: ["Зибан", "Бупропион"] },
      { region: "Germany", names: ["Zyban", "Bupropion"] },
      { region: "Spain", names: ["Elontril", "Bupropion"] }
    ]
  },

  // IMMUNOSUPPRESSANT
  {
    name: "Cyclosporine",
    genericName: "Cyclosporine",
    brandNames: ["Sandimmune", "Neoral", "Gengraf", "Restasis"],
    category: "Immunosuppressant - Calcineurin Inhibitor",
    form: "Capsule, Solution, Injection, Ophthalmic emulsion",
    strength: "Oral: 25mg, 50mg, 100mg capsules; Solution: 100mg/mL; IV: 50mg/mL",
    route: "Oral, IV, Ophthalmic",
    standardDoseAdult: "Transplant: 10-15mg/kg/day initially divided BID, then 5-10mg/kg/day; RA/Psoriasis: 2.5-4mg/kg/day",
    standardDosePediatric: "Similar to adults; adjust based on blood levels",
    maxDailyDose: "Individualized to blood levels",
    dosingFrequency: "Twice daily (oral); Twice daily (ophthalmic)",
    weightBasedDosing: true,
    weightBasedFormula: "5-15mg/kg/day divided BID",
    renalAdjustment: "Reduce dose if creatinine increases >25% above baseline",
    hepaticAdjustment: "May need dose reduction; monitor levels closely",
    contraindications: ["Hypersensitivity", "Psoriasis patients with abnormal renal function, uncontrolled HTN, or malignancies", "Concurrent PUVA in psoriasis"],
    drugInteractions: ["Nephrotoxic drugs", "CYP3A4 inhibitors/inducers", "Potassium-sparing diuretics", "NSAIDs", "Grapefruit"],
    sideEffects: ["Nephrotoxicity", "Hypertension", "Tremor", "Hirsutism", "Gingival hyperplasia", "Hepatotoxicity"],
    blackBoxWarning: "Increased susceptibility to infection and malignancy. Hypertension and nephrotoxicity. Should only be prescribed by physicians experienced in immunosuppressive therapy.",
    pregnancyCategory: "C",
    administrationNotes: "Neoral and Sandimmune are NOT bioequivalent. Take consistently with or without food. Avoid grapefruit.",
    storageRequirements: "Store at controlled room temperature; protect from freezing",
    monitoringParameters: ["Cyclosporine blood levels", "Renal function", "Blood pressure", "LFTs", "Lipids"],
    labsRequired: ["Cyclosporine trough level", "BMP", "LFTs", "Lipid panel", "Magnesium"],
    isControlled: false,
    marketStatus: "active",
    riskEvaluationProgram: "REMS for transplant use",
    regulatoryApprovals: [
      { agency: "FDA", status: "approved", approvalDate: "1983-11-14", brandName: "Sandimmune", indications: ["Organ Transplant", "Rheumatoid Arthritis", "Psoriasis", "Dry Eye"], riskCategory: "Pregnancy Category C" },
      { agency: "EMA", status: "approved", approvalDate: "1983-06-15", brandName: "Sandimmun", indications: ["Transplant", "Autoimmune Diseases", "Atopic Dermatitis"] },
      { agency: "PMDA", status: "approved", approvalDate: "1985-10-25", brandName: "Sandimmun", indications: ["Transplant", "Nephrotic Syndrome", "Aplastic Anemia"], riskCategory: "Use with caution in pregnancy" },
      { agency: "NMPA", status: "approved", approvalDate: "1990-07-20", brandName: "新山地明", indications: ["Transplant", "Autoimmune Diseases"] },
      { agency: "MFDS", status: "approved", approvalDate: "1987-04-15", brandName: "산디문", indications: ["Transplant", "Rheumatoid Arthritis", "Psoriasis"] },
      { agency: "MOHRU", status: "approved", approvalDate: "1992-09-10", brandName: "Сандиммун", indications: ["Transplant", "Autoimmune Diseases"] }
    ],
    regionalDosing: [
      { region: "USA", adultDose: "5-15mg/kg/day divided BID", maxDose: "Per blood levels", notes: "Target trough levels organ-specific" },
      { region: "EU", adultDose: "5-15mg/kg/day", maxDose: "Per blood levels", notes: "Microemulsion (Neoral) preferred" },
      { region: "Japan", adultDose: "6-12mg/kg/day", maxDose: "Per blood levels", notes: "Adjusted based on indication" },
      { region: "Russia", adultDose: "5-15mg/kg/day", maxDose: "Per blood levels", notes: "Standard immunosuppressant" }
    ],
    internationalBrandNames: [
      { region: "Japan", names: ["Sandimmun", "サンディミュン", "Neoral", "ネオーラル"] },
      { region: "China", names: ["新山地明", "环孢素"] },
      { region: "Korea", names: ["산디문", "네오랄"] },
      { region: "Russia", names: ["Сандиммун", "Циклоспорин"] },
      { region: "Germany", names: ["Sandimmun", "Ciclosporin"] },
      { region: "Spain", names: ["Sandimmun", "Ciclosporina"] }
    ]
  },

  // ADDITIONAL PAIN MEDICATIONS
  {
    name: "Diclofenac",
    genericName: "Diclofenac Sodium/Potassium",
    brandNames: ["Voltaren", "Cataflam", "Zipsor", "Cambia"],
    category: "Analgesic - NSAID",
    form: "Tablet, Delayed-release tablet, Gel, Patch, Ophthalmic solution",
    strength: "Oral: 25mg, 50mg, 75mg, 100mg; Gel: 1%, 3%; Patch: 1.3%",
    route: "Oral, Topical, Ophthalmic",
    standardDoseAdult: "Oral: 50mg TID or 75mg BID; Topical gel: Apply to affected area QID",
    standardDosePediatric: "Not recommended under 18 for oral",
    maxDailyDose: "150mg oral; 32g topical gel per joint",
    dosingFrequency: "Two to four times daily",
    weightBasedDosing: false,
    renalAdjustment: "Avoid in advanced renal disease",
    hepaticAdjustment: "Use lowest effective dose; avoid in severe impairment",
    contraindications: ["NSAID allergy", "Active GI bleeding", "CABG surgery", "Severe heart failure"],
    drugInteractions: ["Anticoagulants", "Aspirin", "ACE inhibitors", "Diuretics", "Lithium", "Methotrexate"],
    sideEffects: ["GI bleeding", "Dyspepsia", "Cardiovascular events", "Renal impairment", "Hepatotoxicity"],
    blackBoxWarning: "Increased risk of serious cardiovascular and GI events. Contraindicated for perioperative pain in CABG surgery.",
    pregnancyCategory: "C (D in 3rd trimester)",
    administrationNotes: "Take with food or milk. Do not apply topical to open wounds.",
    monitoringParameters: ["GI symptoms", "Blood pressure", "Renal function", "LFTs"],
    labsRequired: ["CBC", "BMP", "LFTs with prolonged use"],
    isControlled: false,
    marketStatus: "active",
    regulatoryApprovals: [
      { agency: "FDA", status: "approved", approvalDate: "1988-07-21", brandName: "Voltaren", indications: ["OA", "RA", "Ankylosing Spondylitis", "Pain", "Dysmenorrhea"], riskCategory: "Pregnancy Category C/D" },
      { agency: "EMA", status: "approved", approvalDate: "1973-06-15", brandName: "Voltaren", indications: ["Pain", "Inflammation", "Arthritis"] },
      { agency: "PMDA", status: "approved", approvalDate: "1974-10-20", brandName: "Voltaren", indications: ["Pain", "Inflammation", "Arthritis"], riskCategory: "Contraindicated in pregnancy" },
      { agency: "NMPA", status: "approved", approvalDate: "1985-08-15", brandName: "扶他林", indications: ["Pain", "Inflammation", "Arthritis"] },
      { agency: "MFDS", status: "approved", approvalDate: "1980-05-20", brandName: "볼타렌", indications: ["Pain", "Inflammation", "Arthritis"] },
      { agency: "MOHRU", status: "approved", approvalDate: "1988-12-10", brandName: "Вольтарен", indications: ["Pain", "Inflammation", "Arthritis"] }
    ],
    regionalDosing: [
      { region: "USA", adultDose: "50mg TID or 75mg BID", maxDose: "150mg/day", notes: "Various formulations available" },
      { region: "EU", adultDose: "75-150mg/day divided", maxDose: "150mg/day", notes: "Topical widely used" },
      { region: "Japan", adultDose: "25-50mg TID", maxDose: "100mg/day", notes: "Lower max dose" },
      { region: "Russia", adultDose: "75-150mg/day", maxDose: "150mg/day", notes: "Very commonly used NSAID" }
    ],
    internationalBrandNames: [
      { region: "Japan", names: ["Voltaren", "ボルタレン"] },
      { region: "China", names: ["扶他林", "双氯芬酸"] },
      { region: "Korea", names: ["볼타렌", "Voltaren"] },
      { region: "Russia", names: ["Вольтарен", "Диклофенак"] },
      { region: "Germany", names: ["Voltaren", "Diclofenac"] },
      { region: "Spain", names: ["Voltaren", "Diclofenaco"] }
    ]
  },
  {
    name: "Meloxicam",
    genericName: "Meloxicam",
    brandNames: ["Mobic", "Vivlodex"],
    category: "Analgesic - NSAID (preferential COX-2)",
    form: "Tablet, Capsule, Oral suspension",
    strength: "7.5mg, 15mg; Capsule: 5mg, 10mg",
    route: "Oral",
    standardDoseAdult: "OA: 7.5-15mg once daily; RA: 15mg once daily",
    standardDosePediatric: "JRA ≥2 years: 0.125mg/kg once daily (max 7.5mg)",
    maxDailyDose: "15mg",
    dosingFrequency: "Once daily",
    weightBasedDosing: true,
    weightBasedFormula: "0.125mg/kg once daily for JRA (max 7.5mg)",
    renalAdjustment: "Avoid in advanced renal disease; start at 7.5mg",
    hepaticAdjustment: "Max 7.5mg/day in mild-moderate impairment",
    contraindications: ["NSAID allergy", "Active GI bleeding", "CABG surgery", "Severe heart failure"],
    drugInteractions: ["Anticoagulants", "Aspirin", "ACE inhibitors", "Lithium", "Methotrexate"],
    sideEffects: ["GI upset", "Edema", "Dizziness", "Cardiovascular events", "GI bleeding"],
    blackBoxWarning: "Increased risk of serious cardiovascular and GI events. Contraindicated for perioperative pain in CABG surgery.",
    pregnancyCategory: "C (D in 3rd trimester)",
    administrationNotes: "May take with or without food. Once daily dosing convenient.",
    monitoringParameters: ["GI symptoms", "Blood pressure", "Renal function", "Signs of CV events"],
    labsRequired: ["CBC", "BMP periodically"],
    isControlled: false,
    marketStatus: "active",
    regulatoryApprovals: [
      { agency: "FDA", status: "approved", approvalDate: "2000-04-14", brandName: "Mobic", indications: ["Osteoarthritis", "Rheumatoid Arthritis", "JRA"], riskCategory: "Pregnancy Category C/D" },
      { agency: "EMA", status: "approved", approvalDate: "1996-03-20", brandName: "Mobec", indications: ["OA", "RA", "Ankylosing Spondylitis"] },
      { agency: "PMDA", status: "approved", approvalDate: "1996-07-25", brandName: "Mobec", indications: ["OA", "RA"], riskCategory: "Use with caution in pregnancy" },
      { agency: "NMPA", status: "approved", approvalDate: "1999-10-15", brandName: "莫比可", indications: ["OA", "RA"] },
      { agency: "MFDS", status: "approved", approvalDate: "1998-06-20", brandName: "모빅", indications: ["OA", "RA"] },
      { agency: "MOHRU", status: "approved", approvalDate: "2001-02-10", brandName: "Мовалис", indications: ["OA", "RA", "Ankylosing Spondylitis"] }
    ],
    regionalDosing: [
      { region: "USA", adultDose: "7.5-15mg once daily", maxDose: "15mg/day", notes: "Once daily dosing" },
      { region: "EU", adultDose: "7.5-15mg once daily", maxDose: "15mg/day", notes: "Preferential COX-2" },
      { region: "Japan", adultDose: "10mg once daily", maxDose: "15mg/day", notes: "Often 10mg dose" },
      { region: "Russia", adultDose: "7.5-15mg once daily", maxDose: "15mg/day", notes: "Movalis widely used" }
    ],
    internationalBrandNames: [
      { region: "Japan", names: ["Mobec", "モービック"] },
      { region: "China", names: ["莫比可", "美洛昔康"] },
      { region: "Korea", names: ["모빅", "Mobic"] },
      { region: "Russia", names: ["Мовалис", "Мелоксикам"] },
      { region: "Germany", names: ["Mobec", "Meloxicam"] },
      { region: "Spain", names: ["Movalis", "Meloxicam"] }
    ]
  },

  // INSULIN MEDICATIONS
  {
    name: "Insulin Glargine",
    genericName: "Insulin Glargine",
    brandNames: ["Lantus", "Basaglar", "Toujeo", "Semglee"],
    category: "Endocrine - Long-Acting Insulin",
    form: "Injection (prefilled pen, vial)",
    strength: "100 units/mL (Lantus, Basaglar, Semglee); 300 units/mL (Toujeo)",
    route: "Subcutaneous",
    standardDoseAdult: "Type 1: ~0.2-0.4 units/kg/day; Type 2: 10 units or 0.1-0.2 units/kg once daily; titrate based on fasting glucose",
    standardDosePediatric: "Type 1 ≥6 years: Individualized dosing",
    maxDailyDose: "Individualized",
    dosingFrequency: "Once daily at same time each day",
    weightBasedDosing: true,
    weightBasedFormula: "0.1-0.4 units/kg/day depending on type and situation",
    renalAdjustment: "May need dose reduction due to decreased insulin clearance",
    hepaticAdjustment: "May need dose reduction",
    contraindications: ["Hypersensitivity to insulin glargine", "During episodes of hypoglycemia"],
    drugInteractions: ["Antidiabetic agents", "Beta blockers", "ACE inhibitors", "Thiazolidinediones"],
    sideEffects: ["Hypoglycemia", "Injection site reactions", "Weight gain", "Lipodystrophy"],
    pregnancyCategory: "C",
    administrationNotes: "Inject SC in abdomen, thigh, or upper arm. Do not mix with other insulins. Rotate injection sites.",
    storageRequirements: "Refrigerate unopened; in-use may be kept at room temperature up to 28-42 days",
    monitoringParameters: ["Blood glucose", "A1c", "Hypoglycemia symptoms", "Weight"],
    labsRequired: ["Blood glucose", "A1c"],
    isControlled: false,
    marketStatus: "active",
    regulatoryApprovals: [
      { agency: "FDA", status: "approved", approvalDate: "2000-04-20", brandName: "Lantus", indications: ["Type 1 Diabetes", "Type 2 Diabetes"], riskCategory: "Pregnancy Category C" },
      { agency: "EMA", status: "approved", approvalDate: "2000-06-09", brandName: "Lantus", indications: ["Type 1 Diabetes", "Type 2 Diabetes"] },
      { agency: "PMDA", status: "approved", approvalDate: "2003-10-16", brandName: "Lantus", indications: ["Diabetes Mellitus"], riskCategory: "Use with caution in pregnancy" },
      { agency: "NMPA", status: "approved", approvalDate: "2004-07-15", brandName: "来得时", indications: ["Type 1 and Type 2 Diabetes"] },
      { agency: "MFDS", status: "approved", approvalDate: "2002-05-20", brandName: "란투스", indications: ["Type 1 and Type 2 Diabetes"] },
      { agency: "MOHRU", status: "approved", approvalDate: "2005-03-10", brandName: "Лантус", indications: ["Type 1 and Type 2 Diabetes"] }
    ],
    regionalDosing: [
      { region: "USA", adultDose: "10-80 units once daily", maxDose: "Individualized", notes: "Titrate by 2-4 units every 3-4 days" },
      { region: "EU", adultDose: "Individualized", maxDose: "Per glycemic targets", notes: "Once daily at same time" },
      { region: "Japan", adultDose: "Individualized", maxDose: "Per glycemic targets", notes: "Titrate to target" },
      { region: "Russia", adultDose: "Individualized", maxDose: "Per glycemic targets", notes: "Long-acting basal insulin" }
    ],
    internationalBrandNames: [
      { region: "Japan", names: ["Lantus", "ランタス"] },
      { region: "China", names: ["来得时", "甘精胰岛素"] },
      { region: "Korea", names: ["란투스", "Lantus"] },
      { region: "Russia", names: ["Лантус", "Инсулин гларгин"] },
      { region: "Germany", names: ["Lantus", "Insulin glargin"] },
      { region: "Spain", names: ["Lantus", "Insulina glargina"] }
    ]
  },
  {
    name: "Insulin Lispro",
    genericName: "Insulin Lispro",
    brandNames: ["Humalog", "Admelog", "Lyumjev"],
    category: "Endocrine - Rapid-Acting Insulin",
    form: "Injection (prefilled pen, vial, cartridge)",
    strength: "100 units/mL; 200 units/mL (concentrated)",
    route: "Subcutaneous, IV (Humalog only)",
    standardDoseAdult: "0.5-1 unit/kg/day total insulin (rapid-acting portion typically 50-70% of total); Give 0-15 min before meals",
    standardDosePediatric: "Individualized; typically lower requirements per kg in younger children",
    maxDailyDose: "Individualized",
    dosingFrequency: "Before each meal (typically 3 times daily) or with insulin pump",
    weightBasedDosing: true,
    weightBasedFormula: "Meal-time bolus: varies by carb intake and correction factor",
    renalAdjustment: "May need dose reduction",
    hepaticAdjustment: "May need dose reduction",
    contraindications: ["Hypersensitivity to insulin lispro", "During episodes of hypoglycemia"],
    drugInteractions: ["Antidiabetic agents", "Beta blockers", "ACE inhibitors", "Alcohol"],
    sideEffects: ["Hypoglycemia", "Injection site reactions", "Weight gain", "Lipodystrophy", "Allergic reactions"],
    pregnancyCategory: "B",
    administrationNotes: "Give within 15 minutes before or immediately after meals. Rotate injection sites. U-200 pen delivers same units as U-100.",
    storageRequirements: "Refrigerate unopened; in-use may be kept at room temperature up to 28 days",
    monitoringParameters: ["Blood glucose", "A1c", "Hypoglycemia symptoms", "Weight"],
    labsRequired: ["Blood glucose", "A1c"],
    isControlled: false,
    marketStatus: "active",
    regulatoryApprovals: [
      { agency: "FDA", status: "approved", approvalDate: "1996-06-14", brandName: "Humalog", indications: ["Type 1 Diabetes", "Type 2 Diabetes"], riskCategory: "Pregnancy Category B" },
      { agency: "EMA", status: "approved", approvalDate: "1996-04-30", brandName: "Humalog", indications: ["Type 1 Diabetes", "Type 2 Diabetes"] },
      { agency: "PMDA", status: "approved", approvalDate: "2001-02-16", brandName: "Humalog", indications: ["Diabetes Mellitus"], riskCategory: "Use with caution in pregnancy" },
      { agency: "NMPA", status: "approved", approvalDate: "2000-09-15", brandName: "优泌乐", indications: ["Type 1 and Type 2 Diabetes"] },
      { agency: "MFDS", status: "approved", approvalDate: "1999-03-20", brandName: "휴마로그", indications: ["Type 1 and Type 2 Diabetes"] },
      { agency: "MOHRU", status: "approved", approvalDate: "2002-06-10", brandName: "Хумалог", indications: ["Type 1 and Type 2 Diabetes"] }
    ],
    regionalDosing: [
      { region: "USA", adultDose: "Individualized per meal", maxDose: "Individualized", notes: "Give 0-15 min before meals" },
      { region: "EU", adultDose: "Individualized", maxDose: "Per glycemic targets", notes: "Rapid onset, short duration" },
      { region: "Japan", adultDose: "Individualized", maxDose: "Per glycemic targets", notes: "Mealtime insulin" },
      { region: "Russia", adultDose: "Individualized", maxDose: "Per glycemic targets", notes: "Rapid-acting analog" }
    ],
    internationalBrandNames: [
      { region: "Japan", names: ["Humalog", "ヒューマログ"] },
      { region: "China", names: ["优泌乐", "赖脯胰岛素"] },
      { region: "Korea", names: ["휴마로그", "Humalog"] },
      { region: "Russia", names: ["Хумалог", "Инсулин лизпро"] },
      { region: "Germany", names: ["Humalog", "Insulin lispro"] },
      { region: "Spain", names: ["Humalog", "Insulina lispro"] }
    ]
  },

  // MORE RESPIRATORY
  {
    name: "Ipratropium Bromide",
    genericName: "Ipratropium Bromide",
    brandNames: ["Atrovent", "Atrovent HFA"],
    category: "Respiratory - Short-Acting Anticholinergic (SAMA)",
    form: "MDI, Nebulizer solution, Nasal spray",
    strength: "MDI: 17mcg/puff; Neb: 0.02% (0.5mg/2.5mL); Nasal: 0.03%, 0.06%",
    route: "Inhalation, Intranasal",
    standardDoseAdult: "MDI: 2 puffs QID; Neb: 0.5mg every 6-8 hours; Nasal: 2 sprays per nostril BID-TID",
    standardDosePediatric: "Neb: 250-500mcg every 6-8 hours",
    maxDailyDose: "MDI: 12 puffs/day; Neb: 2mg/day",
    dosingFrequency: "Every 6-8 hours or as needed",
    weightBasedDosing: false,
    renalAdjustment: "No adjustment needed",
    hepaticAdjustment: "No adjustment needed",
    contraindications: ["Hypersensitivity to ipratropium or atropine derivatives", "Soy or peanut allergy (some formulations)"],
    drugInteractions: ["Other anticholinergics", "Potassium chloride"],
    sideEffects: ["Dry mouth", "Cough", "Headache", "Dizziness", "Urinary retention", "Paradoxical bronchospasm"],
    pregnancyCategory: "B",
    administrationNotes: "Shake MDI before use. Can be combined with albuterol. Avoid contact with eyes.",
    monitoringParameters: ["Respiratory status", "Anticholinergic effects"],
    labsRequired: ["None routinely"],
    isControlled: false,
    marketStatus: "active",
    regulatoryApprovals: [
      { agency: "FDA", status: "approved", approvalDate: "1986-11-28", brandName: "Atrovent", indications: ["COPD", "Bronchospasm", "Rhinorrhea"], riskCategory: "Pregnancy Category B" },
      { agency: "EMA", status: "approved", approvalDate: "1984-06-15", brandName: "Atrovent", indications: ["COPD", "Asthma", "Rhinitis"] },
      { agency: "PMDA", status: "approved", approvalDate: "1988-09-20", brandName: "Atrovent", indications: ["COPD", "Asthma"], riskCategory: "Use with caution in pregnancy" },
      { agency: "NMPA", status: "approved", approvalDate: "1992-05-15", brandName: "爱全乐", indications: ["COPD", "Asthma"] },
      { agency: "MFDS", status: "approved", approvalDate: "1990-03-20", brandName: "아트로벤트", indications: ["COPD", "Asthma"] },
      { agency: "MOHRU", status: "approved", approvalDate: "1995-08-10", brandName: "Атровент", indications: ["COPD", "Asthma"] }
    ],
    regionalDosing: [
      { region: "USA", adultDose: "2 puffs QID (MDI) or 500mcg q6-8h (Neb)", maxDose: "12 puffs/day", notes: "Often combined with albuterol" },
      { region: "EU", adultDose: "2 puffs TID-QID", maxDose: "12 puffs/day", notes: "SAMA for COPD" },
      { region: "Japan", adultDose: "2 puffs TID-QID", maxDose: "8-12 puffs/day", notes: "COPD maintenance" },
      { region: "Russia", adultDose: "2 puffs TID-QID", maxDose: "12 puffs/day", notes: "Short-acting bronchodilator" }
    ],
    internationalBrandNames: [
      { region: "Japan", names: ["Atrovent", "アトロベント"] },
      { region: "China", names: ["爱全乐", "异丙托溴铵"] },
      { region: "Korea", names: ["아트로벤트", "Atrovent"] },
      { region: "Russia", names: ["Атровент", "Ипратропий"] },
      { region: "Germany", names: ["Atrovent", "Ipratropium"] },
      { region: "Spain", names: ["Atrovent", "Ipratropio"] }
    ]
  },
  {
    name: "Mometasone",
    genericName: "Mometasone Furoate",
    brandNames: ["Nasonex", "Asmanex", "Elocon"],
    category: "Respiratory/Dermatologic - Corticosteroid",
    form: "Nasal spray, Dry powder inhaler, Topical cream/ointment/lotion",
    strength: "Nasal: 50mcg/spray; DPI: 110mcg, 220mcg; Topical: 0.1%",
    route: "Intranasal, Inhalation, Topical",
    standardDoseAdult: "Nasal: 2 sprays each nostril once daily; Inhaled: 220mcg once or twice daily; Topical: Apply thin film once daily",
    standardDosePediatric: "Nasal ≥2 years: 1 spray each nostril daily; Inhaled ≥4 years: 110mcg once daily",
    maxDailyDose: "Nasal: 400mcg; Inhaled: 880mcg",
    dosingFrequency: "Once or twice daily",
    weightBasedDosing: false,
    renalAdjustment: "No adjustment needed",
    hepaticAdjustment: "Use with caution",
    contraindications: ["Primary treatment of status asthmaticus", "Hypersensitivity to mometasone"],
    drugInteractions: ["CYP3A4 inhibitors", "Ritonavir", "Ketoconazole"],
    sideEffects: ["Nasal: Epistaxis, headache; Inhaled: Oral candidiasis, dysphonia; Topical: Skin atrophy, striae"],
    pregnancyCategory: "C",
    administrationNotes: "Nasal: Prime before first use. Inhaled: Rinse mouth after use. Topical: Do not use with occlusive dressings.",
    monitoringParameters: ["Symptom control", "Growth in children", "Adrenal function (high doses)", "Skin integrity (topical)"],
    labsRequired: ["None routinely"],
    isControlled: false,
    marketStatus: "active",
    regulatoryApprovals: [
      { agency: "FDA", status: "approved", approvalDate: "1997-10-01", brandName: "Nasonex", indications: ["Allergic Rhinitis", "Nasal Polyps", "Asthma"], riskCategory: "Pregnancy Category C" },
      { agency: "EMA", status: "approved", approvalDate: "1998-06-15", brandName: "Nasonex", indications: ["Allergic Rhinitis", "Nasal Polyps"] },
      { agency: "PMDA", status: "approved", approvalDate: "2002-09-20", brandName: "Nasonex", indications: ["Allergic Rhinitis"], riskCategory: "Use with caution in pregnancy" },
      { agency: "NMPA", status: "approved", approvalDate: "2001-04-15", brandName: "内舒拿", indications: ["Allergic Rhinitis", "Nasal Polyps"] },
      { agency: "MFDS", status: "approved", approvalDate: "2000-08-20", brandName: "나조넥스", indications: ["Allergic Rhinitis", "Nasal Polyps"] },
      { agency: "MOHRU", status: "approved", approvalDate: "2003-01-10", brandName: "Назонекс", indications: ["Allergic Rhinitis", "Nasal Polyps"] }
    ],
    regionalDosing: [
      { region: "USA", adultDose: "Nasal: 2 sprays/nostril daily; Inhaled: 220-440mcg daily", maxDose: "880mcg/day inhaled", notes: "Once daily nasal dosing" },
      { region: "EU", adultDose: "Nasal: 2 sprays/nostril daily", maxDose: "400mcg/day nasal", notes: "First-line for allergic rhinitis" },
      { region: "Japan", adultDose: "Nasal: 2 sprays/nostril daily", maxDose: "400mcg/day nasal", notes: "Once daily convenient" },
      { region: "Russia", adultDose: "Nasal: 2 sprays/nostril daily", maxDose: "400mcg/day nasal", notes: "Potent topical steroid" }
    ],
    internationalBrandNames: [
      { region: "Japan", names: ["Nasonex", "ナゾネックス"] },
      { region: "China", names: ["内舒拿", "糠酸莫米松"] },
      { region: "Korea", names: ["나조넥스", "Nasonex"] },
      { region: "Russia", names: ["Назонекс", "Мометазон"] },
      { region: "Germany", names: ["Nasonex", "Mometason"] },
      { region: "Spain", names: ["Nasonex", "Mometasona"] }
    ]
  },
  {
    name: "Formoterol",
    genericName: "Formoterol Fumarate",
    brandNames: ["Foradil", "Perforomist", "Oxeze"],
    category: "Respiratory - Long-Acting Beta-2 Agonist (LABA)",
    form: "Dry powder inhaler, Nebulizer solution",
    strength: "DPI: 12mcg; Neb: 20mcg/2mL",
    route: "Inhalation",
    standardDoseAdult: "Asthma/COPD: 12mcg twice daily; EIB prevention: 12mcg 15 min before exercise",
    standardDosePediatric: "≥5 years: 12mcg twice daily",
    maxDailyDose: "48mcg (12mcg QID in acute exacerbations, short-term)",
    dosingFrequency: "Twice daily (12 hours apart)",
    weightBasedDosing: false,
    renalAdjustment: "No adjustment needed",
    hepaticAdjustment: "Use with caution in severe impairment",
    contraindications: ["Monotherapy in asthma (must use with ICS)", "Acute bronchospasm", "Hypersensitivity"],
    drugInteractions: ["Beta blockers", "MAOIs", "TCAs", "QT-prolonging drugs"],
    sideEffects: ["Tremor", "Headache", "Palpitations", "Hypokalemia", "Throat irritation"],
    blackBoxWarning: "LABAs increase the risk of asthma-related death. Use only with an ICS for asthma.",
    pregnancyCategory: "C",
    administrationNotes: "Not for acute symptoms. Always use with inhaled corticosteroid for asthma. Use every 12 hours.",
    monitoringParameters: ["Peak flow", "Symptom control", "Heart rate", "Potassium"],
    labsRequired: ["Potassium periodically"],
    isControlled: false,
    marketStatus: "active",
    regulatoryApprovals: [
      { agency: "FDA", status: "approved", approvalDate: "2001-02-16", brandName: "Foradil", indications: ["Asthma (with ICS)", "COPD", "Exercise-Induced Bronchospasm"], riskCategory: "Pregnancy Category C" },
      { agency: "EMA", status: "approved", approvalDate: "1997-09-15", brandName: "Foradil", indications: ["Asthma", "COPD", "EIB"] },
      { agency: "PMDA", status: "approved", approvalDate: "1999-03-26", brandName: "Oxis", indications: ["Asthma", "COPD"], riskCategory: "Use with caution in pregnancy" },
      { agency: "NMPA", status: "approved", approvalDate: "2003-06-15", brandName: "奥克斯", indications: ["Asthma", "COPD"] },
      { agency: "MFDS", status: "approved", approvalDate: "2001-09-20", brandName: "포라딜", indications: ["Asthma", "COPD"] },
      { agency: "MOHRU", status: "approved", approvalDate: "2004-02-10", brandName: "Форадил", indications: ["Asthma", "COPD"] }
    ],
    regionalDosing: [
      { region: "USA", adultDose: "12mcg twice daily", maxDose: "48mcg/day", notes: "Must combine with ICS for asthma" },
      { region: "EU", adultDose: "12-24mcg twice daily", maxDose: "48mcg/day", notes: "Often in combination products" },
      { region: "Japan", adultDose: "9mcg twice daily", maxDose: "36mcg/day", notes: "Lower typical dose" },
      { region: "Russia", adultDose: "12mcg twice daily", maxDose: "48mcg/day", notes: "LABA with rapid onset" }
    ],
    internationalBrandNames: [
      { region: "Japan", names: ["Oxis", "オーキシス"] },
      { region: "China", names: ["奥克斯", "福莫特罗"] },
      { region: "Korea", names: ["포라딜", "Foradil"] },
      { region: "Russia", names: ["Форадил", "Формотерол"] },
      { region: "Germany", names: ["Foradil", "Formoterol"] },
      { region: "Spain", names: ["Foradil", "Formoterol"] }
    ]
  },

  // ANTICONVULSANTS/NEUROLOGICAL
  {
    name: "Levetiracetam",
    genericName: "Levetiracetam",
    brandNames: ["Keppra", "Keppra XR", "Spritam"],
    category: "Neurological - Anticonvulsant",
    form: "Tablet, Extended-release tablet, Solution, Injection, ODT",
    strength: "250mg, 500mg, 750mg, 1000mg; XR: 500mg, 750mg; Solution: 100mg/mL",
    route: "Oral, IV",
    standardDoseAdult: "Start 500mg BID, increase by 500mg BID every 2 weeks to 1500mg BID",
    standardDosePediatric: "1 month-6 years: 10-25mg/kg BID; 6-16 years: 10-30mg/kg BID",
    maxDailyDose: "3000mg",
    dosingFrequency: "IR: Twice daily; XR: Once daily",
    weightBasedDosing: true,
    weightBasedFormula: "20-60mg/kg/day divided BID",
    renalAdjustment: "CrCl 50-80: 500-1000mg q12h; CrCl 30-50: 250-750mg q12h; CrCl <30: 250-500mg q12h",
    hepaticAdjustment: "No adjustment for hepatic alone; reduce if combined hepatic/renal",
    contraindications: ["Hypersensitivity to levetiracetam"],
    drugInteractions: ["Few significant interactions; may decrease carbamazepine levels slightly"],
    sideEffects: ["Somnolence", "Dizziness", "Behavioral changes", "Asthenia", "Infection"],
    blackBoxWarning: "Antiepileptic drugs increase risk of suicidal thoughts or behavior.",
    pregnancyCategory: "C",
    administrationNotes: "May take with or without food. IV can be given undiluted over 15 min.",
    monitoringParameters: ["Seizure frequency", "Behavioral changes", "Renal function", "Suicidal ideation"],
    labsRequired: ["BMP"],
    isControlled: false,
    marketStatus: "active",
    regulatoryApprovals: [
      { agency: "FDA", status: "approved", approvalDate: "1999-11-30", brandName: "Keppra", indications: ["Partial Onset Seizures", "Myoclonic Seizures", "Primary Generalized Tonic-Clonic Seizures"], riskCategory: "Pregnancy Category C" },
      { agency: "EMA", status: "approved", approvalDate: "2000-09-29", brandName: "Keppra", indications: ["Epilepsy (Partial and Generalized Seizures)"] },
      { agency: "PMDA", status: "approved", approvalDate: "2010-07-23", brandName: "Keppra", indications: ["Epilepsy"], riskCategory: "Use with caution in pregnancy" },
      { agency: "NMPA", status: "approved", approvalDate: "2007-04-15", brandName: "开浦兰", indications: ["Epilepsy"] },
      { agency: "MFDS", status: "approved", approvalDate: "2003-11-20", brandName: "케프라", indications: ["Epilepsy"] },
      { agency: "MOHRU", status: "approved", approvalDate: "2008-06-10", brandName: "Кеппра", indications: ["Epilepsy"] }
    ],
    regionalDosing: [
      { region: "USA", adultDose: "1000-3000mg/day divided BID", maxDose: "3000mg/day", notes: "Titrate over 4-6 weeks" },
      { region: "EU", adultDose: "1000-3000mg/day", maxDose: "3000mg/day", notes: "Well-tolerated AED" },
      { region: "Japan", adultDose: "1000-3000mg/day", maxDose: "3000mg/day", notes: "Newer anticonvulsant" },
      { region: "Russia", adultDose: "1000-3000mg/day", maxDose: "3000mg/day", notes: "First-line for many seizure types" }
    ],
    internationalBrandNames: [
      { region: "Japan", names: ["Keppra", "イーケプラ"] },
      { region: "China", names: ["开浦兰", "左乙拉西坦"] },
      { region: "Korea", names: ["케프라", "Keppra"] },
      { region: "Russia", names: ["Кеппра", "Леветирацетам"] },
      { region: "Germany", names: ["Keppra", "Levetiracetam"] },
      { region: "Spain", names: ["Keppra", "Levetiracetam"] }
    ]
  },
  {
    name: "Lamotrigine",
    genericName: "Lamotrigine",
    brandNames: ["Lamictal", "Lamictal XR", "Lamictal ODT"],
    category: "Neurological - Anticonvulsant/Mood Stabilizer",
    form: "Tablet, Chewable tablet, ODT, Extended-release tablet",
    strength: "25mg, 100mg, 150mg, 200mg; XR: 25mg, 50mg, 100mg, 200mg, 250mg, 300mg",
    route: "Oral",
    standardDoseAdult: "Epilepsy monotherapy: Start 25mg daily x2 weeks, increase to target 100-400mg/day; Bipolar: Start 25mg daily, target 200mg/day",
    standardDosePediatric: "2-12 years: 0.3-1mg/kg/day initially, maintenance 1-15mg/kg/day (max 400mg)",
    maxDailyDose: "600mg (epilepsy); 400mg (bipolar)",
    dosingFrequency: "Once or twice daily",
    weightBasedDosing: true,
    weightBasedFormula: "Pediatric: 0.3-15mg/kg/day depending on concomitant AEDs",
    renalAdjustment: "Reduce dose in significant renal impairment",
    hepaticAdjustment: "Moderate: Reduce by 25%; Severe: Reduce by 50%",
    contraindications: ["Hypersensitivity to lamotrigine"],
    drugInteractions: ["Valproate (reduces metabolism)", "Carbamazepine/Phenytoin (increases metabolism)", "OCPs"],
    sideEffects: ["Dizziness", "Headache", "Diplopia", "Ataxia", "Nausea", "Rash (including SJS/TEN)"],
    blackBoxWarning: "Serious skin rashes, including Stevens-Johnson syndrome and toxic epidermal necrolysis. Risk higher with rapid titration.",
    pregnancyCategory: "C",
    administrationNotes: "MUST titrate slowly to reduce rash risk. Halve dose if adding valproate; double if adding enzyme inducers.",
    monitoringParameters: ["Seizure frequency", "Rash", "Mood symptoms", "LFTs"],
    labsRequired: ["LFTs periodically"],
    isControlled: false,
    marketStatus: "active",
    regulatoryApprovals: [
      { agency: "FDA", status: "approved", approvalDate: "1994-12-27", brandName: "Lamictal", indications: ["Epilepsy", "Bipolar I Disorder Maintenance"], riskCategory: "Pregnancy Category C" },
      { agency: "EMA", status: "approved", approvalDate: "1991-10-15", brandName: "Lamictal", indications: ["Epilepsy", "Bipolar Disorder"] },
      { agency: "PMDA", status: "approved", approvalDate: "2008-10-16", brandName: "Lamictal", indications: ["Epilepsy", "Bipolar Disorder"], riskCategory: "Use with caution in pregnancy" },
      { agency: "NMPA", status: "approved", approvalDate: "2000-07-15", brandName: "利必通", indications: ["Epilepsy", "Bipolar Disorder"] },
      { agency: "MFDS", status: "approved", approvalDate: "1997-06-20", brandName: "라믹탈", indications: ["Epilepsy", "Bipolar Disorder"] },
      { agency: "MOHRU", status: "approved", approvalDate: "2002-03-10", brandName: "Ламиктал", indications: ["Epilepsy", "Bipolar Disorder"] }
    ],
    regionalDosing: [
      { region: "USA", adultDose: "100-400mg/day (epilepsy); 200mg/day (bipolar)", maxDose: "600mg/day", notes: "Slow titration essential" },
      { region: "EU", adultDose: "100-400mg/day", maxDose: "500mg/day", notes: "Adjust for concomitant AEDs" },
      { region: "Japan", adultDose: "100-400mg/day", maxDose: "400mg/day", notes: "Titrate very slowly" },
      { region: "Russia", adultDose: "100-400mg/day", maxDose: "500mg/day", notes: "Mood stabilizer and AED" }
    ],
    internationalBrandNames: [
      { region: "Japan", names: ["Lamictal", "ラミクタール"] },
      { region: "China", names: ["利必通", "拉莫三嗪"] },
      { region: "Korea", names: ["라믹탈", "Lamictal"] },
      { region: "Russia", names: ["Ламиктал", "Ламотриджин"] },
      { region: "Germany", names: ["Lamictal", "Lamotrigin"] },
      { region: "Spain", names: ["Lamictal", "Lamotrigina"] }
    ]
  },
  {
    name: "Topiramate",
    genericName: "Topiramate",
    brandNames: ["Topamax", "Trokendi XR", "Qudexy XR"],
    category: "Neurological - Anticonvulsant",
    form: "Tablet, Capsule (sprinkle), Extended-release capsule",
    strength: "25mg, 50mg, 100mg, 200mg; Sprinkle: 15mg, 25mg; XR: various",
    route: "Oral",
    standardDoseAdult: "Epilepsy: Start 25-50mg daily, increase to 200-400mg/day divided BID; Migraine: 25mg daily, target 100mg/day",
    standardDosePediatric: "2-16 years: Start 25mg nightly, increase to 5-9mg/kg/day divided BID",
    maxDailyDose: "1600mg (epilepsy); 200mg (migraine)",
    dosingFrequency: "IR: Twice daily; XR: Once daily",
    weightBasedDosing: true,
    weightBasedFormula: "5-9mg/kg/day for pediatric epilepsy",
    renalAdjustment: "CrCl <70: Reduce dose by 50%",
    hepaticAdjustment: "Use with caution",
    contraindications: ["Hypersensitivity to topiramate", "Metabolic acidosis with metformin"],
    drugInteractions: ["OCPs (decreased efficacy)", "Carbonic anhydrase inhibitors", "Valproate", "Metformin"],
    sideEffects: ["Paresthesias", "Cognitive dysfunction", "Weight loss", "Kidney stones", "Metabolic acidosis"],
    blackBoxWarning: "Increased risk of oral clefts in infants exposed during first trimester. Suicidal ideation risk.",
    pregnancyCategory: "D",
    administrationNotes: "May take with or without food. Increase fluid intake. Sprinkles can be opened on food.",
    monitoringParameters: ["Seizure frequency", "Bicarbonate level", "Cognitive function", "Weight"],
    labsRequired: ["BMP", "Bicarbonate"],
    isControlled: false,
    marketStatus: "active",
    regulatoryApprovals: [
      { agency: "FDA", status: "approved", approvalDate: "1996-12-24", brandName: "Topamax", indications: ["Epilepsy", "Migraine Prophylaxis"], riskCategory: "Pregnancy Category D" },
      { agency: "EMA", status: "approved", approvalDate: "1996-03-15", brandName: "Topamax", indications: ["Epilepsy", "Migraine Prevention"] },
      { agency: "PMDA", status: "approved", approvalDate: "2007-07-26", brandName: "Topamax", indications: ["Epilepsy"], riskCategory: "Use with caution in pregnancy" },
      { agency: "NMPA", status: "approved", approvalDate: "2001-10-15", brandName: "妥泰", indications: ["Epilepsy", "Migraine"] },
      { agency: "MFDS", status: "approved", approvalDate: "1999-08-20", brandName: "토파맥스", indications: ["Epilepsy", "Migraine"] },
      { agency: "MOHRU", status: "approved", approvalDate: "2003-05-10", brandName: "Топамакс", indications: ["Epilepsy", "Migraine"] }
    ],
    regionalDosing: [
      { region: "USA", adultDose: "200-400mg/day divided BID (epilepsy)", maxDose: "1600mg/day", notes: "100mg/day for migraine" },
      { region: "EU", adultDose: "200-400mg/day", maxDose: "800mg/day", notes: "Slow titration reduces side effects" },
      { region: "Japan", adultDose: "200-400mg/day", maxDose: "600mg/day", notes: "Lower max dose" },
      { region: "Russia", adultDose: "200-400mg/day", maxDose: "800mg/day", notes: "Epilepsy and migraine prophylaxis" }
    ],
    internationalBrandNames: [
      { region: "Japan", names: ["Topamax", "トピナ"] },
      { region: "China", names: ["妥泰", "托吡酯"] },
      { region: "Korea", names: ["토파맥스", "Topamax"] },
      { region: "Russia", names: ["Топамакс", "Топирамат"] },
      { region: "Germany", names: ["Topamax", "Topiramat"] },
      { region: "Spain", names: ["Topamax", "Topiramato"] }
    ]
  }
];

export const getMedicationsByCategory = (category: string): MedicationData[] => {
  return medicationsDatabase.filter(med => 
    med.category.toLowerCase().includes(category.toLowerCase())
  );
};

export const searchMedications = (query: string): MedicationData[] => {
  const searchLower = query.toLowerCase();
  return medicationsDatabase.filter(med =>
    med.name.toLowerCase().includes(searchLower) ||
    med.genericName.toLowerCase().includes(searchLower) ||
    med.brandNames.some(brand => brand.toLowerCase().includes(searchLower)) ||
    med.category.toLowerCase().includes(searchLower)
  );
};

export const getMedicationByName = (name: string): MedicationData | undefined => {
  return medicationsDatabase.find(med =>
    med.name.toLowerCase() === name.toLowerCase() ||
    med.genericName.toLowerCase() === name.toLowerCase() ||
    med.brandNames.some(brand => brand.toLowerCase() === name.toLowerCase())
  );
};

export const getControlledSubstances = (): MedicationData[] => {
  return medicationsDatabase.filter(med => med.isControlled);
};

export const getMedicationsWithBlackBoxWarning = (): MedicationData[] => {
  return medicationsDatabase.filter(med => med.blackBoxWarning);
};

// Get medications by regulatory agency approval
export const getMedicationsByRegulatoryAgency = (agency: RegulatoryAgency): MedicationData[] => {
  return medicationsDatabase.filter(med => 
    med.regulatoryApprovals?.some(approval => 
      approval.agency === agency && approval.status === 'approved'
    )
  );
};

// Get all medications organized by regulatory agencies
export const getMedicationsGroupedByAgency = () => {
  const agencies: RegulatoryAgency[] = ['FDA', 'EMA', 'PMDA', 'NMPA', 'MFDS', 'HSA', 'TGA', 'MOHRU'];
  
  return agencies.reduce((acc, agency) => {
    acc[agency] = getMedicationsByRegulatoryAgency(agency);
    return acc;
  }, {} as Record<RegulatoryAgency, MedicationData[]>);
};

// Get medication approval status by agency
export const getMedicationApprovalStatus = (medicationName: string, agency: RegulatoryAgency) => {
  const medication = getMedicationByName(medicationName);
  if (!medication) return null;
  
  return medication.regulatoryApprovals?.find(approval => approval.agency === agency) || null;
};

// Get medications approved by specific agencies
export const getMedicationsApprovedByAgencies = (agencies: RegulatoryAgency[]): MedicationData[] => {
  return medicationsDatabase.filter(med => 
    agencies.every(agency => 
      med.regulatoryApprovals?.some(approval => 
        approval.agency === agency && approval.status === 'approved'
      )
    )
  );
};

// Get medication count by regulatory agency
export const getMedicationCountByAgency = () => {
  const agencies: RegulatoryAgency[] = ['FDA', 'EMA', 'PMDA', 'NMPA', 'MFDS', 'HSA', 'TGA', 'MOHRU'];
  
  return agencies.reduce((acc, agency) => {
    acc[agency] = getMedicationsByRegulatoryAgency(agency).length;
    return acc;
  }, {} as Record<RegulatoryAgency, number>);
};

// Get medications by regulatory standard category
// Updated with official regulatory information from:
// - FDA: fda.gov (12-month standard review, accelerated/priority pathways available)
// - EMA: ema.europa.eu (Centralized procedure for EU-wide authorization)
// - PMDA: pmda.go.jp (12-month standard, 6-9 month expedited pathways including Sakigake)
// - NMPA: nmpa.gov.cn (30-day IND review for innovative drugs, accelerated pathways)
// - MFDS: mfds.go.kr (12-24 month approval timeline, aligned with ICH standards)
// - MOHRU/Minzdrav: roszdravnadzor.gov.ru (Russian Federal Service for Healthcare Surveillance)
export const getMedicationsByStandard = () => {
  return {
    FDA: {
      name: "U.S. Food and Drug Administration",
      region: "United States",
      standard: "FDA-approved medications following 21 CFR (Code of Federal Regulations) and PDUFA standards",
      description: "Novel drug approvals with standard 12-month review timeline. Expedited pathways include: Breakthrough Therapy, Accelerated Approval, Priority Review, Fast Track",
      website: "https://www.fda.gov/drugs",
      medications: getMedicationsByRegulatoryAgency('FDA')
    },
    EMA: {
      name: "European Medicines Agency",
      region: "European Union (+ EEA: Iceland, Norway, Liechtenstein)",
      standard: "EMA centralized authorization procedure valid across all EU Member States, following EU pharmaceutical directives",
      description: "Scientific evaluation with focus on quality, safety, and efficacy. Mandatory pharmacovigilance and risk management plans. Accelerated assessment available for medicines of major public health interest",
      website: "https://www.ema.europa.eu",
      medications: getMedicationsByRegulatoryAgency('EMA')
    },
    PMDA: {
      name: "Pharmaceuticals and Medical Devices Agency",
      region: "Japan",
      standard: "PMDA approval under Pharmaceuticals and Medical Devices Act (PMD Act), aligned with J-CTD format",
      description: "Standard 12-month review timeline. Expedited pathways: Sakigake (6-month review for innovative drugs first in Japan), Priority Review, Orphan Drug, Conditional Early Approval for regenerative medicine",
      website: "https://www.pmda.go.jp/english",
      medications: getMedicationsByRegulatoryAgency('PMDA')
    },
    NMPA: {
      name: "National Medical Products Administration",
      region: "People's Republic of China",
      standard: "NMPA approval following Chinese Pharmacopoeia 2025 Edition and Drug Administration Law",
      description: "Optimized review process with 30-day IND approval for Class I innovative drugs. Accelerated pathways for clinically urgent medications. Mandatory compliance with GMP and Chinese quality standards",
      website: "https://english.nmpa.gov.cn",
      medications: getMedicationsByRegulatoryAgency('NMPA')
    },
    MFDS: {
      name: "Ministry of Food and Drug Safety",
      region: "Republic of Korea",
      standard: "MFDS approval following Korean GMP (KGMP) standards and aligned with ICH guidelines",
      description: "12-24 month approval timeline. Four drug categories: new drugs with novel materials, drugs requiring data submission, generic pharmaceuticals, OTC products. Science-based regulatory approach with R&D integration",
      website: "https://www.mfds.go.kr/eng",
      medications: getMedicationsByRegulatoryAgency('MFDS')
    },
    MOHRU: {
      name: "Roszdravnadzor / Ministry of Health (Minzdrav)",
      region: "Russian Federation (+ EAEU member states)",
      standard: "Russian Federal Service for Healthcare Surveillance under Minzdrav, following Federal Law No. 61-FZ and EAEU standards",
      description: "Marketing authorization through State Registration Certificate (SRC). Mandatory GMP certification, Russian language requirements. Aligned with EAEU harmonization while maintaining local specifications",
      website: "https://roszdravnadzor.gov.ru/en",
      medications: getMedicationsByRegulatoryAgency('MOHRU')
    },
    HSA: {
      name: "Health Sciences Authority",
      region: "Singapore",
      standard: "HSA-approved medications following Singapore pharmaceutical standards",
      description: "Streamlined approval process for innovative medicines with strong reliance on major regulatory authorities' decisions",
      website: "https://www.hsa.gov.sg",
      medications: getMedicationsByRegulatoryAgency('HSA')
    },
    TGA: {
      name: "Therapeutic Goods Administration",
      region: "Australia",
      standard: "TGA-approved medications following Australian therapeutic goods regulations",
      description: "Risk-based approach to regulation with pathway options including standard and expedited reviews",
      website: "https://www.tga.gov.au",
      medications: getMedicationsByRegulatoryAgency('TGA')
    }
  };
};

// Get medication regulatory summary
export const getMedicationRegulatorySummary = (medicationName: string) => {
  const medication = getMedicationByName(medicationName);
  if (!medication) return null;
  
  return {
    medication: medication.name,
    genericName: medication.genericName,
    approvals: medication.regulatoryApprovals || [],
    regionalDosing: medication.regionalDosing || [],
    internationalBrandNames: medication.internationalBrandNames || [],
    approvedRegions: medication.regulatoryApprovals?.filter(a => a.status === 'approved').map(a => a.agency) || [],
    globalAvailability: medication.regulatoryApprovals?.length || 0
  };
};

// Get medications by therapeutic category and regulatory agency
export const getMedicationsByTherapeuticCategoryAndAgency = (category: string, agency: RegulatoryAgency) => {
  const categoryMeds = getMedicationsByCategory(category);
  return categoryMeds.filter(med => 
    med.regulatoryApprovals?.some(approval => 
      approval.agency === agency && approval.status === 'approved'
    )
  );
};
